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My PhD three years course in Pharmaceutical Sciences at the Department of 
Pharmaceutical and Biomedical Sciences of Salerno University was started in 2010 
under the supervision of Prof. Giuseppe Bifulco. 
My research activity was mainly focused on studies of ligand-receptor 
interactions and structural characterization by computational techniques in order to 
identify new antitumor molecules potentially utilizable in therapy.  
In particular, I was mainly interested into the development of a new 
computational technique named Inverse Virtual Screening. The application of this 
approach led to the identification of the targets of interaction of several natural 
compounds. 
Furthermore, to improve my knowledge on computational chemistry, I moved to 
the The University Pompeu Fabra-PRBB (Parc de Recerca Biomèdica de 
Barcelona) in 2012 (mid-May until end of October 2012) under the supervision of 
Dr. Gianni De Fabritiis. 
During this period in his laboratory, my research work has included learning 
High-throughput Molecular Dynamics simulations, taking the advantage of his 
expertise in the field of molecular simulation applied to relevant systems in a drug 
design perspective, and his unique hardware and software infrastructure (GPU 
grid–ACEMD software).  
In addition to PhD course activities, I was involved in several other projects, 
mainly regarding the characterization of ligand-targets interactions of ligands on 
receptor targets (PXR, PPAR-γ, HSP70 1A), in order to elucidate the molecular 
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Computational chemistry represents today a valid and fast tool for the research 
of new compounds with potential biological activity. The analysis of ligand-
macromolecule interactions and the evaluation of possible “binding modes” have a 
crucial role for the design and the development of new and more powerful drugs. In 
silico Virtual Screening campaigns of large libraries compounds (fragments or 
drug-like) on a specific target allow the selection of promising compounds, leading 
the identification of new scaffolds. The accurate analysis and the comparison of 
different bioactive compounds clarify the molecular basis of their interaction and 
the construction of pharmacoforic models. 
In parallel, another crucial aspect of pharmacological research is the 
identification of targets of interaction of bioactive molecules, and this is 
particularly true for compounds from natural sources. In fact, a wide range of drug 
tests on a large number of biological targets can represent a useful approach for the 
study of natural products, but often one of the main problems is their limited 
availability. 
Starting from these assumptions, a new computational method named Inverse 
Virtual Screening is described in details in this thesis. The different works based on 
this approach were performed considering panels of targets involved in the cancer 
events, determining the identification of the specific antitumor activity of the 
natural compounds investigated.  
Inverse Virtual Screening studies were performed by means of molecular 
docking experiments on different natural compounds, organized in small libraries 
or as single compounds. Firstly, a mathematical method for the exclusion of false 
positive and false negative results was proposed applying a normalization of the 
predicted binding energies (expressed in kcal/mol) obtained from the docking 





compounds extracted from natural sources (paragraph 2.3), obtaining a good 
validation through in vitro biological tests. Afterwards, another study was 
performed on the cyclopeptide namalide. Its biological inhibitory activity and 
selectivity on Carboxipeptidase A target was in accordance with Inverse Virtual 
Screening results (paragraph 2.4).  
Virtual Screening topic was also inspected analyzing the efficacy of Molecular 
Dynamics-based methods for the accurate calculations of the binding affinities. 
This work was conducted on a library of 1588 compounds (44 ligands + 1544 
decoys) extracted from the DUD database on trypsin target, using the Linear 
Interaction Energy (LIE) method by means of extensive Molecular Dynamics 
simulations. Four different LIE results obtained combining different scaling factors 
were compared with docking results, evaluating and comparing ROC and 
enrichment curves for each of the considered methods. Poor results were obtained 
with LIE, and further analysis with MM-GBSA and MM-PBSA approaches are 
under investigation. 
Moreover, in silico screenings were performed for the detailed study of natural 
compounds whose activities are known a priori. With this procedure, several 
binding modes were reported for a library of compounds on PXR target, whose 
activity or inactivity were rationalized comparing their binding poses with that of 
Solomonsterol A, used as a reference compound on this receptor. The 
presence/absence of biological activity of another library of compounds extracted 
from the marine sponge Plakinastrella Mamillaris on PPAR-γ and for the diterpene 
oridonin on HSP70 1A are described at a molecular level respectively in 
paragraphs 4.2 and 4.3 with molecular docking and Molecular Dynamics 
simulations. 
The putative binding modes for the reported molecules was described offering a 





interactions (e.g. hydrophobic, hydrophilic, electrostatic contacts) can influence 










































1.1 Drug discovery process and computational chemistry 
Drug discovery is an expensive process including the identification and 
validation of a drug target (typically a protein), determination of 3-D structure of 
that target, discovery of a lead compound that binds to the target and development 
of the lead into a drug candidate.  
Computational chemistry represents today the preferential tool for predicting the 
putative binding modes and affinities of chemical compounds bound to a target. 
The difficulties and economic cost of the experimental methods explain the fast 
development of computational chemistry during the past years. The early 
development of computational chemistry was dependent on the developments in 
computational power and techniques. Computing power became widely available 
in the 1960s and a great number of new numerical models, or algorithms, were 
constantly produced worldwide. As computer power increased, the mathematical 
equations were refined in order to model real life more accurately. 
Effective use of computational chemistry shortens the development cycle for 
new drugs and provides pharmaceutical companies a competitive advantage with 
faster time-to-discovery and reduced costs. Numerous examples of drugs have been 
discovered and optimized with contributions from computational chemists.
1
 The 
primary goal of computational chemistry in drug discovery is to develop 
quantitative models that are able to predict activities of compounds quickly and 
accurately. Computer hardware and software is used to simulate a chemical process 
or to compute a chemical property. While it is now recognised that high-throughput 
methods are amply capable of producing greater volumes of data, they do not 
always increase the productivity and timeliness of a research effort. The problem in 
laboratories today is not one of acquiring data at each stage of drug discovery, but 





Fortunately, computational power and data-mining techniques are also advancing 
in step with demand. 
Computational methods provide guidance but are by no means able to make 
perfect predictions. Molecular libraries are screened, and the resulting leads are 
optimized in a cycle that features design, synthesis and assaying of numerous 
analogs, and animal studies. Crystal structure determination for complexes of some 
analogs with the biomolecular target is often possible, which enables “structure-
based drug design” (SBDD)
2
 and the efficient optimization of leads. SBDD is 
based on the knowledge of the 3-dimensional structure of the protein and, 
preferably co-complexed with a ligand as an identifier of the binding site are 




Figure 1.1 Number of yearly and total PDB structures available on PDB database from 1972 






As shown in Figure 1.1, a constantly growing number of protein structures have 
become available each year since 1976. As of February 2013, almost 85000 protein 
structures have been deposited at the Protein Data Bank (PDB),
6,7
 and this strongly 
demonstrates that structure-based drug design will continue to play a significant 
role in the field of drug design and discovery. 
Briefly, in the SBDD method, starting from the structure of a protein or a 
nucleic acid (X-ray crystallography, NMR or homology modelling), compounds or 
fragments of compounds from a database are positioned into a selected region of 
the structure. These compounds are scored and ranked, and the best compounds are 
tested with biochemical assays. In a next phase, from the results obtained it is 
possible to reveal parts of the compound that can be optimized to increase potency. 
This processes can be re-iterated, and then the optimazed compounds usually show 
marked improvement in binding and/or specificity for the target.  
The recognition of the binding site or the active site residues in the target 
structure is of high importance in SBDD. Basically, it is a small region, a pocket or 
bumps, where ligand molecules can best fit or bind to activate the receptor and/or 
target and produce the desirable effect. Since the proteins are capable of 
undergoing conformational changes, recognizing the accurate binding site residues 
is difficult;
8







 that can capably spot out the binding site 
residues. For example, Qsite finder locates and clusters the favorable binding sites 
using the interaction energy and Van der Waal’s probes, whereas CASTp employs 
functionally annotated residues for mapping the surface pockets. 
In this context, starting from a defined target structure, one of the most popular 
approaches used is the Virtual Screening (VS) from millions of potential 
compounds. VS computationally screens large chemical libraries to search for 
compounds that possess complementarities toward the targets.
12,13





compounds in VS is carried out using docking calculations where the compounds 
are filtered mainly considering their binding energies against the target.
13,14
 
Because these types of screening techniques are mainly data driven, data 
accessibility remains highly significant. 
Another approach often used is the “ligand-based drug design”, very useful in 
the absence of an experimental 3D structure.
15,16
 Due to the lack of an experimental 
structure, the known ligand molecules that bind to the drug target are studied and 
compared to understand their structural and physico-chemical properties that 
correlate with the desired pharmacological activity.
17
 Ligand-based methods may 
also include natural products or substrate analogues that interact with the target 
molecule yielding the desired pharmacological effect.
18,19
 Here, if sufficient 
number of reported active compounds (10-40) with diverse activity values are 
there, one can build a 3D pharmacophore model of these set of compounds by 
overlapping all of them and finding the common feature among them.  
SBDD and LBDD approaches can be used for the de-novo design, a process of 
creating or building new lead compounds from scratch - the former method being 
more prevalent than the latter. This process complements VS in hit discovery. The 
main principle of de novo design is to construct the small-molecule chemical 
structures that best fit the target space.
20
 In receptor-based de novo design high-
quality protein structures and their respective binding sites are essential because the 
hits are designed based on the target structures by placing small fragments in the 
key interaction sites of the proteins. Receptor-based design can be carried out by 











In the linking process different small fragments from the libraries are added 
simultaneously to different active site residues of the target.
21
 Thus, the small 
fragments positioned at the binding site link to each other and form a final single 
compound. This approach is widely preferred because the fragment design strategy 
is insightful in that most biological targets encompass discrete binding sites for 
each piece of a ligand.  
Whereas, in the growing technique a single small fragment is placed in the 
active site of the target and this fragment grows well complementarily against the 
receptor-binding site – thereby resulting in a library of chemical compounds that 
are more specific to the target. The process flow for the “hit identification” phase 






1.2 Methodologies employed 
A summary of the main methodologies used to realize the project is briefly 
presented in the next paragraphs. 
 
1.2.1 Molecular Docking  
One of the more current and fast computational techniques used in the field of 
the medicinal chemistry is represented by the molecular docking. With this 
computational tool, based on the protein structures, thousands of possible poses of 



















When only the structure of a target and its active or binding site is available, 
high-throughput docking is primarily used as a hit identification tool. The 
determination of the binding mode and affinity between the constituent molecules 
in molecular recognition is crucial to understanding the interaction mechanisms 
and to designing therapeutic interventions. However, similar calculations are often 
also used later on during lead optimization, when modifications to known active 
structures can quickly be tested in computer models before compound synthesis.  
Thus, if a particular target structure is known, one can dock a library of different 
chemical compounds into the same binding site, obtain a scoring value for each 
pose, and in this way virtually screen for affinity towards the target. High 
throughput virtual screening (HTVS), where the library may consist of up to 10
12 
(virtual) compounds, is a procedure commonly employed by pharmaceutical 
companies when starting a new lead discovery process. When desiring more 
detailed information about a potential ligand–protein complex than can be provided 





justify. It is well known that most, if not all, proteins continuously undergo 
conformational changes when exerting their functions in vivo.
30 
Specifically, when 
an agonist binds to a receptor, it is clear that significant conformational changes 
must take place. In light of this, some attempts have been made to take protein 
flexibility into account during docking. However, scoring all possible 
conformational changes is prohibitively expensive in computer time. Docking 
procedures which permit conformational change, or flexible docking procedures, 
must intelligently select small subset of possible conformational changes for 
consideration.  
In general, there are two aims of docking studies: accurate structural modelling 
and correct prediction of activity.  
Basically, a protein-ligand docking program consists of two essential 




Sampling refers to the generation of putative ligand binding 
orientations/conformations near a binding site of a protein and can be further 
divided into two aspects, ligand sampling and protein flexibility.  
Ligand sampling is the most basic element in protein-ligand docking. Given a 
protein target, the sampling algorithm generates putative ligand 
orientations/conformations (i.e., poses) around the chosen binding site of the 
protein.  
Treatment of ligand flexibility can be divided into three basic categories:
31
 
systematic methods (incremental construction, conformational search, databases); 
random or stochastic methods (Monte Carlo, genetic algorithms, tabu search); and 





Systematic search algorithms generate all possible ligand binding conformations 
by exploring all degrees of freedom of the ligand.  
The most straightforward systematic algorithms are exhaustive search methods, 
in which flexible-ligand docking is performed by systematically rotating all 
possible rotatable bonds of the ligand at a given interval. Despite its sampling 
completeness for ligand conformations, the number of the combinations can be 
huge with the increase of the rotatable bonds.  
In stochastic algorithms, ligand binding orientations and conformations are 
sampled by making random changes to either a single ligand or a population of 
ligands at each step in both the conformational space and the 
translational/rotational space of the ligand, respectively. A newly obtained ligand is 
evaluated on the basis of a pre-defined probability function. Two popular random 
approaches are Monte Carlo and genetic algorithms.  
For what concerns simulation methods, Molecular Dynamics and energy 
minimization are the most popular simulation approaches. Molecular Dynamics 
simulations are often unable to cross high-energy barriers within feasible 
simulation time periods, and therefore might only accommodate ligands in local 
minima of the energy surface.  
Therefore, an attempt is often made to simulate different parts of a protein–
ligand system at different temperatures.
32
  
Another strategy for addressing the local minima problem is to perform 
Molecular Dynamics calculations from different ligand positions. In contrast to 
Molecular Dynamics, energy minimization methods are rarely used as stand-alone 
search techniques, as only local energy minima can be reached, but often 
complement other search methods, including Monte Carlo.  
For example, DOCK performs a minimization step after each fragment addition, 





Protein flexibility starts from the assumption that ligand binding commonly 
induces protein conformational changes, which range from local rearrangements of 
side-chains to large domain motions. Methods to account for protein flexibility can 
be grouped into three categories: soft docking, side-chain flexibility, and protein 
ensemble docking.  
Soft docking is the simplest method which considers protein flexibility 
implicitly. It works by allowing for a small degree of overlap between the ligand 
and the protein through softening the interatomic van der Waals interactions in 
docking calculations.  
In side-chain flexibility method backbones are kept fixed and side-chain 
conformations are sampled.  
The third type of methods account for protein flexibility by firstly using rigid-
body docking to place the ligand into the binding site and then relaxing the protein 
backbone and side-chain atoms nearby. 
Specifically, the initial rigid-body docking allows for atomic clashes between 
the protein and the placed ligand orientations/conformations in order to consider 
the protein conformational changes. Then, the formed complexes are relaxed or 
minimized by Monte Carlo (MC), Molecular Dynamic simulations, or other 
methods.  
In general, the most widely-used type of methods for incorporating protein 
flexibility utilizes an ensemble of protein structures to represent different possible 
conformational changes.  
The ensemble docking algorithm is not used for generating new protein 
structures, but instead for selecting the induced-fit structure from a given protein 
ensemble. Following a similar procedure, Abagyan and colleagues expanded 
Huang and Zou’s algorithm to create ICM’s ensemble docking algorithm, referred 








Scoring is the prediction of the binding tightness for individual ligand 
orientations/conformations with a physical or empirical energy function. The top 
orientation/conformation, namely the one with the lowest energy score, is typically 
predicted as the binding mode. The scoring function is a key element of a protein-
ligand docking algorithm, because it directly determines the accuracy of the 
algorithm.
34,35,36,37
 Speed and accuracy are the two important aspects of a scoring 
function and an ideal scoring function would be both computationally efficient and 
reliable. Scoring functions have been developed can be grouped into three basic 
categories:  
 force field 
 empirical 
 knowledge-based scoring functions. 
Force field (FF) scoring functions
25,38,39
 are based on decomposition of the 
ligand binding energy into individual interaction terms such as van der Waals 
(VDW) energies, electrostatic energies, bond stretching/bending/torsional energies, 





 force fields. In general, the enthalpic contributions are essentially 
given by the electrostatic and van der Waals terms, and also considering taking into 
account the hydrogen bond formation between drug and biological target. 
The van der Waals potential energy is often modeled by the Lennard-Jones 12-6 
function (Equation 1.1) 
 
            
 
   
 
   
  
   




   









where ε is the well depth of the potential and σ is the collision diameter of the 
respective atoms i and j. The exp(12) is responsible for small-distance repulsion, 
whereas the exp(6) is related to an attractive term which approaches zero as the 
distance between two atoms increases (Figure 1.3).  
 
 
Figure 1.3 Graphical representation of the Lennard-Jones 12-6 function 
 
This Lennard-Jones 12-6 function is also used to describe the hydrogen bond in 
macromolecule-ligand complex, but is less smooth and angle dependent if 
compared to the van Der Waals function. 
The electrostatic potential energy is represented as the summation of Coulombic 
interactions, as described in Equation 1.2: 
 
           
    
       
  
   
  
   
 
Equation 1.2 
Where N is the number of atoms in molecules A and B, respectively, and q is the 
charge on each atom. The functional form of the internal ligand energy is typically 
very similar to the ligand-protein interaction energy, and also includes van der 





One of the major challenges in FF scoring functions is how to account for the 
solvent effect. The simplest method is to use a distance-dependent dielectric 
constant (rij) such as the force field scoring function in DOCK
39
 (Equation 1.3) 
 
     
   
   
    
   
   
   
    





where rij stands for the distance between protein atom i and ligand atom j, Aij 
and Bij are the VDW parameters, and qi and qj are the atomic charges. ε(rij) is 
usually set to 4rij, reflecting the screening effect of water on electrostatic 
interactions. The most rigorous FF methods are to treat water molecules explicitly. 
However, these methods, together with their simplified approaches such as 
LIEPROFEC, and OWFEG are computationally expensive.
43
 To reduce the 
computational expense, accelerated methods have been developed while preserving 
the reasonable accuracy by treating water as a continuum dielectric medium. The 
Poisson-Boltzmann/surface area (PB/SA) models
44,45,46
 and the generalized-
Born/surface area (GB/SA) models
47,48,49
 are typical examples of such implicit 
solvent models. 
In addition to the challenge on solvent effect, how to accurately account for 
entropic effect is an even more severe challenge for FF scoring functions. 
Moreover, whether the free energy of ligand binding can be decomposed into a 
linear combination of individual interaction terms without calculating the partition 
function (“ensemble average”) also remains in question, referred to as the 
nonadditive problem. 
The second type of scoring function (empirical scoring functions) works on the 





energy, hydrogen bonding energy, desolvation term, entropy term, hydrophobicity 
term, etc.(Equation 1.4): 
 




where {ΔGi} represent individual empirical energy terms, and the 
corresponding coefficients {Wi} are determined by reproducing the binding affinity 
data of a training set of protein-ligand complexes with known three-dimensional 
























 are examples of empirical scoring functions. 
In knowledge-based scoring functions protein-ligand complexes are modeled 
using relatively simple atomic interaction-pair potentials. In essence, it is designed 
to reproduce experimental structures rather than binding energies. A number of 
atom-type interactions are defined depending on their molecular environment. 
Compared to the force field and empirical scoring functions, the knowledge-based 
scoring functions offer a good balance between accuracy and speed. Namely, 
because the potentials are extracted from a large number of structures rather than 
attempting to reproduce the known affinities by fitting, the knowledge-based 
scoring functions are relatively robust and general. Their pairwise characteristic 
also enables the scoring process to be as fast as empirical scoring functions.  
A technique to improve the performances of scoring functions is clustering-
based scoring methods, which incorporate the entropic effects by dividing 
generated ligand binding modes into different clusters.
61,62,63
 The entropic 
contribution in each cluster is measured by the configurational space covered by 





One restriction in clustering-based scoring methods is that its performance depends 
on the ligand sampling protocol that is used, i.e., it is docking program-dependent. 
These methods in combination with ligand conformational sampling using 
AutoDock have significantly improved binding mode prediction. 
 
1.2.1.3 Autodock: An Overview 
AutoDock currently represents one of the most cited docking softwares,
64
 
especially in a virtual screening of a compound libraries.
65
 For the purposes of this 








 have been 
used.  
Basically, the differences between them are related to the speed, macromolecule 
sidechains flexibility, optimization of the free-energy scoring function based on a 
linear regression analysis, AMBER force field, larger set of diverse protein-ligand 
complexes with known inhibition constants; moreover the Lamarckian Genetic 
Algorithm (LGA) is a big improvement on the Genetic Algorithm, and both genetic 
methods are much more efficient and robust than SA in the new version of the 
software. 
In AutoDock there are different available search methods, but the Lamarckian 
Genetic Algorithm (LGA) has been selected for the aim of this study, because it 
has demonstrated to give the best results compared to the other algorithms.
25
  
The vast majority of genetic algorithms mimics the characteristics of Darwinian 
evolution and applies Mendelian genetics. This is briefly illustrated in Figure 1.4. 
This is called the Lamarckian genetic algorithm (LGA), and is an allusion to 
Jean Batiste de Lamarck’s (discredited) assertion that phenotypic characteristics 









Figure 1.4 This figure illustrates genotypic and phenotypic search, and contrasts Darwinian and 
Lamarckian search.
67
 The space of the genotypes is represented by the lower horizontal line, and the 
space of the phenotypes is represented by the upper horizontal line. Genotypes are mapped to 
phenotypes by a developmental mapping function. The fitness function is f(x). The result of 
applying the genotypic mutation operator to the parent’s genotype is shown on the right-hand side 
of the diagram, and has the corresponding phenotype shown. Local search is shown on the left-hand 
side. It is normally performed in phenotypic space and employs information about the fitness 
landscape. Sufficient iterations of the local search arrive at a local minimum, and an inverse 
mapping function is used to convert from its phenotype to its corresponding genotype. In the case of 
molecular docking, however, local search is performed by continuously converting from the 
genotype to the phenotype, so inverse mapping is not required. The genotype of the parent is 
replaced by the resulting genotype, however, in accordance with Lamarckian principles. 
 
The most important issues arising in hybrids (LGA) of Genetic Algorithm (GA) 
and the Local Search (LS) revolve around the developmental mapping, which 
transforms genotypic representations into phenotypic ones.  
The genotypic space is defined in terms of the genetic operators mutation and 
crossover in our experiments by which parents of one generation are perturbed to 





namely, the energy function being optimized. The local search operator is a useful 
extension of GA global optimization when there are local ‘‘smooth-ness’’ 
characteristics (continuity, correlation, etc.) of the fitness function that local search 
can exploit. In hybrid GA + LS optimizations, the result of the LS is always used to 
update the fitness associated with an individual in the GA selection algorithm. If, 
and only if, the developmental mapping function is invertible, will the Lamarckian 
option converting the phenotypic result of LS back into its corresponding genotype 
become possible. The fitness or energy is usually calculated from the ligand’s 
coordinates, which together form its phenotype. The developmental mapping 
simply transforms a molecule’s genotypic state variables into the corresponding set 
of atomic coordinates. A novel feature of this application of hybrid global-local 
optimization is that the Solis and Wets LS operator searches through the genotypic 
space rather than the more typical phenotypic space. This means that the 
developmental mapping does not need to be inverted. Nonetheless, this molecular 
variation of the genetic algorithm still qualifies as Lamarckian, because any 
‘‘environmental adaptations’’ of the ligand acquired during the local search will be 
inherited by its offspring. At each generation, it is possible to let a user defined 
fraction of the population undergo such a local search. The local search frequencies 
of just 0.06 have found improved efficiency of docking, although a frequency of 
1.00 is not significantly more efficient.
67
 Both the canonical and a slightly modified 
version of the Solis and Wets method have been implemented. In canonical Solis 
and Wets, the same step size would be used for every gene, but we have improved 
the local search efficiency by allowing the step size to be different for each type of 
gene: a change of 1 Å in a translation gene could be much more significant than a 
change of 1° in a rotational or torsional gene. In the Lamarckian genetic algorithm, 
genotypic mutation plays a somewhat different role than it does in traditional 





allowing small, refining moves that are not efficiently made by crossover and 
selection alone. With the explicit local search operator, however, this role becomes 
unnecessary, and is needed only for its role in replacing alleles that might have 
disappeared through selection. In LGA, mutation can take on a more exploratory 
role.  
The LGA yields a maximum number of 256 potential bioactive conformations: 
run, whose number can be increased performing more docking calculations. Each 
conformational solution is the result of a selection. The GA, starting from the input 
geometry, gives rise to a group of n conformations or individuals (whose number 
can be set up) defining for them translational, rotational and torsional variables. By 
the scoring function, each individual is labeled by the total interaction energy 
(fitness).  
Random pairs of individuals are mated using a process of crossover, in which 
new individuals inherit geometrical features from their parents leading to new 
generation of individuals. In addition, some offspring undergo random mutation, in 
which the translational, rotational and torsional variables are mutated randomly. 
Selection of the offspring of the current generation occurs based on the individual’s 
fitness: thus the better solutions go on into the next generations, whereas 
conformations with a low fitness are discarded. This cycle of crossover, mutation 
to lead new generation is repeated until the better bioactive conformation (run) is 
given.  
The LS performs an energy minimization of the current found conformation. In 
each generation a fraction of conformations population undergoes the geometry 
optimization, based on the local search frequency. Rapid energy evaluation is 
achieved by precalculating atomic affinity potentials (grid maps) for each atom 







These maps are calculated by AutoGrid. In this procedure the protein is 
embedded in a three dimensional grid and a probe atom is placed at each grid point 
(Figure 1.5). The energy of interaction of this single atom with the protein is 
assigned to the grid point.  
An affinity grid is calculated for each type of atom in the substrate, typically 
carbon, oxygen, nitrogen and hydrogen, as well as a grid of electrostatic potential, 
either using a point charge of +1 as the probe, or using a Poisson-Boltzmann finite 
difference method, such as DELPHI.
69
 The energetic of a particular substrate 
configuration is then found by tri-linear interpolation of affinity values of the eight 
grid points surrounding each of the atoms in the substrate.  
The electrostatic interaction is evaluated similarly, by interpolating the values of 
the electrostatic potential and multiplying by the charge on the atom (the 
electrostatic term is evaluated separately to allow finer control of the substrate 
atomic charges).  
The time to perform an energy calculation using the grids is proportional only to 
the number of atoms in the substrate, and is independent of the number of atoms in 
the protein. An estimated free energy of binding is used to evaluate the docked 
ligand conformations. This scoring function, based of force field AMBER,
70
 
comprises terms above described (directional hydrogen bonding, electrostatics, 
Van der Waals, internal energy) and entropic contribution: desolvation and 
torsional entropy. The latter describes the loss of entropy upon interaction with 
macromolecule followed by immobilization in the active site.  
The desolvation belongs the displacement of water molecules from the active 
site upon the binding of ligand to the macromolecular surface and the 







Figure 1.5 Schematic representation of the grid map. 
 
The scoring function was implemented using the thermodynamic cycle of 
Wesson and Eisenberg. The function is: 
 
          
   
   
    
   
   
  
   
                
   
   
    
   
   
   
   
   
         
     
            
                                     
 
     
 











where the five ΔG terms on the right hand side are coefficient empirically 




For what concerns AutoDock Vina,
28
 this is a open-source program for drug 
discovery, molecular docking and virtual screening, offering multi-core capability, 
high performance and enhanced accuracy and ease of use. Vina uses a sophisticated 
gradient optimization method in its local optimization procedure.  
The calculation of the gradient effectively gives the optimization algorithm a 
“sense of direction” from a single evaluation. In the spectrum of computational 
approaches to modelling receptor ligand binding molecular dynamics with explicit 
solvent, Molecular Dynamics and Molecular Mechanics with implicit solvent, 
molecular docking can be seen as making an increasing trade-off of the 
representational detail for computational speed.
71
 Among the assumptions made by 
these approaches is the commitment to a particular protonation state of and charge 
distribution in the molecules that do not change between, for example, their bound 
and unbound states.  
Additionally, docking generally assumes much or all of the receptor rigid, the 
covalent lengths, and angles constant, while considering a chosen set of covalent 
bonds freely rotatable (referred to as active rotatable bonds here). Importantly, 
although Molecular Dynamics directly deals with energies (referred to as force 
fields in chemistry), docking is ultimately interested in reproducing chemical 
potentials, which determine the bound conformation preference and the free energy 
of binding. It is a qualitatively different concept governed not only by the minima 
in the energy profile but also by the shape of the profile and the temperature.
72
 
Docking programs generally use a scoring function, which can be seen as an 
attempt to approximate the standard chemical potentials of the system. When the 





Coulomb energies are used in the scoring function, they need to be significantly 
empirically weighted, in part, to account for this difference between energies and 
free energies.
72  
The afore mentioned considerations should make it rather unsurprising when 
such superficially physics-based scoring functions do not necessarily perform 
better than the alternatives.  
This approach was seen to the scoring function as more of “machine learning” 
than directly physics-based in its nature. It is ultimately justified by its performance 
on test problems rather than by theoretical considerations following some, possibly 
too strong, approximating assumptions 
The general functional form of the conformation-dependent part of the scoring 
function AutoDock Vina is designed to work with is: 
 
        
   
      
Equation 1.6 
where the summation is over all of the pairs of atoms that can move relative to 
each other, normally excluding 1–4 interactions, i.e., atoms separated by three 
consecutive covalent bonds.  
Here, each atom i is assigned a type ti, and a symmetric set of interaction 
functions fti-tj of the interatomic distance rij should be defined. 
This value can be seen as a sum of intermolecular and intramolecular 
contributions: 
 






The optimization algorithm attempts to find the global minimum of c and other 
low-scoring conformations, which it then ranks. 
The predicted free energy of binding is calculated from the intermolecular part 
of the lowest-scoring conformation, designated as 1: 
 
                                 
Equation 1.8 
where the function g can be an arbitrary strictly increasing smooth possibly 
nonlinear function. 
In the output, other low-scoring conformations are also formally given s values, 
but, to preserve the ranking, using cintra of the best binding mode: 
 
                     
Equation 1.9 
For modularity reasons, much of the program does not rely on any particular 
functional form of fti-tj interactions or g. Essentially, these functions are passed as a 
parameter for the rest of the code.  
In summary the evaluation of the speed and accuracy of Vina during flexible 
redocking of the 190 receptor-ligand complexes making up the AutoDock 4 
training set showed approximately two orders of magnitude improvement in speed 
and a simultaneous significantly better accuracy of the binding mode prediction. In 
addition, Vina can achieve near-ideal speed-up by utilizing multiple CPU cores. 
However, AutodockVina does not provide very good weight of the energetic 
contribution derived from the hydrogen bond and electrostatic interactions, 






1.2.2 Molecular Dynamics 
One of the principal tools in the theoretical study of biological molecules is 
represented by Molecular Dynamics simulations (MD). This computational method 
calculates the time dependent behavior of a molecular system. MD simulations 
have provided detailed information on the fluctuations and conformational changes 
of proteins and nucleic acids. These methods are now routinely used to investigate 
the structure, dynamics and thermodynamics of biological molecules and their 
complexes, representing an important tool in the drug discovery process.
73
  
Crystallographic studies demonstrate that protein flexibility plays a fundamental 
role in ligand binding, but they represents long and very expensive methods. As a 
consequence, computational techniques that can predict protein motions are 
needed. Unfortunately, the calculations required to describe the absurd quantum-
mechanical motions and chemical reactions of large molecular systems are often 
too complex and computationally intensive for even the best supercomputers. 
Molecular Dynamics (MD) simulations, first developed in the late 1970s,
74
 seek to 
overcome this limitation by using simple approximations based on Newtonian 
physics to simulate atomic motions, thus reducing the computational complexity. 
The forces acting on each of the system atoms are then estimated from an equation 
like that shown in Equation 1.10
75
 and represented in Figure 1.6: 
 
                 
 
     
           
 




              
         
   
   
   
      
   
   
     
    
    
 








Figure 1.6 Atomic forces that govern molecular movement can be divided into those caused by 
interactions between atoms that are chemically bonded to one another and those caused by 
interactions between atoms that are not bonded 
 
Briefly, these forces arise from interactions between bonded and non-bonded 
atoms contribute. Chemical bonds and atomic angles are modeled using simple 
virtual springs, and dihedral angles are modeled using a sinusoidal function that 
approximates the energy differences between eclipsed and staggered 
conformations. Non-bonded forces arise due to van der Waals interactions, 
modeled using the Lennard-Jones 6-12 potential, and charged (electrostatic) 
interactions, modeled using Coulomb’s law.  
The energy terms described above are parameterized in order to fit quantum-
mechanical calculations and experimental data. The main aim of this 
parameterization is the identification of the ideal stiffness and lengths of the 
springs that describe chemical bonding and atomic angles, determining the best 
partial atomic charges used for calculating electrostatic-interaction energies, 
identifying the proper van der Waals atomic radii, and so on. Collectively, these 
parameters are called a ‘force field’ because they describe the contributions of the 
various atomic forces that govern Molecular Dynamics. Several force fields are 







 These differ principally in the way they are 
parameterized but generally give similar results. 
Different parameters determine the better or worse “quality” of a Molecular 





This can be done at several levels. The simplest treatment is to simply include a 
dielectric screening constant in the electrostatic term of the potential energy 
function. In this implicit treatment of the solvent, water molecules are not included 
in the simulation but an effective dielectric constant is used. Often the effective 
dielectric constant is taken to be distance dependent. Although this is a crude 
approximation, it is still much better than using unscreened partial charges. Other 
implicit solvent models have been developed that range from the relatively simple 
distance-dependent dielectric constants to models that base the screening on the 
solvent exposed surface area of the protein. The distance-dependent dielectric 
coefficient is the simplest way to include solvent screening without including 
explicit water molecules and it is available in most simulation programs. Recently, 
several implicit solvent models based on continuum electrostatic theory have been 
developed. 
If water molecules are explicitly included in the simulation, they can provide the 
electrostatic shielding. In this more detailed treatment of the solvent boundary 
conditions must be imposed, first, to prevent the water molecules from diffusing 
away from the protein during the simulation, and second to allow simulation and 
calculation of macroscopic properties using a limited number of solvent molecules. 
Several different treatments of the boundary exist, the use of one over another 
depends strongly on the type of problem the simulation is to address. 
Periodic boundary conditions enable a simulation to be performed using a 
relatively small number of particles in such a way that the particles experience 
forces as though they were in a bulk solution. The coordinates of the image 
particles, those found in the surrounding box are related to those in the primary box 
by simple translations along the three axes (Figure 1.7). The simplest box is the 





same box as well as in the image box. The cutoff is chosen such that a particle in 
the primary box does not see its image in the surrounding boxes. 
 
 
Figure 1.7 Periodic boundary conditions (PBC). Primary box (red) translated along the three axes 
(white) 
 
Once the forces acting on each of the system atoms have been calculated, the 
positions of these atoms are moved according to Newton’s laws of motion. The 
simulation time is then advanced, often by only 1 or 2 quadrillionths of a second, 
and the process is repeated, typically millions of times. Because so many 
calculations are required, Molecular Dynamics simulations are typically performed 
on computer clusters or supercomputers using dozens if not hundreds of processors 
in parallel (CPUs) or, more recently, moving to the GPU architecture. Many of the 












are compatible with multiple processors operating simultaneously. 
In the field of the drug discovery, Molecular Dynamics and the insights they 
offer into protein motion often play important roles. In fact, a single protein 
conformation tells little about protein dynamics. The static models produced by 
NMR, X-ray crystallography, and homology modelling provide valuable insights 
into macromolecular structure, but molecular recognition and drug binding are very 
dynamic processes. Moreover, it represents the best method for the identification of 
the sites not immediately obvious from available structures (cryptic sites), or for 
the allosteric ones.  
A link between molecular docking (fast, but with a poor accuracy) and 
Molecular Dynamics (computationally expensive, but accurate) is a new virtual-
screening protocol called the relaxed complex scheme (RCS),
82,83
 in which each 
potential ligand is docked into multiple protein conformations, typically extracted 
from a Molecular Dynamics simulation. Thus, each ligand is associated not with a 
single docking score but rather with a whole spectrum of scores. Ligands can be 
ranked by a number of spectrum characteristics, such as the average score over all 
receptors. Thus, the RCS effectively accounts for the many receptor conformations 
sampled by the simulations; it has been used successfully to identify a number of 





Moreover, another important application of Molecular Dynamics simulations in 
the drug discovery is the accurate calculation of the free energy (or binding 
affinities), widely described in the paragraph 1.2.3. 
With constant improvements in both computer power (from CPU to GPU 
architecture) and algorithm design, the future of computer-aided drug design is 
promising and Molecular Dynamics simulations are likely to play an increasingly 





1.2.3 Methods for the accurate calculation of the binding 
affinities 
Docking calculations are widely used in high-throughput virtual screening of 
structurally diverse molecules from available compound libraries/databases against 
specific targets, but often show many limits, especially in the lead identification 
stage.  
One of the ultimate goals in computer-aided drug design is the accurate 
prediction of ligand-binding affinities to a macromolecular target. As free energy 
methods have improved and computational power has continued to grow 
exponentially, this promise has begun in small part to be fulfilled. Low-throughput 
computational approaches for the calculation of ligand binding free energies can be 




1.2.3.1 “Pathway” methods 
In pathway methods, the system is converted from one state (e.g., the complex) 
to the other (e.g., the unbound protein/ligand). This can be achieved by introducing 
a set of finite or infinitesimal “alchemical” changes to the energy function (the 
Hamiltonian) of the system through free-energy perturbation (FEP) or 
thermodynamic integration (TI), respectively. In an alchemical transformation, a 
chemical species is transformed into another via a pathway of nonphysical 
(alchemical) states. Many physical processes, such as ligand binding or transfer of 
a molecule from gas to solvent, can be equivalently expressed as a composition of 
such alchemical transformations. Combined with atomistic Molecular Dynamics 
(MD) or Monte Carlo (MC) simulations in explicit water solvent models, they 
represent the most accurate approaches for calculating absolute or relative ligand 





computational power, due to the emerging implementation of biomolecular codes 
on GPU architectures.  
 
1.2.3.1.1 Free energy perturbation 
Free energy perturbation (FEP) starts from the assumption that internal energy, 
enthalpy, entropy, and Gibb's free energy all include contributions from the motion 
of a molecule. Therefore, Molecular Dynamics provides a way to estimate these 
important thermodynamic parameters. The hypothesis that makes the most sense is 
that the internal energy, U, is the time average of the total energy of the molecule. 
The total energy of the molecule is the kinetic plus potential energy (Equation 
1.11): 
 
                                  
Equation 1.11 
The potential energy is just the molecular mechanics steric energy. Molecular 
Dynamics provides us with the time dependent energy of the molecule; all we need 
do to get U is average the total energy during the trajectory calculation.  
Now we turn to the relationship of the steric energy to the Gibb's free energy. In 
statistical mechanics, we find that the probability of a given state of a system 
occurring is proportional to the Boltzman weighting factor (Equation 1.12): 
 
                                  
Equation 1.12 
where E is the total energy of the system. In other words, states with low total 
energy are more likely to occur than states with high energy. A state of the system 





The conformation determines the steric energy and the motions determine the 
kinetic energy. In perturbation theory, we look at the effect of a small change in the 
structure of a molecule on its energy. To do the perturbation, the total energy is 
divided into two parts (Equation 1.13): 
 
           
Equation 1.13 
where E0 is a reference structure and E1 is a small perturbation from the 
reference structure.  
The perturbation is a small change that we place upon the system, say a small 
change in bond angle or a small change in the charge on an atom. The 
corresponding change in free energy of the system caused by the perturbation is 




               
         
Equation 1.14 
where      denotes the time average over the motion of the reference structure 




 term is the probability of occurrence 
for the small change in energy caused by the perturbation, from Equation 1.14. The 
free energy then depends on the time average of the probability of occurrence of 
the perturbed structure. In other words, if the perturbation produces a small change 
in energy, that change will contribute to the Gibb's free energy. In our case 
however, we wish to find the change in free energy for large changes in a molecule. 
These changes, can contribute to the mutation of a molecule from one state 
(molecule B) to another (molecule A). First we define a total energy for mutating 






               
Equation 1.15 
where EA is the total energy for A and EB is that for B, and is the coupling 
parameter. When = 1 the energy corresponds to molecule A, and when = 0 the 
energy corresponds to molecule B.
When is at intermediate values, the system is a hypothetical superposition of 
A and B. It mightseem quite strange to have such a combination of two molecules, 
in fact it is very unphysical;however.  
For the complete mutation to take place we vary from 0 to 1 over the course of 
the dynamicsrun. We divide this full range into short time slices, which are short 
enough that we can treat thechange in each time slice as a perturbation.  
Then we apply Equation 1.15 to each time slice and then addup the result for all 
the time slices. Let the value at each time slice be numbered 1, 2, 3, etc.Then 
the difference in Equation 1.15 is G(i) for each time slice, i=1, 2 ,3,...n, for n 
total time slices. In words, this simple result means that the change in Gibb's free 
energy for a perturbation is justthe time average of the total perturbation energy. 
 
1.2.3.1.2 Thermodynamic integration 
Similarly, the thermodynamic integration method (TI) is often used for the 
“alchemical” computation of differences in binding affinities (known as relative 
affinities) among a set of related ligands for the same target protein. In this case, 
the free energy difference is calculated by defining a thermodynamic path between 





These approaches can be used in a thermodynamic cycle, as illustrated in Figure 
1.8, often applied in studying the relative strength of ligand-receptor interactions 
and the relative stability of proteins differing in one or a few amino acids.  
 
 
Figure 1.8 Thermodynamic cycle linking the binding of two ligands L1 and L2 to a protein in 
solution. 
 
Thermodynamic cycle methods were developed because relatively large, 
complicated changes need to taken into account when considering the physical 
phenomena that occur in ligand-receptor binding or the effect of a mutation on 
protein stability. That is, binding of a drug to a receptor will produce relatively 
large conformational changes (i.e., the protein will favor a particular set of 
conformational substates). Binding of a very similar drug to the same site should 
produce most of the same changes. The thermodynamic cycle is designed to cancel 
out the large changes that are common to binding of either drug to the receptor. 
The horizontal legs describe the experimentally accessible actual binding 
processes, with free energies ∆Gbind(L1) and ∆Gbind(L2). Since the free energy is a 
state function, the relative binding free energy ∆∆Gbind is exactly equal to the 





                         (L1)  Equation 1.16 
                                  
Equation 1.17 
The simulations follow the vertical steps (Equation 1.17) or unphysical 
processes, by simulations in water solution that gradually change the energy-
function of the system from one “endpoint” to the other through a series of 
intermediate hybrid states. From Figure 1.8, this involves the stepwise 
“alchemical” transformation of ligand L1 to L2 both in its ‘free’ state (unbound) 
and in the bound complex, through gradual changes in the forcefield parameters 
describing the ligand interactions. This leads to the free energy changes 
∆Gfree(L1→L2) and ∆Gcomplex(L1→L2), respectively. Averaging over both 
transformation directions is often used to improve the free-energy estimates, 
although this is not always the case. These calculations can be accurate, if 
conducted with the appropriate care. 
 
1.2.3.2 “Endpoint” methods 
Although we are assisting on a constant improvement in the computational 
power, much less computationally demanding “endpoint” methods are often 
successfully applied, such as the molecular mechanics – Poisson Boltzmann (MM-
PBSA) and the related molecular mechanics – generalised Born (MM-GBSA) 
approximation and the linear interaction energy (LIE). All these methods compute 
binding free energies along the horizontal legs of Figure 1.8, but use only models 






1.2.3.2.1 LIE (Linear Interaction Energy) 
The binding of a ligand to a biological macromolecule can be viewed as a 
process in which the ligand (l) is transferred from one medium, i.e., free in water 






Figure 1.9 Reference state (left) and bound state (right) of a ligand solvated in water  
 
As a consequence, bound state of the ligand and reference state (water-solvated 
ligand) must be taken into account for a proper description of the total change in 
free energy associated to the formation of a ligand–receptor molecular complex. 
This is the correlation behind the LIE method, where the binding free energy is 
estimated as the free energy of transfer between water and protein environments as: 
 
               
          
 
    
Equation 1.18 
The main difference with respect to a regular transfer process between two 
solvents is that the standard state in water (1 M and free rotation) is replaced by 





In order to calculate the free energy of binding as a solely function of these two 
physical, relevant states of the ligand, we can draw a thermodynamic cycle (Figure 
1.10), where the upper corners represent these two states (left: free, solvated in 
water; right: bound to the protein). The two bottom corners will account for two 
unphysical, intermediate states: a pseudo-ligand without any (intermolecular) 
electrostatic interactions, in its free (left) or bound (right) state.  
 
 
Figure 1.10 The thermodynamic cycle on which is based the estimation of the binding free energies 
with the linear interaction energy (LIE)  
 
The resolution of such a thermodynamic cycle leads to the following equation: 
 
               
     
       
     
         
        
        
     
        
        
 
Equation 1.19 
where the entropic confinement contributions are hidden in the nonpolar term. 
Thus, the free energy of binding can be expressed as a sum of the corresponding 
polar and nonpolar components of the free energy. This is quite convenient, since 
molecular mechanics force fields analogously split the nonbonded potential 
energies into electrostatic and nonelectrostatic components. Potential energies (U) 





a useful approximation comes from the linear response theory for electrostatic 
forces,
89,90
 which states that the electrostatic part of the solvation free energy is: 
 
     
   
 
 
      
           
        
Equation 1.20 
where the brackets     indicate thermodynamic averages of the ligand–
surrounding (l–s) interaction energies as calculated with standard force-field 
Molecular Dynamics (or, alternatively, MC or other relevant statistical sampling). 
The term with the electrostatic interactions turned off in the sampling,      
      , 
corresponds to the average electrostatic energy that would be obtained from the 
sampled configurations if the interactions instead were turned on (i.e., a 
“preorganization” term). This term is assumed to be constant or negligible 
compared to      
      (the corresponding energies sampled with the interactions 
turned on). Thus we will write Equation 1.20 as  
     
   
 
 
     
     , omitting a possible constant that will be considered below. In 
applying the linear response approximation to the problem of ligand binding we 
must also consider the reference state with a dissociated ligand in water. 
Furthermore, seemingly minor deviations from the exact linear response scaling 
factor of ½ have been demonstrated for hydration-free energies that, in fact, are 
important to take into account in order to improve the accuracy of the method.
91,92
 
Thus, we will write the expression for the polar component of the free energy in the 
general form of: 
 
      
     
        
          
            






The other main idea behind the LIE method is to estimate the nonpolar 
component of the free energy of binding analogously as: 
 
      
        
        
           
              
        
Equation 1.22 
where the α parameter is the empirically-derived nonpolar scaling factor and γ a 
constant. This was motivated by the observation of linear dependencies of both 
solvation free energies for nonpolar compounds and      
     on molecular size 
(which can also be compared to semi-macroscopic approximations such as 
     
        
           
    , representing the creation of a cavity and insertion of van 
der Waals centers into this cavity, where g is the surface tension, A the surface area, 
and c a scaling factor). However, due to the fact that      
     not only represents 
“steric” interactions but also is an efficient size measure, Equation 1.22 takes into 
account all size dependent and constant contributions to the binding free energy, 
approximating contributions from “cavity creation” confinement effects, and the 
second term of Equation 1.20.
93
 It follows that the full LIE equation, for the 
estimation of binding affinities based on force-field averaged energies, can be 
written as: 
 
              
            
      
Equation 1.23 
It is important to note that with this equation, one can calculate the free energy 
of binding by averaging the ligand-surrounding potential energies, which are 
collected only for the two physical states of the ligand involved in the binding 
process (represented in the upper corners of Figure 1.10): the free state (ligand 
solvated in water        ) and the bound state (ligand in the solvated protein-





methods for the estimation of free energies, e.g., in more complicated methods, 
such as FEP or thermodynamic integration (TI), intermediate unphysical states 
resulting from mixing of end-point potentials must be explicitly simulated. On the 
other side, statistical methods such as scoring functions generally only take into 
account descriptors collected for the bound state, and not the free state, which tends 
to yield artificial dependencies of binding free energies on ligand size (molecular 
weight). 
 
1.2.3.2.2  MM-GB(PB)SA 
In the MM-GB(PB)SA formulation,
94,95,96
 the binding free energy of a ligand 
(L) to a protein (P) to form the complex (PL) is obtained as the following 
difference (Equation 1.24): 
 
                        
Equation 1.24 
The free energy of each of the three molecular systems P, L, and PL is given by 
the Equation 1.25: 
 
                            
Equation 1.25 
In Equation 1.25, EMM is the total molecular mechanics energy of molecular 
system X in the gas phase, Gsolv is a correction term (solvation free energy) 
accounting for the fact that X is surrounded by solvent, and S is the entropy of X. 
To apply the MM-GB(PB)SA formulation, a representative set of equilibrium 
conformations for the complex, free protein and free ligand are first obtained by 





In this post-processing phase, the solvent is discarded and replaced by a 
dielectric continuum. Changes (Δ) in the individual terms (ΔEMM, ΔGsolv, -TΔS) of 
Equation 1.25 between the unbound states and the bound (complex) states are 
calculated, and contribute to the binding free energies according to Equation 1.26.  
EMM is the sum of the bonded (internal), and non-bonded electrostatic and van 
der Waals energies 
 
                         
Equation 1.26 
These energy contributions are computed from the atomic coordinates of the 
protein, ligand and complex using the (gas phase) molecular mechanics energy 
function (or forcefield). The solvation free energy term Gsolv contains both polar 
and non-polar contributions.  
The polar contributions are accounted for by the generalized Born, Poisson, or 
Poisson-Boltzmann model, and the non-polar are assumed proportional to the 
solvent-accessible surface area (SASA) (Equation 1.27): 
 
                      
Equation 1.27 
Finally, the entropy S is decomposed into translational, rotational and 
vibrational contributions. To improve the accuracy of the computed binding free 
energies, the various terms of Equation 1.27 are averaged over multiple 
conformations or MD snapshots (typically a few hundred for the EMM and Gsolv 
contributions). Depending on the extent of conformational fluctuations in the 
system under consideration, the convergence into stable values may require 
relatively long (multi-ns) simulations. The computation of the entropy term, 





the protein, ligand and complex to local minima on the potential energy surfaces, 
followed then by normal mode analysis. The internal energy terms (Ebonded) of the 
protein and complex can be on the order of a few thousand kcal/mol, and can 
introduce large uncertainties in the computed binding free energies. For what 
concerns the second contribution in the free energy (Gsolv(X)), it is important to 
note that the solvent modifies in a non-trivial manner the intramolecular and 
intermolecular interactions, an accurate inclusion of solvent effects in biomolecular 
modelling and simulation is a challenging task. The most rigorous treatment of the 
solvent in a molecular dynamics simulation is to include explicit molecules in the 
calculation, with a notable increase in the computational cost. A much less costly 
approach is to represent the solvent implicitly in the simulation, through the 
incorporation of additional “potential of mean force” terms in the gas-phase energy 
function (e.g., Equation 1.28 below). These terms depend only on the atomic 
coordinates of the solute, and express the solute free energy for a given 
configuration, after the solvent degrees of freedom have been “integrated out”. 
Thus, the simulation system has the same number of degrees of freedom as in the 
gas phase and there is no need for explicit sampling over solvent degrees of 
freedom. The MM-PB(GB)SA method combine atomistic simulations in explicit 
solvent for the generation of representative biomolecular conformations with an 
implicit-solvent estimation of the binding free energies, in a post-processing step.  
There are two approaches to generating the necessary ensembles for the bound 
and unbound state of binding energy calculations: all ensembles can be extracted 
from a single Molecular Dynamics (MD) or Monte Carlo (MC) trajectory of the 
bound complex, or trajectories can be generated for each state using separate 
simulations.  
These approaches are called the single trajectory protocol (STP) and multiple 





and disadvantages. STP is less computationally expensive than MTP, because only 
a single trajectory is required to generate all three ensembles. Furthermore, the 
internal potential terms (e.g., bonds, angles, and dihedrals) cancel exactly in the 
STP, because the conformations in the bound and unbound ensembles are the same, 
leading to lower fluctuations and easier convergence in the binding free energy. 
The STP is appropriate if the receptor and ligand ensembles are comparable in the 
bound and unbound states. However, the conformations populating the unbound 
ensembles typically adopt strained configurations when extracted from the bound 
state ensemble, thereby overstabilizing the binding, compared to the MTP. 
Conceptually, most implicit solvent models decompose the solvation process into 
three sequential steps: i) creation of a cavity in solution to accommodate the 
biomolecule; ii) switching-on dispersion interactions between the biomolecule and 
surrounding medium, while all atomic charges are set to zero; and iii) switching-on 
the biomolecular charges. The solvation free energies of steps i) and ii) are 
normally assumed to be proportional to the SASA of the biomolecule and represent 
the non-polar contributions (GSASA) to Gsolv in Equation 1.27, although the validity 
of this approximation has been questioned for step ii). With a positive coefficient 
of proportionality, an increase in the SASA is associated with an unfavorable 
increase in solvation free energy, which is partly accounted for by the tendency of 
non-polar residues to be solvent-excluded. The equation typically used is of the 
form (Equation 1.28): 
 
                   
Equation 1.28 
with the γ and β parameter values dependant on the method and solvation model 
(PBSA or GBSA) used. Meanwhile, step iii) calculates the contribution to solvation 





surrounding solvent, the polar contributions (GPB(GB)) to Gsolv in Equation 1.27. In 
continuum-electrostatics models such as PB and GB, the solute is treated as a low-
dielectric cavity embedded in a high dielectric medium. The solute charges are in 
the simplest and most common approximation centered on the individual atoms. 
The resulting solvation free energy of a molecule X is expressed as (Equation 
1.29): 
 
           
 
 
        
        




where the summation is over all the atomic charges {qi}. The quantity gij
PB(GB)
 is 
determined using the PB model by numerical solution of the Poisson or Poisson-
Boltzmann equation (depending on the existence of salt), or using the GB model by 
an analytical expression with the functional form (Equation 1.30):  
 
   
       
 
 
        
          
   
 
    
  
    
 
Equation 1.30 
The parameters Bij depend on the position (distance from the solute-solvent 
dielectric boundary) of atoms i and j, and the shape of the entire biomolecule; ε is 
the solvent dielectric constant, and rij is the distance between i and j. The constants 
n and A were set to n=2 and A=4 in the original formulation of Still and 
coworkers.
95
 In the PB model, the solute dielectric constant (εin) affects the 
computed functions gij
PB
 and Equation 1.29. Meanwhile, in the GB model, the 
solute dielectric constant drops out from the final expression in Equation 1.30, due 
to the approximations used to arrive at an analytic formula. An εin value other than 





Equation 1.30 becomes (1/ε –1/εin) and the GB expression yields the free energy of 
transfer ring the solute from an infinite reference medium with dielectric constant 
εin into solution. Application of Equation 1.29 to a protein:ligand complex (PL) 
and the dissociated protein (P) and ligand (L) yields the electrostatic (polar) 
solvation free energy contribution to Equation 1.24 (Equation 1.31): 
 
                                             
Equation 1.31 
An advantage of these methods is that they facilitate the decomposition of the 
total solvation free energy into insightful components. Hou and co-workers 
evaluated the performance of MM-GBSA and MM-PBSA for predicting binding 
free energies based on Molecular Dynamics simulations.
97
 Their results showed 
that MM-PBSA performed better in calculating absolute binding free energies 
compared to MM-GBSA but not necessarily for the relative binding free energies, 
sufficient for most applications in computational drug design. Interestingly, in a 
study of the accuracy of continuum solvation models for drug-like molecules, GB 
methods typically were more stable and gave more accurate results that the widely 
used PB methods.
98
 Recently, Miller et al.
99
 implemented the free Python program 
MMPBSA.py, speeding up the calculation by dividing frames evenly across 
available processors. The source code is released under the GNU General Public 
License. 
 
















Inverse Virtual Screening 
2 Inverse Virtual Screening 
  




2.1 Inverse Virtual Screening: Introduction 
The identification of the biological targets of a natural and/or synthetic 
compound represents a fundamental aim in medicinal chemistry and in the field of 
natural products. The discovery of the activity of a molecule on a specific target 
and the careful analysis at a molecular level of the main interactions can be used to 
rationalize its binding mode. In this context, computational chemistry represents 
today a valid and fast tool for the scientific research of new compounds with 
potential pharmacological activity. It is possible to analyze a large number of 
molecules in very short times, evaluating their binding mode with receptors of 
pharmacological interest (Virtual Screening
100
). The availability of the 
crystallographic structures of specific targets permits the evaluation of the binding 
mode of specific compounds before the synthesis, with a reduction of costs and 
timing of a drug discovery project. Nevertheless, there are only few examples 
where the calculations are performed on different targets characterized by their 
involvement in specific disease processes. This new type of computational 
approach is known as Inverse Virtual Screening,
101,102,103,104
 in which libraries of 
compounds are tested on panel of targets with the aim of identifying a specific 
pharmacological activity (panel of antitumour, antiviral, antibacterial targets). This 
in silico tool could allow the identification of new specific biological actions for 
ligands with a well-known activity and explain in some cases the selectivity or the 
presence of side effects of a compound.
105,106
  
This could be particularly advantageous for the natural products, because the 
small amounts of compounds obtained from natural sources usually prohibit the 
performance of pharmacological tests against a large number of receptors. In fact, 
the chemistry of the natural products has been investigated thoroughly in recent 
decades, resulting in a better understanding of enzymatic processes and in the 
development of biosynthetic knowledge and biogenetic theories for a logical 




classification connecting a large variety of compounds. Many interesting secondary 
metabolites are produced by organisms in small quantities. Thus, for the isolation 
of a few milligrams of pure active metabolites, just enough to conduct preliminary 
in vitro biological tests, it is often necessary to extract kilograms of an organism. A 
useful approach for the study of natural products would be to carry out drug tests 
on a large number of biological targets with a better chance of evaluating their 
potential activity. Computational methods have been recently shown to be an 




In this chapter, the molecular docking of several small molecules (organized in 
libraries or as single compound) against panels of receptor sites in an attempt to 
find ligands and binding conformations to direct experimental assays on specific 
biological targets. This approach has been initially applied to the discovery of 
potential antitumor compounds through the interaction with a number of protein 
targets involved in cancer, but there are on course other Inverse Virtual Screening 
studies for the evaluation of the antiviral and antibacterial activities. The panels of 
targets were built from the Protein Data Bank (PDB), by the selection of proteins 
involved in different pathologies and if commercially available for subsequent 
biological tests. The large number of available models for proteins is particularly 
useful for studying a wide range of molecules with variable biological activity. 
It is noteworthy that this approach is also potentially applicable to libraries of 
synthetic compounds, to accelerate the analysis and to evaluate structure-activity 
relationships through a virtual method before the experimental study. The Inverse 
Virtual Screening method is also useful to provide information regarding ligand-
protein interactions potentially affecting the physiology of the protein. 
Summarizing, this method was applied on: 
 a library of natural and marine compounds from LIBIOMOL library113 




 a second library of natural products (10 compounds) with well-known 
antiproliferative and antioxidative biological activities
114
 
 namalide, a synthetic peptidic compound115  
In all these cases, using this approach, we were able to identify the targets of 
interaction of these compounds, confirming these results with biological tests. This 
highlights the promising usability of this new computational method for the 
accelerated discovery of the biological activity of natural and synthetic compounds. 
Finally, it is important to underline that in each one of the Inverse Virtual 
Screening studies performed, we used a different number of targets, because the 
panel was constantly updated. For example, in the first study a panel of 126 targets 
was used, while in the present state a panel of 210 targets involved in the cancer 
events is available (Table 2.1). In parallel, we are building other two panels of 
targets, respectively for the viral (so far, 85 targets) and mycotic infections (so far, 
130 targets). 
Even if the scope of this thesis is mainly focused on the development of new 
computational methods for the screening of targets involved in pathological events, 
it is proper to give an overview of the main events occurring in the cancer 
deasease, that represents the pathology mainly investigated in this type of study. 
This information are summarized in Appendix A. 
 
  




protein PDB code protein PDB code protein PDB code 
14_3_3_epsilon 2BR9 egfr 2J6M mek4_anp 3ALN 
14_3_3_gamma 2B05 enolase1_site_1 2PSN mek4_no_anp 3ALN 
14_3_3_sigma 1YWT enolase1_site_2 2PSN mek5_pb1_domain 1WI0 
14_3_3_theta 2BTP enolase2_site_1 1TE6 metap2 1YW9 
14_3_3_zeta 1QJA enolase2_site_2 1TE6 mk2 3M42 
abl2 3HMI enolase3_site_1 2X6X mlk1 3DTC 
abl 2HYY enolase3_site_2 2X6X mmp13 830C 
aif 1M6I EPHa3 3DZQ mmp3 1HY7 
akt1 3MVH EPHb4 2X9F mmp8 2OY2 
akt2 3D0E erbB2 1S78 mrp1 2CBZ 
alk 2XP2 erbB4 2R4B msk1 3KN5 
alk5 2WOU erk1 2ZOQ mthfs 3HY3 
ape1 2ISI erk2 2OJG mtor 3FAP 
ask1 3VW6 fak 3BZ3 mtsp1 3NCL 
aurkinA 2W1D fgf1 1HKN nek2 2XKF 
aurkinB 2VG0 fgfr1 1AGW nek7 2WQN 
bap1 2W15 fgfr2 2PVF nnos 3JT4 
bcl2 2O21 flt3 3QS7 nqo1 2F1O 
bcl2a1 2VM6 fpps_allo 3N1V p300 3BIY 
bcl6 3LBZ fpps_ipp 1ZW5 p38 3HEG 
bclw 1ZY3 fpps_no_ipp 1ZW5 p53_mut 2X0V 
bclxl 1BXL ftase 1LD8 parp 2JVN 
braf 3C4C fxr 1OSV pcaf 2RNW 
brd2_bd1 2YDW galectin1 1W6M pcna 1VYJ 
brd2_bd2 3ONI galectin3 1KJL pd 3BIK 
brd3_bd1 3S91 galectin7 3GAL pdk1 3NAX 
brd3_bd2 3S92 gsk3 3F7Z peroxiredoxin_1 2RII 
brd4_bd1 3MXF gstm2_2 3GUR peroxiredoxin_hORF6 1PRX 
brd4_bd2 2YEM gstp1 2A2R pgm 1YFK 
btk 3PIX hdac1 homology_modelling pi3k 3ENE 
calmodulin 3EWT hdac2 homology_modelling pig3 2J8Z 
camKIIB 3BHH hdac3 homology_modelling pimkin 3JYA 
caspase1 2FQQ hdac4 homology_modelling pka 3L9L 
caspase2 1PYO hdac6 homology_modelling pkca 3IW4 
caspase3 3EDQ hdac7 homology_modelling pkcbII 2I0E 
caspase7 1SHL hdac8b homology_modelling pkc_eta 3TXO 
caspase8 1QTN hdac8 homology_modelling pkc_iota_2 1ZRZ 
cathepsinB 1GMY hgfr_cmet_alt 2WD1 pkc_iota 3A8W 
cathepsinG 1AU8 hmt 3HNA pkc_iota_apo 3A8X 
cathepsinK 2R6N hsc70 3FZH pkct 2JED 
cathepsinL 3HWN hsp90 2WI6 plk1 3FVH 
cbp 2RNY hspa1a 3JXU pnk 2W3O 
cdc42_no_alf3 2NGR hspa1l 3GDQ pop 3DDU 
cdk2 2VV9 hspa2 3I33 ppar_g 3AN3 
cdk2_alt 2WIH hspa5 3IUC pten 1D5R 
cdk2_altern 2WFY hspa6 3FE1 pxr 1M13 
cdk4 3G33 ido 2D0T pyk2 3FZS 
cdk5 1H4L igf 3F5P raf 3C4C 
cdk6 2F2C irak4 2NRU ras 3GFT 
cdk7 1UA2 jak1 3EYG ret 2X2K 
cdk8 3RGF jak2 3E64 srpk 1WBP 
cdk9 3BLQ jak3 1YVJ stat3 1BG1 
chk1 2QHN jmjd3 2XXZ survivin 1XOX 
chk2 2W7X jmjd3_akg 2XXZ syk 3FQH 
ciap1 3D9U jnk1 3KVX tank1 2RF5 
ck2 3FL5 jnk2 3NPC tank2 3KR8 
clk1 1Z57 jnk3 2ZDT tao2 2GCD 
clk3 2WU6 kit_kinase 3G0E tdp1 1RFF 
cmet 2WGJ kras 3GFT tie2 2OO8 
CPA 1CBX lck 3AD4 topI 1K4T 
CPU 3D67 lsd1 2EJR topII 1ZXM 
cSRC 3F3V lyn 2ZVA topII_atp 1QZR 
cxcr4 2K05 mcl1 3D7V tp 1UOU 
dapk 3EH9 mdm2 3EQS ts 3NCL 
dhfr 1PD8 mdmx 3EQY upa 2VIP 
diaminoox 3HIG mek1 3DV3 vegfr1 1FLT 
dnmt3a 3A1B mek1_adp 1S9J vegfr2 3EWH 
dnmt3l 2QRV mek1_no_adp_no_lig 1S9J wee1 1X8B 
dyrk_1a 3ANQ mek2_adp 1S9I xiap 1TFT 
e-cadherin 2O72 mek2_no_adp_no_lig 1S9I zap70 1U59 
Table 2.1 Panel of 210 targets involved in cancer processes built for Inverse Virtual Screening 
studies 
  




2.2 Pilot Inverse Virtual Screening study: LIBIOMOL library 
A pilot Inverse Virtual Screening was initially conducted on a library of 
bioactive compounds (“Library on Bioactive Molecules” - www.libiomol.unina.it) 
classified as: (a) molecules with an action on the cytoskeleton; (b) cytotoxic 
compounds; (c) antitumor agents; (d) antiproliferative substances, and (e) 
antiangiogenic compounds. When this pilot study was performed 43 molecules 
were examined, comprising 27 natural compounds, three semisynthetic 
compounds, and 13 synthetic compounds designed for mimicking selected natural 
skeletons. This library was screened against a panel of targets selected for their 
correlations in cancer on the basis of the Inverse Virtual Screening method, 
allowing the obtainment of a restricted group of promising candidates for 
subsequent biological tests.  
In particular, Autodock-Vina
28
 calculations were performed. This software has 
been shown to produce an increased efficiency in predicting the experimental 
binding poses and energies, and a two orders of magnitude speed-up compared 
with Autodock 4.0.
25
 It has been designed for parallel computing, representing a 
particularly suitable tool for this study, for large virtual screening studies in 
general, and for the investigation of ligands presenting large numbers of active 
torsion angles, such as naturally occurring compounds.  
Docking calculations were perfomed between 43 molecules (Chart 2.1) 
previously tested for their potential activity (antitumor, cytotoxic, antiangiogenic, 
antiproliferative, activity on the cytoskeleton) against a panel of 126 protein targets 
(Table 2.2). The library used for the calculations included several types of 
molecules, characterized by similar or different chemical structures. 
 
 










































































































































































































































































































































Chart 2.1 Structures of compounds 1-43 




protein PDB code protein PDB code protein PDB code 
abl 2HYY diaminoox 3HIG mek1 3DV3 
abl2 3HMI dnmt3a 3A1B metap2 1YW9 
aif 1M6I dnmt3l 2QRV mmp3 1HY7 
akt 3MVH e-cadherin 2O72 mmp8 2OY2 
apaf1 1Z6T egfr 2J6M mmp13 830C 
ape1 2ISI epsilon 2BR9 mrp1 2CBZ 
aurkin 2W1H erbB2 1S78 mTor 3FAP 
bap1 2W15 erk1 2ZOQ nnos 3JT4 
bcl2 2O21 erk2 2OJG nqo1 2F1O 
bcl2a1 2VM6 fak 3BZ3 p38 3HEG 
bclw 1ZY3 fgf1 1HKN parp 2JVN 
bclxl 1BXL fgfr1 1AGW pcaf 2RNW 
braf 3C4C fgfr2 1EV2 pcna 1VYJ 
calmodulin 3EWT fgfr3 3GRW pd 3BIK 
caspase1 2FQQ ftase 1LD8 pgm 1YFK 
caspase2 1PY0 galectin1 1W6M pi3k 3ENE 
caspase3 3EDQ galectin3 1KJL pik3 1E7U 
caspase7 1SHL galectin7 3GAL pimKin 3JYA 
caspase8 1QTN gamma 2B05 plk1 3FWH 
cathepsin B 1GMY gsk3 3F7Z pop 3DDU 
cathepsin G 1AU8 gstp1 2A2R pten 1D5R 
cathepsin K 2R6N hdac1 homology modelling pyk2 3FZS 
cathepsin L 3HWN hdac2 homology modelling raf 3IDP 
cbp-p300a 1JJS hdac3 homology modelling srpk 1WBP 
cd20 3BKY hdac4 homology modelling stat1-s1 1BF5 
cdk2 2VV9 hdac6 homology modelling stat1-s2 1BF5 
cdk6 2F2C hdac7 homology modelling stratifin 1YWT 
cdk7 1UA2 hdac8 homology modelling survivin 2RAW 
cdk9 3BLQ hdac8b homology modelling tdp1 1RFF 
chk1 2QHN hmt 3HNA teta 2BTP 
chk2 2W7X hsp90 2WI6 tie2 2OO8 
ciap1 3D9U ido 2D07 topI 1K4T 
ciap2 3EB5 igf 3F5P topII 1ZXM 
ck2 3FL5 jak1 3EYG topII_atp 1QZR 
clk1 1Z57 jak2 3E64 tp 1UOU 
clk3 2WU6 jak3 1YVJ upa 2VIP 
cmet 2WGJ kit-kinase 3G0E vegfr1 1FLT 
ctl4 1I8L kras 3GFT vegfr2 3EWH 
cxcr4 2K05 lsd1 2EJR wee1 1X8B 
cyclA-cdk2 2IW9 mcl1 3D7V xrcc1 2W3O 
cyclin A 2WFY mdm2 3EQS zeta 1QJA 
dhfr 1PD8 mdmx 3EQY   
 Table 2.2 The panel of targets used in the pilot Inverse Virtual Screening study 
  




2.2.1 Analysis of Predicted Binding Energies 
The results of Inverse Virtual Screening were collected in different tables and 
initially sorted by single ligand vs. target, with the energies expressed in kcal/mol 
from the highest to the lowest values, in order to explore the possibility of identify 
ligands with good affinity and selectivity by evaluation of the predicted binding 
energies.
116
 The mere analysis of the binding energies highlighted a restricted 
group of targets selected with high values of predicted binding energies on a 
significant number of ligands tested, thus suggesting the use of a re-modulation of 
the results using a different criterion. 
 
2.2.2 Comparing Standard Ligands  
Accordingly, docking calculations of crystallized ligands, with a well-known 
binding mode, were performed in order to obtain a standard energy to be 
introduced as a filter in the evaluation of the binding energies of the matrix used. In 
general, in order to assess the efficiency of the docking experiments, the root-mean 
square deviations (RMSD, expressed in Å) of the docked conformations related to 
the crystallized ones were calculated. Choosing an exhaustiveness value of 16 for 
Autodock-Vina calculations and cutoff of 2 Å (an upper limit indicative of a good 
superimposition), 63% of the correlated structures within this range were identified 
(Table 2.3 and Figure 2.1).  
 
 
Figure 2.1 Distribution of RMSD for the 90 co-crystallized ligands in the PDB files docked with 
Autodock-Vina software. 
 
RMSD ≤ 2 Å
RMSD ≥ 2 Å
63 %
37 %




abllig 0.917 cathepsinGlig 2.157 epsilonlig 1.402 kraslig 1.527 pimkinlig 1.285 
abl2lig 0.906 cathepsinKlig 1.501 erk1lig 1.408 lsd1lig 2.467 plk1lig 2.670 
aiflig 1.416 cathepsinLlig 1.674 erk2lig 0.458 mcl1lig 9.474 poplig 0.800 
AKTlig 0.730 cd20lig 3.280 faklig 0.956 mdm2lig 9.524 ptenlig 0.854 
aurkinlig 0.729 cdk6lig 1.735 fgfr1lig 8.920 mdmxlig 5.776 pyk2lig 0.770 
bap1lig 1.619 cdk7lig 1.803 ftaselig 0.467 mek1lig 1.715 raflig 0.170 
bcl2lig 0.945  cdk9lig 3.034 galectin3lig 1.299 metap2lig 1.401 srpklig 7.934 
bcl2a1lig 2.215 chk1lig 0.951 galectin7lig 1.143 mmp13lig 0.946 stratifinlig 2.200 
bclwlig 2.146 chk2lig 0.350 gammalig 3.655 mmp3lig 2.040 tetalig 4.531 
bclxllig 7.838 ciap1lig 1.609 gsk3lig 0.805 mmp8lig 0.154 tie2lig 1.341 
braflig 0.410 ck2lig 0.837 gstp1lig 1.398 mrp1lig 4.235 topIlig 1.250 
calmodulinlig 6.137 clk1lig 0.307 hgfrlig 0.453 mtorlig 0.219 topIIlig 0.837 
caspase1lig 1.688 clk3lig 1.108 hmtlig 2.073 nnoslig 1.035 topII_atplig 2.563 
caspase2lig 5.858 cmetlig 1.025 idolig 0.541 nqo1lig 4.185 tplig 0.693 
caspase3lig 4.380 diaminooxlig 2.257 igflig 2.478 p38lig 1.247 upalig 0.919 
caspase7lig 2.372 dnmt3alig 1.974 jak1lig 0.331 pcaflig 15.307 vegfr2lig 0.399 
caspase8lig 2.270 dnmt3llig 2.729 jak2lig 1.135 pcnalig 10.441 wee1lig 0.330 
cathepsinBlig 1.992 egfrlig 1.256 kit_kinaselig 1.202 pgmlig 2.042 zetalig 2.250 
Table 2.3 Root mean square deviations (RMSD, expressed in Å) calculated between crystallized 
and docked conformations for the 90 ligands in complex with related targets in the PDB files. 
 
This procedure was initially assessed to 44 targets of the panel for which docked 
ligands (standards) complied with this requirement. In particular, the efficiency in 
the binding was evaluated through the ratio between the binding energies of the 
ligands and the standards, as indicated in Equation 2.1: 
 
                          
Equation 2.1 
Compounds showing a δ ≥ 1 were selected from the library.  
From this analysis, 335 associations between the ligands and the targets on 1892 
(43 ligands of the library × 44 targets investigated) calculations performed showed 
a δ ≥ 1, suggesting a consistent number of false positives.
116
 Careful analysis of the 
chemical structures highlighted a connection between high values of δ and high 
molecular weights of Libiomol ligands, especially when these were correlated to 
low molecular weights of standard ligands.  
Examples are the crystallized ligands (standards) for the targets pten (PDB code 
= 1D5R; standard C4H6O6, mw = 150.09 g/mol), tp (PDB code = 1UOU; standard 
C9H11ClN4O2, mw = 242.66 g/mol), clk1 (PDB code = 1Z57; standard C11H11N5O2, 
mw = 245.24 g/mol). 




This trend could be explained by considering the importance of molecular size 
in the predicted docking energy; in particular an increase of this parameter may 
influence the amount of van der Waals interactions representing an important factor 




2.2.3 Introducing Ligand Efficiency (LE)  
For the above considerations, subsequent analysis were performed considering 
the “ligand efficiency” of all the molecular structures. Ligand efficiency, a term 
that has recently attracted the attention of researchers involved in the drug 
discovery field, is generally defined as the binding energy of a ligand normalized 
by its size.  
Successful drug discovery involves the optimization of many variables, such as 
compound potency, selectivity, cellular activity, solubility, metabolic stability, 
bioavailability, and acceptable toxicity.  
Recently, the concept of ligand efficiency as a measure for lead selection was 
suggested. Ligand efficiency reduces the number of variables by combining 
potency with molecular weight and polar surface area, and it represents a 
particularly suitable parameter in the field of the drug discovery.   
This parameter is useful for effective and efficient drug discovery, and might 




The ligand efficiency depends on the size of the ligand, as smaller ligands have 
a higher efficiency than the larger ligands.  
One of the reasons behind this principle is the reduction in the area accessible to 
the ligand increasing the size of the ligand. These findings have important 
implications in the screening of libraries of compounds.  
 




Ligand efficiency is calculated using the Equation 2.2: 
 
           
Equation 2.2 
where N is the number of non-hydrogen atoms.
117
 
On this basis, we calculated the ligand efficiency of our database of compounds 
and for the standard ligands, and the results are reported as ratios between the 
values obtained for the ligands and the standards, as indicated in Equation 2.3: 
 
                                
Equation 2.3 
For each receptor considered, selected compounds were those complying with 
the following conditions (Equation 2.4): 
 
                  ≥ M + 3σ 
Equation 2.4 
where M is the average value of δLE for all the compounds and σ is the standard 
deviation (a value of 3σ was used in order to select the best results from this type of 
screening). 
Histograms associated to each target were drawn to assess the overall behavior 
of the compounds analyzed for ligand efficiency.
116
  
The trends observed for each target proved to be very similar, as shown in 
histograms related to a sample of 6 targets (Figure 2.2). In a matrix of 43 
compounds and 44 targets, the molecules with a low molecular weight showed the 





with 18 targets, 2-hydroxynephthenol
122
 in docking with eight targets, iodocionin
123
 




 in docking 




with 17 and 14 targets, respectively. The common targets for these compounds 
were abl2, akt, bap1, cathepsin B, cathepsin K, cdk6, egfr, mtor, and pyk2.  
The most important feature of this analysis is that small molecules with a better 




Figure 2.2 Histograms of δLE values for six target samples. On the x axis the id of the compound 
and on the y axis the δLE are reported. Also considering different y axis scales, it is clear the same 
distribution of δLE for the compounds investigated. 
 
Ligand efficiency is very important to establish limits in the building of new 
structures adapted on an active protein site, but the evaluation of this parameter 
was not considered a useful method of screening in this study. 
 
 




2.2.4 Normalization of the Matrix  
To overcome the lack of selectivity of the molecules chosen for the library to the 
panel of receptors, the binding energy (kcal/mol) data were organized in a matrix 
of 43 structures vs. the 126 targets of antitumor panel.  
The aim was to exclude the false positives through a mathematical filter aimed 
at eliminating systematic errors associated with molecules and targets in their 
interaction. 
To obtain the normalization of binding energy values in the matrix, Equation 2.5 
was applied: 
  
                         
Equation 2.5 
In this convention, V is the new value associated to each compound, V0 is the 
value of binding energy obtained from the docking calculation, ML is the average 
binding energy of each ligand (on different targets), and MR is the average binding 
energy associated to each target (on the various ligands). Every single value in the 
matrix representing a single ligand vs. a specific receptor was accordingly 
normalized taking simultaneously into account the influence of the two specific 
averages contained in Equation 2.5.
116 
 
In this case, the values obtained led to the creation of histograms showing a 
different trend on the individual compounds against every single target , as shown 
in Figure 2.3 for the same sample of targets shown previously in Figure 2.2.  
The molecules were selected through calculation of the standard deviation from 
the average of matrix (M); in particular the molecules were chosen up to the value 
of M + 3σ to classify compounds with the best interactions. Selected results are 
reported in Table 2.5.  
 






1 2 3 MR
a 
abl -7.5 -7.0 -7.9 -8.2 
abl2 -6.2 -6.1 -8.2 -7.5 
aif -9.4 -9.3 -8.1 -8.6 
akt -8.6 -8.2 -7.1 -8.0 
ape1 -6.6 -6.7 -5.7 -6.6 
aurkin -7.4 -7.0 -8.2 -8.2 
bap1 -6.0 -6.0 -6.7 -7.0 
bcl2 -7.9 -7.9 -6.9 -7.5 
bclxl -8.2 -8.0 -6.6 -7.4 
braf -8.6 -8.8 -7.6 -8.5 
calmodulin -6.6 -6.6 -5.7 -6.8 
caspase1 -5.7 -5.5 -4.6 -5.3 
caspase2 -5.2 -5.2 -4.9 -5.0 
caspase3 -7.2 -7.4 -6.4 -7.1 
caspase7 -8.4 -8.4 -6.8 -7.7 
caspase8 -6.9 -6.9 -6.3 -6.6 
cathepsin B -8.0 -7.9 -6.4 -6.9 
cathepsin G -7.7 -7.7 -6.5 -6.8 
cathepsin K -6.3 -6.5 -5.8 -6.1 
cathepsin L -6.4 -6.1 -5.9 -6.3 
cdk2 -8.5 -8.6 -7.8 -8.1 
cdk6 -7.9 -8.6 -6.9 -7.8 
cdk7 -8.9 -9.0 -7.8 -8.3 
cdk9 -8.3 -8.4 -6.1 -7.6 
chk1 -7.3 -7.4 -7.2 -7.3 
chk2 -6.2 -6.3 -8.7 -8.0 
ciap1 -5.9 -5.7 -5.6 -5.9 
ck2 -7.8 -7.9 -7.7 -8.1 
clk1 -7.6 -8.0 -7.8 -8.1 
clk3 -8.7 -9.1 -7.4 -8.5 
cmet -6.4 -6.5 -7.4 -7.6 
cyclin A -7.5 -7.5 -5.5 -6.4 
dhfr -8.5 -8.5 -7.4 -7.9 
ML
b -7.2 -7.2 -6.6   
     
Table 2.4 Values of Binding Energies for Three Sample Ligands and 33 Sample Targets 
(
a
Average of values for targets. 
b
Average of the values for ligands). 
  





Figure 2.3 Histograms related to the same six target samples reported in Figure 2.2 after 
normalization of predicted binding energies 
 
compounds targets V 
19 topI 1.418 




28 caspase2 1.409 
31 abl2 1.398 
41 mTor 1.438 
43 wee1 1.429 
Table 2.5 Selected compounds after normalization of the matrix 
Analysis of the tables confirmed the validity of the method. In particular, as 
reported in the literature, both camptothecin-7-carbaldehyde-O-3-hydroxypropyl-
oxime (19)
126
 (Figure 2.4 a) and camptothecin-7-methylene-O-tolyl-amine (20)
127
 
(Figure 2.4 b) are semisynthetic derivatives of the naturally occurring 




camptothecin, which in biological assays show an action on topoisomerase I.
128
 
They stimulate topoisomerase I-mediated DNA cleavage and the persistence of the 
cleavable complex; these compounds were evaluated for their cytotoxicity against 
the H460 human non-small lung carcinoma cell line, using topotecan as a reference 
compound (IC50 = 0.40 μM; topotecan 1.38 μM).
129
  
Topotecan and these compounds are very well overlapped in the pocket-
receptor, establishing many common interactions. From Figure 2.4 the accuracy of 
Autodock-Vina calculations on these two compounds on the panel of receptors in 
identifying the target of choice was clear. 
The two derivatives of camptothecin establish van der Waals interactions with 
the same residues of the pocket occupied by topotecan (Asn722, Lys 532, Asp533, 
Arg364), with Kd = 2.65 x 10
-9
 M (19) and Kd = 2.96 x 10
-10 
M (20). As a 
reference, the same Vina calculation has been performed on topotecan used as 





Figure 2.4 (a) Superimposition of topotecan (colored by atom type: O red, N blue, C 
grey)/camptothecin-7-carbaldehyde-O-3-hydroxypropyl-oxime (19) (colored by atom type: O red, N 
blue, C green) in docking with topoisomerase I (PDB code = 1K4T). (b) Superimposition of 
topotecan (colored by atom type: O red, N blue, C grey)/camptothecin-7-methylene-O-tolyl-amine 
(20) (colored by atom type: O red, N blue, C yellow) in docking with topoisomerase I.
130
 




Two other positive results were obtained in the calculated interactions, between 
the natural cytotoxic thiaplidiaquinone A
131
 (41)with the receptor mTor (PDB code 
= 3FAP) and the cytotoxic topopyrone C
132,133
 (43) with the receptor wee1 kinase 
(PDB code = 1X8B; Figure 2.5 a).
134
  
Topopyrone C is very well superimposed on a crystallized inhibitor reported in 
the literature on wee1 kinase (9-hydroxy-4-phenylpyrrolo[3,4-c]-carbazole-
1,3(2H,6H)-dione). It establishes van der Waals interactions with Ile305, Val313, 
Lys323, Ala326, Phe433, and Gly382, like the crystallized ligand, with a Kd = 1.35 
x 10
-9
 M, when compared with a Kd for the standard ligand of 5.81 x 10
-10
 M.  
Moreover, topopyrone C is a synthetic compound evaluated for its cytotoxicity 
against the H460 cell line, using topotecan as a reference compound (IC50 = 29.50 
μM; topotecan 1.38 μM). It induces the same sequence selectivity of topoisomerase 
I-mediated DNA cleavage shown by camptothecin derivatives.  
As reported in the literature on pharmacological assays, the interaction with 
topoisomerase I has been found.  
Topotecan and topopyrone C are very well overlapped in the pocket receptor 
(Figure 2.5 b); topopyrone C establishes van der Waals interactions with the same 
residues of the pocket occupied by topotecan (Asn722, Lys532, Asp533, and 
Arg364) with Kd = 2.65 x 10
-9
 M, while for topotecan the value is Kd = 3.34 x 10
-8
 
M. The high V value related to the interaction of 43 with TopI (V = 1.379) 
confirms these observations. 
To obtain confirmation of the proposed method, the table organized in a matrix 
has been integrated with the Autodock-Vina results on two standard known 
molecules as ligands of the targets abl2 (PDB code = 3HMI) and FTase (PDB code 
= 1LD8). Both ligands (5-amino-3-{[4-(aminosulfonyl)phenyl]amino}-N-(2,6-
difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide for abl2 and (20S)-
19,20,21,22-tetrahydro-19-oxo-5H-18,20-ethano-12,14-etheno-6,10-metheno-18H-




benz [d] imidazo [4,3-k] [1,6,9,12] oxatriaza-yclooctadecosine-9-carbonitrile for 
FTase) are as crystals in the corresponding PDB. Docking calculations of the two 
compounds were performed on all the target members of the panel. The aim was to 
verify that the two known ligands would show significant V values when 
interacting with their specific target.  
The candidate targets for these molecules were selected through calculation of 
the standard deviation from the average of matrix (M) choosing V values up to M + 
3σ to classify the targets with the best interactions.  
 
 
Figure 2.5 (a) Superimposition of 9-hydroxy-4-phenylpyrrolo[3,4-c]-carbazole-1,3(2H,6H)-
dione (colored by atom type: O red, N blue, H white, C yellow)/topopyrone C (colored by atom 
type: O red, N blue, H white, C cyan) in docking with wee1-kinase (PDB code = 1X8B). (b) 
Superimposition of topotecan (colored by atom type: O red, N blue, C violet)/topopyrone C (colored 










Figure 2.6 Interactions of the crystallized ligand of abl2 (colored by atom type: F green, O red, 
N blue, H and C grey) with nNos. 
 
For the crystallized ligand of abl2, two receptors were selected, namely, its 
receptor abl2 and nNos (PDB code = 3JT4). The structures obtained from Vina 
calculations for the abl2 ligand were very well superimposed to the crystallized 
compound, finding the same interactions with the receptor reported in 
www.pdb.org (Ligand Explorer). 
On the other hand, the good interaction of the same ligand with the receptor 
nNos (Figure 2.6) is due to common interactions with its known ligand (N-5-[(3-
(ethylsulfanyl)propanimidoyl]-l-ornithine).
135
 The molecule establishes van der 
Waals interactions with Phe584, Glu592, and Tyr588, and one H-bond with 
Gln478, as reported in the literature for the crystallized ligand, and is very well 
accommodated in the pocket of the receptor. Also, the structure obtained from Vina 
calculations for FTase ligand
136
 is well superimposed to the crystallized compound 
for this receptor, displaying analogous interactions.  
The data discussed above are useful to confirm the validity of the proposed 
computational method, and, besides the interactions with experimentally known 
targets, apparently discordant results are justifiable through careful analysis of the 




observed interactions and can open the way for the discovery or further inspections 
of the targets of interaction of bioactive compounds. 
  




2.3 Re-evaluation of the biological activity of a small library of 
natural compounds 
Starting from the encouraging results on the first pilot Inverse Virtual Screening 
study, we proposed an application of the Inverse Virtual Screening on a small set of 
phenolic natural compounds tested on a panel enlarged to 163 targets involved in 
the cancer processes (Table 2.6).  
The small library of molecules used in this second study consisted of 10 
compounds with a certain variability of the scaffolds (Chart 2.2) and included 
compounds extracted from various plants and widely examined for their different 
























































47. genistein 48. isoliquiritigenin 49. sinapic acid






















Chart 2.2 The library of 10 natural compounds used for the screening. 




protein PDB code protein PDB code protein PDB code 
abl 2HYY epsilon (14-3-3) 2BR9 mmp13 830C  
abl2 3HMI erbB2 1S78 mrp1 2CBZ 
aif 1M6I erbB4 2R4B msk1 3KN5 
akt1 3MVH erk1 2ZOQ mthfs 3HY3 
akt2 3D0E erk2 2OJG mTor 3FAP 
alk 2XP2 fak 3BZ3 mtsp1 3NCL 
alk5 2WOU fgf1 1HKN nek2 2XKF 
ape1 2ISI fgfr1 1AGW nek7 2WQN 
aurkin 2W1H fgfr2 2PVF nnos 3JT4 
aurkin B 2VGO ftase 1LD8 nqo1 2F1O 
bap1 2W15 galectin1 1W6M p300 3BIY 
bcl2a 2O21 galectin3 1KJL p38 3HEG 
bcl2a1 2VM6 galectin7 3GAL p53_mut 2X0V 
bcl6 3LBZ gamma (14-3-3) 2B05 parpa 2JVN 
bclwa 1ZY3 gsk3 3F7Z pcafa 2RNW 
bclxla 1BXL gstm2_2 3GUR pcna 1VYJ 
braf 3C4C gstp1 2A2R pd 3BIK 
btk 3PIX hdac1 homology modelling pdk1 3NAX 
calmodulin 3EWT hdac2 homology modelling peroxiredoxin hORF6 1PRX 
camKIIB 3BHH hdac3 homology modelling pgm 1YFK 
caspase1 2FQQ hdac4 homology modelling pi3k 3ENE 
caspase2 1PYO hdac6 homology modelling pig3 2J8Z 
caspase3 3EDQ hdac7 homology modelling pimKin 3JYA 
caspase7 1SHL hdac8 homology modelling pka 3L9L 
caspase8 1QTN hdac8b homology modelling pkcα 3IW4 
cathepsin B 1GMY hgfr (c-MET alternat) 2WD1 pkcθ 2JED 
cathepsin G 1AU8 hmt 3HNA plk1 3FVH 
cathepsin K 2R6N hsc70 3FZH pnk 2W3O 
cathepsin L 3HWN hsp90 2WI6 pop 3DDU 
cbpa 2RNY  hspa1a1 3JXU pten 1D5R 
cdk2 2VV9 hspa1l 3GDQ pyk2 3FZS 
cdk6 2F2C hspa2 3I33 raf 3IDP 
cdk7 1UA2 hspa5 3IUC ret 2X2K 
cdk9 3BLQ hspa6 3FE1 srpk 1WBP 
chk1 2QHN ido 2D0T stratifin (14-3-3-sigma) 1YWT 
chk2 2W7X igf 3F5P survivin 1XOX 
ciap1 3D9U irak4 2NRU syk 3FQH 
ck2 3FL5 jak1 3EYG tank1 2RF5 
clk1 1Z57 jak2 3.00E+64 tdp1 1RFF 
clk3 2WU6 jak3 1YVJ theta (14-3-3) 2BTP 
cmet 2WGJ jmjd3 2XXZ tie2 2OO8 
CPA 1CBX jmjd3_akg 2XXZ topI 1K4T 
CPU 3D67 kit-kinase 3G0E topII 1ZXM 
cSRC 3F3V kras 3GFT topII_atp 1QZR 
cxcr4a 2K05 lck 3AD4 tp 1UOU 
cyclin A (cdk2_altern) 2WFY lsd1 2EJR ts 1HVY 
dapk 3EH9 lyn 2ZVA upa 2VIP 
dhfr 1PD8 mcl1 3D7V vegfr1 1FLT 
diamineox 3HIG mdm2 3EQS vegfr2 3EWH 
dnmt3a 3A1B mdmx 3EQY wee1 1X8B 
dnmt3l 2QRV mek1 3DV3 xiap 1TFT 
e-cadherin 2O72 metap2 1YW9 zap70 1U59 
egfr 2J6M mk2 3M42 zeta (14-3-3) 1QJA 
EPHa3 3DZQ mmp3 1HY7   
 EPHb4 2X9F mmp8 2OY2   
 Table 2.6 The panel of 163 targets used  
  




The biological properties of these compounds were recognized and their 
involvement in metabolic disorders,
137





 and also in cancer prevention
140,141,142 
was largely demonstrated. 
The bioactivity of several of these compounds was noteworthy and in some cases 
the specific targets of interactions were already known. Moreover, the complexity 
of the pharmacological activity of a given compound could be often explained 
considering its capacity of interacting with more than one target.  
The chemopreventive activity of most of the compounds featuring these 
scaffolds was largely investigated and often proven by testing them on several 
cancer cell lines.
143,144
 This capacity was mainly attributed to their well-known 
antioxidant properties.
145
 However, many different actions on several targets 




In particular, compounds 45, 46, 48 and 53 belong to the class of chalcones, for 
which antioxidant, chemopreventive, anticancer, anti-inflammatory, antifungal and 
antibacterial activities are reported.
149
 
A number of chalcone derivatives have also been found to inhibit several 
important enzymes in cellular systems, including xanthine oxidase, aldose 
reductase, heme oxygenase, protein tyrosine kinase, quinine reductase and 
tyrosinase.
141 
Among chalcone derivatives, the prenylated chalcone xanthohumol 
(53) and its derivative isoxanthohumol (52) occurring in the cones of Humulus 
lupulus, have attracted a lot of attention because of their biological activities, 
among which a broad-spectrum antiinfective activity against several 
microorganisms.
150
 Xanthohumol (53) has been shown to inhibit the initiation, 








Recently, it was demonstrated that xanthohumol (53) decreases the viability of 
the T98G human malignant glioblastoma cell line. 
Apoptosis induced by xanthohumol is associated with activation of caspase-3, 
caspase-9, and PARP cleavage and is mediated by the mitochondrial pathway, as 
exemplified by mitochondrial depolarization, cytochrome c release, and 
downregulation of the antiapoptotic Bcl-2 protein. Moreover, xanthohumol induces 
intracellular reactive oxygen species (ROS), which provides a specific environment 
that results in MAPK-induced cell death.
152
  
The small library of selected antioxidative phenolic compounds comprises also 
sinapic acid (49), a cinnamic acid derivative, with anti-anxiety properties,
153
 
rosmarinic acid (50) exerting antiinflammatory, antimutagen, antibacterial and 
antiviral activities
154
 and resveratrol (51), the well known natural phytoalexin 
found in considerable amounts in the skin of grapes. In the last years resveratrol 
(51) has received a lot of attention because of its biological activities, as 
antimutagenic, antiviral, antiinflammatory, and cancer preventing. In particular it is 
believed that because of its antioxidant properties, resveratrol is responsible for the 
reduced risk of cardiovascular disease associated with a moderate consumption of 
red wine.
155,156 
Moreover the isoflavone genistein (47) showed a 
topoisomerase
149,157
 and tyrosine kinase
158
 activity.  
By considering the wide spectrum of activity of these compounds, a re-
evaluation of their biological properties may further clarify their modulatory 
activity in the cancer events. On the other hand, the phases of extraction and 
purification imply small quantities of compounds from natural sources and make 
complex the performance of biological tests on more than one target. In this 
context, Inverse Virtual Screening represents a useful tool for the re-evaluation 
and/or the identification of the specific interactions of the library of compounds 
here considered. 




Using the Inverse Virtual Screening approach we screened the library of 10 
compounds on a panel of 163 targets involved in the cancer progression and 
collected the results in a matrix. Then we normalized the predicted binding 
energies, using the Equation 2.5, as previously described: 
 
                         
Equation 2.5 
where V is the normalized value associated to each compound, V0 is the value of 
predicted binding energy obtained from the docking calculation (kcal/mol), ML is 
the average binding energy of each ligand (on different targets, kcal/mol), and MR 




It is noteworthy that V is an absolute number. This mathematical manipulation 
causes the loss of the original significance of the binding energy as a value for the 
prediction of activity of a given compound. The normalized values can be used to 
generate a ranking in which the best values represent a promising interaction 
between a compound and a target from the panel. Moreover, taking into account 
the average trends in the Equation 2.5
 
the selection of false positive results can be 
avoided,
113
 reminding that the main aim of this study is the identification of the 
targets interacting with a compound. 
 It is important to underline that the correspondence between the predicted and 
the calculated binding energies is much more difficult with respect to a classical 
Virtual Screening, in which only one target is studied, and mainly for two reasons. 
First, the comparison of the results for several targets even if normalized reduces 
but does not completely eliminate the problem of the variability of the interacting 
binding sites. In the second place, Autodock-Vina is a very fast and accurate 
software for the docking calculations, but in some cases a sensible deviation from 
the experimental results could be observed in the prediction of the binding 




energies. This could depend in a variable way also by the number of active 
rotatable bonds of the investigated compounds.
28 
 
The selection of the best results was so conducted sorting and analyzing the 
normalized results of the screening from the best to the worse value. We observed 
that the best two normalized results highlighted the correlation between 
isoxanthohumol (52) with PKC-α
160
 (Protein Kinase C α, V value=1.286, position 
nr.1 in the final ranking on 1630 total calculations) and xanthohumol (53) with 
PDK1
161
 (phosphoinositide-dependent kinase 1, V value=1.264, position nr.2 in the 
final ranking).  
Moreover, the presence in the panel of the PKC-θ
162
 isoform, characterized by a 
binding site related to PKC-α,
163
 prompted us to explore the behavior of 
isoxanthohumol (52) with this target. Interestingly, the normalized result 
(V=1.213) is at the significant position number 14. On the other hand the 
normalized results for 53 indicated a poor value of V for PDK1 (V=0.982, position 
number 921).  
 
  44 45 46 47 48 49 50 51 52 53 MR 
abl -8.4 -8.5 -9 -9.8 -9.1 -6.7 -8.9 -9.1 -7.6 -9 -8.6 
abl2 -8.3 -8.2 -7.7 -8.3 -8.8 -7 -9.8 -8.8 -6.9 -9.1 -8.3 
aif -8.7 -8.6 -8.5 -8.4 -8.7 -6.7 -8.7 -8.2 -9.1 -9.6 -8.5 
akt1 -8.5 -8 -7.8 -7.8 -8.2 -6.3 -8.3 -7.4 -8.7 -8.3 -7.9 
akt2 -8.1 -8.1 -7.6 -8.2 -8 -6.4 -8.7 -7.5 -8.6 -7.7 -7.9 
alk -7.4 -6.7 -6.2 -7.7 -7.1 -5.6 -7.2 -6.6 -7.7 -7.5 -7 
alk5 -8.1 -7.3 -7.7 -8.3 -8.2 -6.4 -8.8 -7.8 -8.5 -8 -7.9 
ape1 -6.9 -6.4 -6.1 -7.3 -6.9 -5.5 -6.8 -6.8 -7.1 -6.6 -6.6 
aurkin -9 -8 -8 -8.7 -8.4 -6.7 -8.7 -8.5 -9.7 -8.5 -8.4 
aurkinB -7.7 -7.2 -7.1 -7.8 -7.7 -5.7 -7.1 -7 -7.8 -7.3 -7.2 
Other targets                       
            
ML -7.7 -7.2 -7.1 -7.6 -7.5 -5.9 -7.8 -7.1 -7.8 -7.6 
  
Table 2.7 Predicted binding energies (V0, kcal/mol), MR and ML average values for a sample of 
10 ligands on 30 targets for the calculations of the V normalized values. 
 
 




For what concerns 53, while the normalized value and the related position in the 
ranking showed a good predicted activity for PDK1, poor results are observable for 
PKC-α and PKC-θ (positions 892 and 563, respectively). In Table 2.8 the values of 
V and the positions in the final ranking for 52 and 53 with PDK1, PKC-α and 
PKC-θ are reported.  
These targets identified from the screening play a fundamental role in the 
progression of the tumour events,
164,165,166
 and new inhibitors are searched for the 
development of new anti-cancer agents. For these reasons, in the next phase we 
validated these preliminary observations with in vitro biological tests (Table 2.9). 
 
 PDK1 PKC-α PKC-θ 
52 0.982 (921) 1.286 (1) 1.213 (14) 
53 1.264 (2) 0.986 (892) 1.038 (563) 
 
Table 2.8 V normalized values for 52 and 53 on PDK1, PKC-α and PKC-θ targets. On 
parenthesis are shown the relative positions in the final ranking on the 1630 total calculations. 
 
  PDK1 PKC-α PKC-θ 
52 58.7  μM 45.3 μM 31.6 μM 
53 6.6  μM > 100μ M > 100 μM 
 
Table 2.9 IC50 values for 52 and 53 on PDK1, PKC-α and PKC-θ targets. 
 
In order to validate the efficacy of the screening also negative controls were 
considered in this phase (52 on PDK1, 53 on PKC-α and PKC-θ). Regarding the 
most promising results, we observed that these compounds confirmed our 
predictions, showing an inhibitory activity in the μM range. In more detail, 
xanthohumol (53) show a best activity and selectivity on PDK1 (6.6 μM). 
Moreover, IC50 value calculated for 53 on PKC-α and θ isoforms show no 
inhibitory activity at concentrations as high as 10
-4
 M and this is in perfect 




agreement with the normalized results from the screening. Isoxanthohumol (52) is 
active (less than the previous result) and not selective on PKC-α and θ confirming 
the selection of the related good positioning from the final ranking. Surprisingly a 
moderate activity of 52 on PDK1 was highlighted, in spite of the low V value 
(0.982) and of the low position in the ranking (921). It is important to observe that 
the best V value found is 1.286, and this means that in this case 921 interactions 
out of 1630 total calculation are found within a restricted difference of V values of 
0.304.  
Firstly, we wondered whether this lack of sensibility of the approach to avoid a 
false negative result was caused by the normalization of the affinities. In this 
context, the range from the best to the worse value for the normalized binding 
energies and for the predicted binding energies before the normalization (RangeV 
and RangeBE, respectively, Equation 2.6) was considered: 
 
                                                        –                  
               
Equation 2.6 
For the interaction of 52 on PDK1, we calculated the deviations of the V value 
and of the predicted binding energy from the best ones (Equation 2.7). 
 
                                                         
Equation 2.7 
Where Vbest and BEbest are the best values of V and predicted binding energies 
for the 1630 total calculations, and V52-PDK1 and BE52-PDK1 are the V and the 
predicted binding energies values for the interaction of 52 with PDK1. 
Then we divided the these two deviations for the two ranges for the two types of 
calculation (Equation 2.8). 




              
           
      
                   
            
       
 
Equation 2.8 
These parameters indicated the nearness of the two values for the interaction of 
52 with PDK1 to the best ones in the two rankings. We found two very similar 
values (RatioV52-PDK1 = 0.41; RatioBE52-PDK1 = 0.40). We can conclude that this 
unexpected result strongly depends from the original value of predicted binding 
energy.  
Moreover, it is important to note that the evaluation of the binding energies 
before the normalization do not allow the selection of this false negative. 
Furthermore, we can observe a low value of DevBE52-PDK1 that corresponds in an 
overcrowding of many values better than BE52-PDK1 in a restricted range, as we 
have initially observed for the normalized values.  
This means that low variations of the values of predicted binding energies may 
cause large variations in the two final rankings. For these reasons, in an Inverse 
Virtual Screening study the choice of the parameters that can affect the estimation 
of the calculated affinities (i.e the protein preparation, the exhaustiveness values 
and the grid boxes for Autodock-Vina) is of primary importance.  
Accordingly, as we have previously demonstrated that in other case,
113,115
 the 
normalization could be a useful tool to avoid false positive and negative results.  
In order to give a further validation the method, we performed a similar study 
using another library of 10 compounds able to bind 10 targets in the panel of 163 
targets with high efficacy. We chose these compounds considering the availability 
of the crystallographic structures of the complexes with the partner receptors. 
Also in this case we obtained a matrix of 1630 calculations and then we 
normalized them. In Table 2.10 are listed the V values, the positions in the ranking, 
the experimental and predicted values of IC50 for the 10 compounds with their 
specific targets. 




Reference ligands V (positions in the ranking) Exper IC50* Predicted affinities 
ABL_lig 1.421 (4) 170.0 nM 0.35 nM 
ALK5_lig 1.145 (168) 72.0 nM 65 nM 
CK2_lig 1.446 (3) 52.0 nM 5.2 nM 
CLK3_lig 1.062 (451) 29.2 nM 129 nM 
JAK1_lig 1.097 (304) 1.6 nM 497 nM 
PDK1_lig 1.585 (1) 1.0 nM 0.0085 nM 
PKC-α_lig 1.230 (38) 2.1 nM 6.2 nM 
PKC-θ_lig 1.341 (8) na 1.35 nM 
RAF_lig 1.495 (2) 1.6 nM 0.055 nM 
TP_lig 1.115 (242) 20.0 nM 1160 nM 
Table 2.10 V values, positions in the ranking, the experimental IC50 and predicted affinities for 
the 10 reference compounds with their specific targets; *Values extracted from the papers related to 
the PDB codes listed in Table 2.6 
 
For the listed compounds Autodock-Vina found the crystallographic poses with 
high accuracy (RMSD < 2 Å), and so the predicted binding energies could be 
related to the experimental ones. Also in this case, using the Inverse Virtual 
Screening approach we can highlight that four right correlations between ligands 
and targets are found in the first four positions, a fifth is identified in the first eight 
positions, and a sixth in the first thirthyeight.  
The remaing four correct correlations are found far from the high ranking 
positions, so resulting as false negative mainly for their lower values of predicted 
binding energies.  
The availability of the ligands crystallized in the binding sites of the targets 
PDK1, PKC-α, and PKC-θ and active in the nM range allowed a more precise 
comparison with the V values calculated for the compounds 52 and 53 emerging 
from the screening. We built a third matrix for the 163 targets interacting with 52, 
53, (μM range of activity on the targets identified) PDK1_lig, PKC-α_lig, and 
PKC-θ_lig (nM range of activity on their related targets).  
In Table 2.11 are reported the V values for 52 and 53 on the three targets 
compared with the V values of the reference compounds. 
 




 52 53 Reference compounds 
PDK1 0.898 1.154 1.529 
PKC-α 1.147 0.878 1.235 
PKC-θ 1.050 0.897 1.291 
 
Table 2.11 V values for 52, 53, PDK1_lig, PKC-α_lig and PKC-θ_lig on PDK1, PKC-α and 
PKC-θ targets. 
 
In this way a more precise and accurate correspondence between the V values 
and the experimental IC50 was found. Above all, these new scale of values also 
justified the moderate activity of the compounds 52 and 53 on the three kinases. 
In summary, while the normalization method could reduce the possibility of 
selection of false positive and negative results, the comparison with the the V 
values of reference compounds could give qualitative indications for the prediction 
of the range of activity for a given set of compounds. In particular, for compounds 
44-53, five predictions of activity on six actually fitted with the biological tests. 
Finally, an accurate analysis of the main interactions of the compounds selected 
from the screening in the binding sites of the different targets allows an explanation 
of the different activity and selectivity of the different compounds on the panel of 
targets used. The best pose from the docking calculations for each compound on 
the three specific targets was considered in this phase.  
Regarding the xanthohumol (53) case we observed a very good occupancy of the 
binding site of PDK1. As illustrated in Figure 2.7 a, 53 is able to establish a set of 
hydrophobic and electrostatic interactions in the binding pocket composed by 
Val96, Tyr126, Met134, Phe142, Val143, Leu159, and Phe224. It also involved in 
two Hydrogen bonds with the nitrogen in the side chain of Lys111 (with the 
oxygen of the -OCH3 in 6’position) and with the nitrogen in the backbone of the 
Asp223 (with the –OH in 2’ position). Moreover, the isopentenyl portion of the 
compound is accommodated in an internal hydrophobic pocket of PDK1. A good 




superposition between 53 and 1- (3,4- difluorobenzyl) -2-oxo-N- { (1R)-2- [(2-oxo-
2,3-dihydro-1H-benzimidazol-5-yl)oxy] -1-phenylethyl} -1,2-dihydropyridine-3-
carboxamide crystallized in the binding site of PDK1
161
 could be considered as a 
further confirm (Figure 2.7 b). The two phenil portions of 53 are overlapped to two 
aromatic portions of the crystallized ligand, respecting their distances and 
orientations. For what concerns the interactions between isoxanthohumol (52) and 
PDK1, we can primarily observe a most external occupancy of the binding site than 
the xanthohumol (53) and an inversion of the aromatic ring presenting the 
isopentenyl part, that in this case is oriented on the external face of the binding site. 
The different accommodation of the two compounds and of their pharmacophoric 
portions in a more deep position of the PDK1 binding site could explain the 
different activities on this target (Figure 2.8). The binding pocket of PDK1 
involved in the interactions with 52 is composed by Leu88, Gly89, Ala109, 
Val143, Leu159, Glu166, Leu212, Thr222 and Phe224. A Hydrogen bond is 
established between the oxygen of the carbonyl in position 4 of 52 and the nitrogen 
in the backbone of Ala162 (Figure 2.9a). The analysis of the docked structures of 
52 with the PKC (α and θ isoforms) revealed the accommodation of the compound 
in the binding sites mainly through hydrophobic interactions. In fact, in the case of 
the α isoform the compound interacts with the following residues: Leu345, Phe350, 
Val353, Ala366, Thr401, Met417, Tyr419, Val420, Ala480 and Asp481. A 
hydrogen bonds is also observable between the nitrogen in the backbone of Val420 
and the oxygen in position 4 of the carbonyl of 52 (Figure 2.9 b). On the other 
hand, the best binding pose in the binding site of PKC-θ isoform show the 
involvement of a pocket of residues composed by Leu386, Phe391, Val394, 
Ala407, Thr442, Met458, Ala521, Asp522 and Phe664. Also in this case, a 
hydrogen bond is established between the nitrogen in the backbone of the Leu461 
and the 4-carbonylic oxygen of 52 (Figure 2.9c).  




We considered this theoretical ipothesis of binding modes reliable for two 
reasons. In the first place. the good result from the biological tests could be 
considered as an experimental proof of the binding of 52 and 53 in these specific 
sites of action. Moreover, these compounds shows a simple chemical structure 
mainly characterized by a small number of aromatic rings and of active rotatable 
bonds. 
In these conditions Autodock-Vina software shows an high accuracy of the 
prediction of the experimental crystallographic poses, with low RMSD values 
compared to the predicted ones. For these reasons these results could be considered 
as reasonable models of binding. 
  





Figure 2.7 a) 53 (coloured by atom types: C green, H grey, O red) in docking with PDK1. 
Hydrogen bonds are displayed with green spheres; b) Superimposition between 53 (coloured by 
atom types: C green, H grey, O red) and 1-(3,4-difluorobenzyl)-2-oxo-N-{(1R)-2-[(2-oxo-2,3-
dihydro-1H-benzimidazol-5-yl)oxy]-1-phenylethyl}-1,2-dihydropyridine-3-carboxamide (coloured 
by atom types: C dark grey, H grey, O red, N blue) with PDK1. 
 
 
Figure 2.8 Superimposition between 52 (coloured by atom types: C yellow, H grey, O red) and 
53 (coloured by atom types: C green, H grey, O red) in the binding site of PDK1. 
 
Figure 2.9 52 (coloured by atom types: C green, H grey, O red) in docking with: a) PDK1; b) 
PKC-α; c) PKC-θ. Hydrogen bonds are displayed with green spheres. 
  




2.4 Discovery of peptidase inhibitory activity of the new-
anabaenopeptin cyclopeptide namalide. 
The diversity of natural products coming from marine invertebrates and 
possessing interesting biological activities has been well-documented, yet 
discovery of new compounds and their associated modes of action continues 
apace.
167
 To mention only a few examples, marine natural products that can inhibit 




 and bacterial cell 
division
173
 have been reported. Here the identification and Fmoc-based solid phase 
synthesis of a new ureido-containing cyclic peptide, namalide (54), and its potent 
inhibitory activity on carboxypeptidase A (CPA) is described. Namalide was 
isolated from the same collection of the marine sponge Siliquariaspongia mirabilis 
that provided the anti-HIV lipopeptides mirabamides A−D,
174
 the antitumor 
polyketide mirabalin,
175
 and the known antifungals aurantosides A and B.
176
 
Namalide represents a new anabaenopeptin-type scaffold possessing a 13-
membered macrolactam core.  
Previously, the discovery of three separate classes of natural products coming 
from the aqueous extract of a single collection of the marine sponge S. mirabilis 
was reported.
174,175,176
 Mirabamides, mirabalin, and aurantosides were isolated from 
the n-BuOH fraction of the aqueous extract after fractionation on a Sephadex LH-
20 column eluting with MeOH, followed by HPLC purification. During these 
studies, a separate group of Sephadex fractions containing what appeared to be a 
novel compound on the basis of its molecular weight (ESI-MS) was detected. In 
addition, these fractions showed strong inhibition of the enzyme CPA. Active 
fractions were combined and purified by C12 RP-HPLC to give just 0.4 mg of the 
active compound (∼90% pure), a new natural product named namalide (54, Figure 
2.10). Combining HR-ESI-MS and 2D NMR experiments (HSQC, HMBC, 
HOHAHA, ROESY and DQF-COSY) a structural characterization of 54 was 




determined. In particular, the molecular formula requires 54 to be a cyclic peptide 
and ROESY experiments indicated that 54 comprised a three-residue macrocycle 
N-linked to an exocyclic Phe residue via a ureido bridge.  
 
 
Figure 2.10 Structure of namalide (54) (left) and key HMBC and ROE correlations (right). 
 
The absolute configurations of the alpha carbons for both Phe residues and Ile 
were readily established as L from LC-MS analyses of the L- and D-FDLA (1-
fluoro-2,4-dinitrophenyl-5-L/ D-leucinamide) derivatives
177
 of an acid hydrolysate 
of 54, in conjunction with comparison of retention times with authentic standards. 
However, because of our limited material or the limitations of the method, this 
analysis did not allow us to assign confidently the configuration of the Lys residue 
and C-3 of Ile. It is worth noting that although all anabaenopeptin-type compounds 
derived from cyanobacteria contain D-Lys exclusively,
178,179
 peptides reported to 
contain L-Lys rather than D have been isolated from marine sponges.
180,181,182,183
 
To address these unknowns and provide additional compound for biological 
screening, a synthetic route to provide namalide and its stereoisomers was 
developed. ticle 
To establish configurations at C-3 of Ile and C-2 of Lys, two additional 
namalide analogs containing L-Ile/L-Lys and L-allo-Ile/D-Lys (56, 57, Figure 
2.11) were synthesized. Comparisons of the NMR spectra and RP-HPLC retention 
times of the three synthetic peptides 54, 56, and 57 with that of the natural product 








Figure 2.11 Synthetic namalide analogs.  
 
Members of the anabaenopeptin
184
 family of cyclic peptides are known to inhibit 
carboxypeptidases and other proteases.
185,186,187,188
 Although a high resolution 
structure of an anabaenopeptin-type peptide in complex with any carboxypeptidase 
has not been determined, selectivity profiles of natural products and synthetic 
analogs provide good evidence that the C-terminal ureido amino acid confers 
specificity toward different proteases.
188,189
 Peptides 54, 55, and 56−59 (Figure 
2.11) were evaluated as inhibitors of bovine pancreas CPA using N-(4-
methoxyphenylazoformyl)-phenylalanine as a colorimetric substrate in a 96-well 
plate format. The results are summarized in Table 2.12.  
The synthetic version of natural namalide (54) containing D-Lys and L-Ile was 
the most potent inhibitor of CPA with an IC50 value of 250 ± 30 nM. Peptide 56, 
the corresponding L-Lys analog, was inactive at concentrations as high as 30 μM, 




and analog 57 bearing L-allo-Ile/D-Lys appeared to be inactive, although its 
insolubility yielded poor assay results. The linear version of namalide, 58, showed 
an 18-fold reduction in activity relative to 54 with an IC50 value of 4.5 μM. In 
contrast cyclic tripeptide 59, which lacks the C-terminal exocyclic ureido Phe, and 
the namalide dimer 55 were inactive.  
For comparison, compounds 54, 56, 58, and 59 were tested against 
carboxypeptidase U (CPU), also known as activated thrombin-activable fibrinolysis 
inhibitor (TAFIa), an enzyme known to recognize C-terminal basic amino acids in 
its S1 pocket, 25 and α-chymotrypsin, a serine protease that recognizes aliphatic 
and aromatic amino acids.
190
  
None of these peptides inhibited either enzyme at concentrations as high as 60 
μg/mL. Together, these results demonstrate the importance of the lysine 
configuration for CPA inhibition in this new tricyclic peptide scaffold. The lack of 
inhibitory activity of the des-ureido-Phe analog 59 further suggests that namalides 
may inhibit through a similar mode of binding as the larger anabaenopeptin-type 
compounds. 
 
Peptide IC50 (M) 




58 4.5 ± 0.9 
59 nab 
 
aTested in duplicate; bnot active at 30 M; 
cinsoluble 
Table 2.12 Inhibition of carboxypeptidase A. 
 
Because namalide represents a new natural product scaffold, we were interested 
in applying our recently described Inverse Virtual Screening in silico approach
113
 
using Autodock Vina software
28
 to assist in identifying other possible new targets 




of namalide. For docking calculations, a 3-D model of namalide was prepared by 
performing combined Monte Carlo conformational searches and Molecular 
Dynamics simulations, followed by energy and geometry minimization of the 
obtained structure. When this study was performed, the minimized model was used 
against a panel of 159 receptors involved in cancer processes and whose 
coordinates were extracted from the Protein Data Bank (Table 2.13).  
For normalization of the results, a prebuilt matrix containing the affinity values 
of a library of 22 natural compounds (used as “blanks”) with structural and 
molecular weight properties similar to those of 54 was employed.  
In particular, we calculated an average value of binding energy for each target 
receptor on all of the compounds in the matrix and then normalized the affinity 
values of 1 using the Equation 2.9: 
 
        
Equation 2.9 
where V is the normalized value of binding energy, V0 is the value of binding 
energy before the normalization, and VR is the average value of binding energy for 
each targets. We were gratified to find that of the 159 proteins screened, CPA was 
identified as the third best hit on the basis of normalized binding energy (Table 
2.14).  
The top two hits corresponded to galectin 7 and calmodulin (CaM). Inspection 
of the docked models showed 54 to be located in the galactose binding site of 
galectin 7, anchored through the exocyclic Phe residue (Figure 2.12), and in an 
extensive hydrophobic channel in CaM, making only partial contacts with this site 
(Figure 2.13). Because these interactions were not optimal relative to the known 
ligands, we did not pursue them further. 
 




protein PDB code protein PDB code protein PDB code 
abl 2HYY egfr 2J6M mk2 3M42 
abl2 3HMI EPHa3 3DZQ mmp3 1HY7 
aif 1M6I EPHb4 2X9F mmp8 2OY2 
akt 3D0E epsilon 2BR9 mmp13 830C 
akt1 3MVH erbB2 1S78 mrp1 2CBZ 
alk 2XP2 erbB4 2R4B msk1 3KN5 
alk5 2WOU erk1 2ZOQ mthfs 3HY3 
ape1 2ISI erk2 2OJG mTor 3FAP 
aurkin 2W1H fak 3BZ3 mtsp1 3NCL 
aurkin B 2VGO fgf1 1HKN nek2 2XKF 
bap1 2W15 fgfr1 1AGW nek7 2WQN 
bcl2a 2O21 fgfr2 1EV2 nnos 3JT4 
bcl2a1 2VM6 ftase 1LD8 nqo1 2F1O 
bcl6 3LBZ galectin1 1W6M p38 3HEG 
bclwa 1ZY3 galectin3 1KJL p53_mut 2X0V 
bclxla 1BXL galectin7 3GAL parpa 2JVN 
braf 3C4C gamma 2B05 pcafa 2RNW 
btk 3PIX gsk3 3F7Z pcna 1VYJ 
calmodulin 3EWT gstm2_2 3GUR pd 3BIK 
camKIIB 3BHH gstp1 2A2R pdk1 3NAX 
caspase1 2FQQ hdac1 homology modelling peroxiredoxin 1PRX 
caspase2 1PY0 hdac2 homology modelling pgm 1YFK 
caspase3 3EDQ hdac3 homology modelling pi3k 3ENE 
caspase7 1SHL hdac4 homology modelling pimKin 3JYA 
caspase8 1QTN hdac6 homology modelling pka 3L9L 
cathepsin B 1GMY hdac7 homology modelling plk1 3FWH 
cathepsin G 1AU8 hdac8 homology modelling pop 3DDU 
cathepsin K 2R6N hdac8b homology modelling pten 1D5R 
cathepsin L 3HWN hgfr 2WD1 pyk2 3FZS 
cbpa 2RNY  hmt 3HNA raf 3IDP 
cd20 3BKY hsc70 3FZH ret 2X2K 
cdk2 2VV9 hsp90 2WI6 srpk 1WBP 
cdk6 2F2C hspa1a1 3JXU stratifin 1YWT 
cdk7 1UA2 hspa1l 3GDQ survivin 2RAW 
cdk9 3BLQ hspa2 3I33 syk 3FQH 
chk1 2QHN hspa5 3IUC tank1 2RF5 
chk2 2W7X hspa6 3FE1 tank2 3KR8 
ciap1 3D9U ido 2D07 tdp1 1RFF 
ck2 3FL5 igf 3F5P teta 2BTP 
clk1 1Z57 irak4 2NRU tie2 2OO8 
clk3 2WU6 jak1 3EYG topI 1K4T 
cmet 2WGJ jak2 3.00E+64 topII 1ZXM 
CPA 1CBX jak3 1YVJ topII_atp 1QZR 
CPU 3D67 kit-kinase 3G0E tp 1UOU 
cSRC 3F3V kras 3GFT ts 1HVY 
cxcr4a 2K05 lck 3AD4 upa 2VIP 
cyclin A 2WFY lsd1 2EJR vegfr1 1FLT 
dapk 3EH9 lyn 2ZVA vegfr2 3EWH 
dhfr 1PD8 mcl1 3D7V wee1 1X8B 
diamineox 3HIG mdm2 3EQS xiap 1TFT 
dnmt3a 3A1B mdmx 3EQY xrcc1 2W3O 
dnmt3l 2QRV mek1 3DV3 zap70 1U59 
e-cadherin 2O72 metap2 1YW9 zeta 1QJA 
Table 2.13 The panel of 159 targets used in the study on namalide  




Position in the 
ranking 
Targets V values 
Position in the 
ranking 
Targets V values 
Position in the 
ranking 
Targets V values 
1 calmodulin 1.267 54 pd 1.047 107 peroxiredoxin 0.954 
2 galectin7 1.221 55 EPHa3 1.045 108 tie2 0.950 
3 CPA 1.218 56 galectin3 1.045 109 aurkin 0.948 
4 bclw 1.193 57 cathepsinK 1.044 110 ck2 0.948 
5 lsd1 1.190 58 hdac3 1.044 111 clk3 0.946 
6 bcl6 1.182 59 erk2 1.037 112 egfr 0.942 
7 bcl2a1 1.166 60 mrp1 1.037 113 topI 0.941 
8 stratifin 1.159 61 nqo1 1.035 114 xrcc1 0.932 
9 mcl1 1.153 62 plk1 1.032 115 mmp3 0.924 
10 caspase7 1.150 63 mthfs 1.032 116 cyclinA 0.923 
11 vegfr1 1.149 64 ape1 1.029 117 pi3k 0.921 
12 bclxl 1.149 65 caspase2 1.023 118 cathepsinB 0.921 
13 mtor 1.137 66 fgf1 1.021 119 tank1 0.920 
14 survivin 1.133 67 pcaf 1.018 120 cdk9 0.919 
15 tdp1 1.132 68 lck 1.016 121 ts 0.917 
16 caspase3 1.125 69 cSRC 1.011 122 hspa5 0.908 
17 mdmx 1.118 70 hdac6 1.011 123 alk 0.908 
18 hsc70 1.117 71 parp 1.009 124 cdk2 0.907 
19 e-cadherin 1.116 72 nek7 1.008 125 pten 0.907 
20 ido 1.113 73 tank2 1.008 126 galectin1 0.897 
21 srpk 1.110 74 hspa1a 1.007 127 vegfr2 0.895 
22 caspase1 1.110 75 hdac8b 1.005 128 clk1 0.894 
23 kras 1.107 76 AKT 1.005 129 topII_atp 0.892 
24 p38 1.095 77 dnmt3a 1.004 130 msk1 0.888 
25 nnos 1.092 78 caspase8 1.003 131 zap70 0.886 
26 xiap 1.090 79 topII 1.002 132 pgm 0.879 
27 ftase 1.088 80 bap1 1.002 133 jak3 0.878 
28 mtsp1 1.088 81 hdac2 0.999 134 gsk3 0.876 
29 erbB2 1.087 82 zeta 0.999 135 jak2 0.875 
30 cd20 1.081 83 bcl2 0.995 136 dhfr 0.874 
31 gstm2_2 1.080 84 hspa6 0.994 137 EPHb4 0.870 
32 tp 1.078 85 pyk2 0.993 138 ret 0.867 
33 cathepsinL 1.076 86 cathepsinG 0.989 139 erk1 0.867 
34 pop 1.076 87 p53_mut 0.988 140 fak 0.855 
35 mdm2 1.075 88 epsilon 0.984 141 pimkin 0.845 
36 aif 1.072 89 upa 0.983 142 camKIIB 0.844 
37 lyn 1.070 90 cmet 0.983 143 hspa2 0.844 
38 syk 1.069 91 raf 0.982 144 mmp8 0.842 
39 ciap1 1.067 92 dnmt3l 0.982 145 fgfr1 0.839 
40 hdac8 1.066 93 mk2 0.981 146 chk1 0.823 
41 hdac7 1.066 94 pcna 0.975 147 irak4 0.809 
42 hsp90 1.066 95 mmp13 0.973 148 cdk6 0.806 
43 aurkinB 1.065 96 btk 0.973 149 CPU 0.800 
44 teta 1.064 97 pdk1 0.970 150 wee1 0.794 
45 hspa1l 1.060 98 cxcr4 0.969 151 abl2 0.786 
46 igf 1.059 99 diaminoox 0.968 152 dapk 0.772 
47 akt1 1.056 100 cbp 0.968 153 jak1 0.767 
48 gamma 1.054 101 metap2 0.965 154 erbB4 0.766 
49 abl 1.053 102 nek2 0.964 155 braf 0.751 
50 hdac4 1.053 103 gstp1 0.964 156 alk5 0.732 
51 hdac1 1.051 104 hmt 0.963 157 chk2 0.695 
52 fgfr2 1.050 105 cdk7 0.962 158 pka 0.624 
53 kit_kinase 1.048 106 mek1 0.955 159 hgfr 0.582 
Table 2.14 Normalized V values related to compound 54 





Figure 2.12 Superposition between 54 (yellow) and galactosamine (colored by atom type: C 
grey, O red, N blue and H light grey) in the Galectin7 binding site of sugars. 
 
 








As shown in Figure 2.14, a refined molecular docking model of 54 to CPA using 
Autodock 4.2
27
 software places the C-terminal carboxylate in close proximity to 
the Zn
2+
 atom and within hydrogen bonding distance with the guanidine groups of 
Arg 127 and Arg 145, key residues in the active site and specificity pocket of 
CPA
190,191
 as well as the side chain of Asn 144. Additional interactions are seen 
between the amide of Ile and the hydroxyl of Tyr 248. Similarly, the ureido group 
is involved in electrostatic interactions with Arg 127 and Tyr 248. Despite its 
reduced size relative to the pentapeptide core of anabaenopeptins, both electrostatic 
and aliphatic interactions are observed between CPA and residues in the cyclic 
portion of 54 in the docked model. In particular, the side chain of D-Lys is 
positioned close to Phe 279, and the amide of Ile is hydrogen-bonded to the -OH of 
Tyr 248.  
 
 
Figure 2.14 Docked model of 54 to CPA. Protein is shown as a gray surface, Zn
2+
 atom is 
shown as a magenta sphere, and residues in contact with 54 are shown as yellow (C atoms), blue (N 
atoms), red (O atoms),and gray (H atoms) sticks; namalide (54) is rendered as green (C atoms), blue 
(N atoms), red (O atoms), and gray (H atoms) sticks and balls. 
 




Consistent with other models and the biological activity, the C-terminal Phe is 
directed toward the hydrophobic specificity pocket formed in part by Ile247, Tyr 
248, and Ala 250, and is well superimposed with the similar moieties in the 
chemical structure of the crystallized inhibitor L-benzylsuccinate (Figure 2.15). 
 
 
Figure 2.15 Superposition between 54 (colored by atom type: C grey, O red, N blue and H light 
grey) and the crystallized inhibitor L-benzylsuccinate (green). Zn
2+
 is as a magenta sphere. 
 
To investigate the specificity of namalide for CPA, we performed molecular 
docking of 56, the L-Lys-containing analog, to CPA and of 54 to CPU using the 
same protocol as above. In the lowest energy model of 56 bound to CPA, 
interactions between the exocyclic Phe and its carboxylate group with CPA are 
preserved. However, the inverted configuration of Lys results in a flipping of the 
ring that moves the ureido group far from the Zn
2+
 atom and reduced interactions 
between the ring amino acids and CPA (Figure 2.16 and Figure 2.17). 





Figure 2.16 Docked model of 56 to CPA. Protein is shown as a grey surface, Zn
2+
 atom as a 
magenta sphere, and residues in contact with 56 as grey (C atoms), blue (N atoms), red (O atoms), 
light grey (H atoms) sticks; 56 is rendered as yellow (C atoms), blue (N atoms), red (O atoms), light 
grey (H atoms) sticks and balls. Hydrogen bonds are displayed as green spheres. 
 
 
Figure 2.17 Superposition between 54 (colored by atom type: C green, O red, N blue and H 
light grey) and 56 (colored by atom type: C yellow, O red, N blue and H light grey). Zn
2+
 is as a 
magenta sphere. 




Docking of 54 to CPU failed to give any reasonable models with 54 bound to or 
near the active site. For the above considerations, the possibility of Namalide to 
interact with Carboxypeptidase U is restricted on the external face of this binding 
cavity and then far from the Zinc ion.  
However, it is important to observe that in this case the Autodock-Vina value of 
binding energy is of -6.5 kcal/mol, with a corrispondent V value of 0.800 and a 
position nr.149 on the final classification of the 159 targets. The binding poses 
found in which the molecule is able to interact with the metal ion present positive 
values of energy, due to steric hindrance effects (Figure 2.18). 
 
 
Figure 2.18 54 (colored by atom types: C grey, N blue, H cyan, O red) in docking with the CPU. 
Zinc is coloured in violet. 
 
Both CPU and carboxypeptidase B are exopeptidases that preferentially cleave 
basic C-terminal residues, recognizing Arg and Lys as opposed to the aromatic 




residues preferred by CPA. The lack of inhibitory activity toward CPU lends 




In summary, structure elucidation and synthesis of the natural product establish 
the absolute configuration of all amino acids as L, with the exception of D-Lys. In 
contrast with other anabaenopeptins, the macrocycle comprises just three rather 
than the typical five amino acids, leading to a 13-membered macrolactam ring 
versus the usual 19-membered one. The presence of this strained ring likely 
accounts for the side product of a namalide dimer formed during the on-resin 
cyclization employed in the synthesis of 54. In keeping with specificity patterns 
described for a few peptides of this class, the carboxypeptidase inhibitory activity 
depends on the presence of D-Lys, and the exocyclic amino acid appears to dictate 
specificity. Because namalide inhibits CPA with potencies comparable to the more 
common hexapeptides, it will be interesting to evaluate other designed namalide 




















High-throughput Molecular Dynamics for the 
accurate calculations of the binding affinities 
3 Chapter  
 
  




3.1 Molecular Dynamics: from CPU to GPU architecture 
The constant and notable improvement of the computational power determined 
the advance of the computational chemistry as a basic tool in the drug discovery. 
Remarkable results in less and less times can be obtained, providing potential 
indications for the subsequent experimental phases and allowing a strong reduction 
of the costs of a synthetic chemistry project. As mentioned in paragraph 1.2.2, 
Molecular Dynamics (MD) simulations are often required in order to clarify 
molecular mechanism of interaction of a ligand to a biological target. 
Contemporary Molecular Dynamics simulations are able to access microseconds
192
 
for all-atom systems. This impressive increase in speed if compared with time-
scales of the previous years is accounted for in part by increasing algorithmic 
sophistication, but is mainly due to the parallelization of code to run on 
multiprocessor supercomputers.
81,193
 Although these parallel MD codes represent a 
new frontier in the field of the drug discovery, they must be run on expensive, and 
high performance computing (HPC) resources. As a consequence, MD studies have 
focused on obtaining and analyzing a small number of trajectories that are long 
enough to completely sample the process of interest. The future of this approach 
could be represented by the development of novel,
194,195
 specialized hardware and 
new MD protocols.
196,197,198
 In particular, modern graphics processing units (GPUs) 
have recently been shown to be highly capable at MD simulations. This is a 
profound qualitative change, mainly because the cost of performing long 
simulations is now low. This represents a shift from MD as an expensive activity to 
a low cost one that can be performed on cheap commodity hardware. 
In this context, another challenge was the development of the MD softwares 
able to exploit GPUs in parallel. Recently, ACEMD
194
 software was implemented, 
allowing microsecond long trajectories on workstation hardware. It reads 
CHARMM/NAMD and AMBER input files with a simple and powerful 




configuration interface, and represents the computational engine behind one of the 
largest distributed computing project worldwide GPUGRID.net nowadays 






Figure 3.1. Comparative performance on DHFR (dihydrofolate reductase, solvated in water, 23558 
atoms) system for ACEMD, DESMOND, GROMACS4, NAMD2.7b1. Fermi is a GTX580 GPU. 
Kepler is a GTX680 GPU.T esla is a M2090. ECC off. CUDA4.2 and ACEMD ver 2400. Periodic 
boundary conditions, 9 Å cutoff, PME long range electrostatic 64×64×64, hydrogen mass 
repartitioning, rigid bonds, Langevin thermostat, time step 4 fs. Time step 2 fs NAMD and 
AMBER, 2.5 DESMOND and 4 fs GROMACS. AMBER 8 Å cutoff. 
 
3.2 Re-ranking of molecular docking calculations using the 
Linear Interaction Energy (LIE) method 
In the field of drug discovery, molecular docking methodology represents a 
particularly fast and suitable tool in the search of new potential active scaffolds 
related to a specific target. In particular, the main interest is to obtain in fast times 
ranking of compounds of potential pharmaceutical interest (Virtual Screening), 
whose biological activities would be in agreement with their calculated binding 
free energies toward a given protein. On the other hand, the affinity characterizes 




the strength of the specific recognition of a ligand by a protein and plays a 
noteworthy role in correlating the structure and function of proteins.  
From a general point of view, molecular docking methods are in point of fact 
limited by a poor accuracy in the prediction of the binding free energies, and this is 
mainly due to the simplified energy models. Scoring functions are often built and 
parameterized in order to have the maximum correspondence with the experimental 
affinities values, but actually are not derived from a well-defined physical model. 
For example, most of the scoring functions usually have poor treatment of the 
electrostatic and solvation contributions that limit the achievement of truthful 
results. Numerous docking methods are capable of producing near native docking 
poses with a good accuracy, but the development of a consistent scoring function 
still remains a challenge.  
In particular, a low computational cost is evermore required, in order to obtain 
reliable results in short times for the applicability of the docking to large set of 
compounds. This aspect is of fundamental relevance in a Virtual Screening study, 
in which an inaccurate scoring function can produce a final ranking with a large 
number of false positives and more importantly false negatives, that will be 
excluded from the next phase of validation by experimental biological tests.  
An improvement is required to assign better energy scores to select high affinity 
ligands from a large set of decoy compounds (enrichment), trying to correlate at the 
same time scores with measured binding affinities of known ligands.  
Another important point is that the scoring functions, derived from empirical 
equations, are often system dependent, and different methods perform better on 
different systems. Results are sometimes improved when compared from multiple 
scoring functions, and this because a ligand that simultaneously ranks high using 
different scoring functions is more likely to bind strongly.
200,201,202
 Thus the 




development of a reliable and accurate scoring function has been the focus of many 
ongoing studies.  
On the other hand, Molecular Dynamics simulations clarifies protein-ligand 
binding processes, but can be used also for the accurate estimations of the binding 
affinities (Paragraph 1.2.3). Obviously, the reliability of the results of these 
simulations is strictly related to their accuracy, and in particular the use of the 
explicit solvent models is often required.  
Considering the huge and constant progress of the computational power, even 
more time-dispending computational techniques are advancing.  
The development of ACEMD,
194
 a software able to exploit the accelerated 
graphical processing units (GPUs) on a distributed computing network 
(GPUGRID) notably contributed to the performance of high-throughput Molecular 
Dynamics, providing detailed descriptions of a single ligand-protein binding, 
simulating this process in the order of the microseconds.  
For the topic of interest of this study, these huge timescales can be exploited not 
only on one defined system, but it is possible to split the Molecular Dynamics 
simulations to a consistent number of different systems.  
During the period mid May-November 2012 I was involved, under the 
supervision of Dr. Gianni De Fabritiis (University Pompeu Fabra, Barcelona), in a 
project regarding a Virtual Screening study using Molecular Dynamics simulations 
on 1588 systems involving different ligands and decoys from the DUD database, 
previously docked to the trypsin receptor.  
The schedule was based on the investigation and the comparison of the efficacy 
of molecular docking, linear interaction energy (LIE),
88
 and molecular mechanics 
Poisson-Boltzmann (MM-PBSA)
94
 and Generalized-Born (MM-GBSA)
95
 solvent 
accessible surface area methods.  
All these studies are ongoing, and here only partial results are shown. 




The main aim of this study was to give a more careful view of the applicability 
of these different accurate methods for a better estimation of the predicted binding 
affinities, comparing these results with those deriving from the docking 
calculations.  
In particular, we performed for each of these systems (complex and ligand 
alone) 3 × 10 ns simulations in explicit solvent, obtaining a total time of simulation 
of ~ 100 μs (~ 50 μs for the complexes, ~ 25000 atoms for each solvated system; ~ 
50 μs for the ligands alone systems, ~ 3500 atoms for each solvated system). 
As known in the Linear Interaction Energy theory, the binding energy is 
calculated taking into account the polar and nonpolar contributions of potential 
energy, and averaging the ligand-surrounding potential energies, collected only for 
the two physical states of the ligand involved in the binding process, that are the 
free state and the bound state (Equation 1.23). 
 Moreover, into this equation three scaling factors (α,β,γ) empirically derived are 
used to fit the experimental affinity values. In literature several combinations of 
these scaling factors have been reported, and each of these is related and optimazed 
to a specific system. In this study, four different combinations of different scaling 
factors were considered, in order to verify how much LIE is able to predict binding 
affinities in a dependent way from these scaling factors. Scaling factors considered 
were: 
 
a) α=0.476, β=0.165, γ=0.000
203
 
b) α=0.236, β=0.146, γ=0.010
203
 
c) α=0.418, β = 0.087, γ = 0.000
204
 








These initial parameters were chosen considering the different related influence 
of α and β (and then the weight of polar and non polar parts) on the final 
calculations of the binding energy. For example, the a) and c) cases differ for the 
different weight of β; b) and d) cases show lower α values with respect to a) and c), 
and moreover differ from each other for the different weight of β .  
The results were analyzed using enrichment and Receiver Operating 
Characteristic (ROC) curves.  
In the first case, the ratio between the true positive percentage rate (ligands) and 
the percentages of the ranked database is considered. It represents a useful tool in a 
Virtual Screening study, because it indicates on a certain percentage of the whole 
database how many true positive compounds are identified (enrichment factor). 
The most interesting enrichment factors considered are at 1, 2, 5 and 10% (EF1, 
EF2, EF5, EF10) of the ranked database. 
Figure 3.2, Figure 3.3, Figure 3.4 respectively show the enrichment curves 
considering the 100% (whole), 10% and 5% of the ranked database, while 
enrichment factors are summarized in Table 3.1.  
These data show from a general point of view slightly better results for the four 
LIE methods versus docking until the 2% of the ranked database, but over this 
point docking curve is significantly able to overtake LIE curves.  
 
% of ranked database 
EF LIE (α=0.476; 
β=0.165, γ=0.000) 
EF LIE  (α=0.236; 
β=0.146, γ=0.010) 
EF LIE (α=0.418; 
β=0.087, γ=0.000) 
EF LIE (α=0.224; 
β=0.085,  γ=0.000) 
EF docking 
(GOLD) 
1 11.364 13.636 11.364 11.364 9.091 
2 7.955 7.955 7.955 9.091 7.955 
5 6.364 5.909 5.455 6.364 9.091 
10 4.318 4.318 3.636 4.091 7.500 
Table 3.1 Enrichment factors (EF) calculated for the different methods analyzed at 1, 2, 5, and 10 % 









Figure 3.2 Enrichment curves for docking and LIE calculations related the whole ranked database 
 
 




Figure 3.4 Enrichment curves for docking and LIE calculations related the first 5% of the ranked 
database 




All these observation are confirmed by the ROC curve, where the ratio between 
the true positive (ligands) rate and the false positive (decoys) rate is taken into 
account (Figure 3.5).  
 
 
Figure 3.5 ROC curves related to molecular docking and LIE calculations 
 
In general, the data presented highlight the poor results obtained by the four LIE 
methods used, especially considering the fastness of the molecular docking 
calculations. These data seems to be interesting concerning the reliability of the 
LIE calculations. On the other hand, remaining in the field of the LIE, further 
investigations are in progress regarding the dependence of results from the scaling 
factors used. In parallel, we are considering other MD-based methods for the re-
ranking of the docking calculations. 
For these reasons, other studies are under evaluation, specifically concerning: 
- Use of ligand specific LIE scaling factors206 
- MM-PB(GB)SA methods. 
 
  
















Further applications of in silico screenings on 
natural compounds 
 
4 Marine drugs 
 
  




4.1 Discovery of cholestan disulfate as a potent pregnane-X-
receptor agonist 
PXR (pregnane-X-receptor) is a master gene regulating the activity of a variety 




Once activated, PXR heterodimerizes with the retinoid-X-receptor (RXR), binds 
to regulatory DNA sequences in the promoter of responsive genes and modulating 
their  transcription. PXR is a master gene orchestrating the expression/function of a 
number of genes involved in the detoxification/excretion of endo-and xeno-biotics 
thus preventing toxic accumulation of metabolites within cells. In addition, PXR is 
recognized as an important regulatory factor in modulation of important effector 
functions in the immune system through inhibition of proinflammatory 
transcription factor NF-κB in epithelial and immune cells.
211,212
  
A role for PXR in the pathogenesis of inflammatory bowel disease (IBD) is 
increasingly supported by genetic and pharmacological evidence. Thus, gene 
expression analysis of colon tissues from ulcerative colitis and patients with 
Crohn's disease have revealed a significant reduction in the expression/function of 
PXR and its target genes compared with normal intestinal samples.
213
 Moreover 
rifaximin, a human PXR activator, is in clinical trials for treatment of IBD and has 
demonstrated efficacy in Crohn's disease and active ulcerative colitis.
214,215
 It is 
speculated that by activating PXR, rifaximin could contribute to the maintenance of 
the intestinal barrier integrity by regulating the metabolism of xenobiotics and 
increasing the expression and activity of PXR and PXR-regulated genes.
216
  
Therefore PXR represents an important pharmacological target and the 
discovery of potent and selective PXR agonists holds potential in the discovery of 
new drugs for the treatment of human disorders characterized by dysregulation of 
innate immunity. 




Recently research group of Professor Angela Zampella reported the biochemical 
decodification of several steroids of marine origin as ligands of two nuclear 
receptors, FXR and PXR.
217-223
 Among these, two sulfated steroids, solomonsterols 
A (1) and B (Chart 4.1) isolated from the sponge Theonella swinhoei,
224
 were 
proved to be potent inducers of PXR transactivation in human hepatocyte cell line 
(HepG2 cells) stimulating the expression of CYP3A4 and MDR1 (Cytochrome 
P450 3A4 and multidrug resistance 1), two well characterized PXR responsive 
genes in the same cell line (Chart 4.1).
225
  
In addition, through a deep pharmacological investigation on transgenic mice 
expressing the human PXR, we have demonstrated that solomonsterol A (60) 
effectively protects against development of clinical signs and symptoms of colitis, 
reduces the generation of TNF-α and enhances the expression of TGF- and IL-10, 
two potent counter-regulatory cytokines in IBD, via inhibition of NF-B activation 
in a PXR dependent mechanism.
226
  
All these data pointed towards the identification of solomonsterol A (60) as a 
new lead in the treatment of IBD. One of the possible limitation to its use in 
clinical settings is that, when administered per os, solomonsterol A (60) could 
undergo absorption from the GIT before reaching the colon causing severe 


















Chart 4.1 Chemical structures of solomonsterol A and B 
 
 




One of the best approaches used for colon specific drug delivery is based on the 
formation of a prodrug through chemical modification of the drug structure, usually 
by the conjugation with a suitable carriers, such as amino acids, sugar, glucuronic 
acid, dextrans or polysaccharides. 
Since the luxuriant microflora presents in the colon, the prodrugs undergo 
enzymatic biotransformation in the colon thus releasing the active drug molecule.  
Another challenging task is the design of dual-drugs able to release in the colon 
two molecules acting in a synergic manner. For example the possible eventual 
chemical linkage of solomonsterol A (60) to 5-ASA, one of the oldest anti-
inflammatory agents in use for the treatment of IBD, could produce a dual-drug 
with enhanced potency. Upon enzymatic hydrolysis in the colon, this kind of 
molecule could release solomonsterol A and 5-ASA, potent agonists of PXR and 
PPAR-,
227
 respectively, two nuclear receptors playing key rules in colon 
inflammation diseases.  
When synthesizing prodrugs, the first step is the introduction of a functional 
group on the drug molecule suitable of conjugation with a selected carrier (e.g., an 
hydroxyl group that could enter into a glycosidic linkage with various sugars, or 
alternatively a carboxyl group to form ester e/o amide conjugates with 
cyclodextrin, amino acids etc).  
Inspection of chemical structure of solomonsterol A (60) revealed that the 
presence of three sulfate groups hampered any further derivatization e/o 
conjugation. In order to introduce a function group suitable for further 
derivatization, several solomonsterol A derivatives with a modified side chain but 
preserving the steroidal tetracyclic nucleus (compounds 61-67 in Chart 4.2) were 
prepared. Another opportunity was to speculate the pharmacoforic role played by 
ring A, preparing derivatives 68-69 with a sulfate group at C3 in  and  
orientation, respectively. 






























































Side chain modified deivatives
Ring A modified deivatives
 
Chart 4.2 Modified solomonsterol A derivatives 
 
The small library of derivatives obtained (Chart 4.2) was subjected to 
pharmacological evaluation and docking analysis. This study allowed the discovery 
of a synthetic solomonsterol analogue, 2β,3α-cholestan disulfate (ColdiSolf, 67), as 
simplified new potent PXR agonist. 
 
4.1.1 Biological studies 
To investigate whether these compounds act on PXR and eventually PXR 
regulated genes, we have carried out a luciferase reporter assay on human 
hepatocyte cell line (HepG2 cells) transiently transfected with pSG5-PXR, pSG5-
RXR, pCMV-galactosidase, and p(CYP3A4)-TK-Luc vectors (Figure 4.1). Cells 
were then stimulated with rifaximin, a well known PXR agonist, and with 
compounds 62-65 at the concentration of 10 μM each. 






Figure 4.1 Luciferase reporter assay. HepG2 cells were transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-βgalactosidase and p(CYP3A4)-TK-Luc vectors and then stimulated with (A) 
10 μM rifaximin or compounds 60–69 for 18 h, or (B) 10 μM rifaximin alone or in combination 
with50 μM of compounds 61, 62, 67 and 68. N.T., not treated. Rif, rifaximin. *P < 0.05 versus cells 
left untreated. Data are mean ± SE of three determinations.  
 
As shown in Figure 4.1 A, beside the closely structural resemblance with 
solomonsterol A (60), only carboxylate (62) showed a slight activity in 
transactivating PXR. Besides at first sight this behaviour should be ascribable to a 
scarce bioavailability, the scarce activity also for the methyl ester 61 and the 
complete loss of activity for C-24 alcohol 66, obtained through LiBH4 reduction of 
61 (75% yield), pointed towards unfavourable pharmacodinamic features. Indeed, 
although compounds 62-65 (COOH, taurina, gly, asa) possess a negative charge on 
their side chains, most likely they are unable to form polar interactions with 
Lys210 or alternatively with other polar amino acids of PXR LBD. As previously 
reported, PXR presents a large ligand binding cavity
228,229,230
 allowing the 
accommodation of different kind of molecules and the possible binding modes are 
characterized an adequate balance between hydrogen bond and Van der Waals 
interactions established between a small molecule and the receptor.  




Therefore the lack of a polar interaction should be get over by increasing the 
contribution of the hydrophobic interactions on the side chain and the derivative 
67, 2β,3α-cholestan disulfate (ColdiSolf), has been prepared.  
As shown in Figure 4.1 a, compound 67 with its hydrophobic side chain is able 
to transactivate PXR with a potency comparable with the parent solomonsterol A 
(60). Although compound 68 induces a slight PXR transactivation, the lack of 
sulfate group at C-2 as well as the inversion of configuration at C-3 are responsible 
for a general loss in the agonistic activity towards PXR (Figure 4.1 a). To 
investigate whether these compounds could act as potential antagonists of PXR we 
have carried out a transactivation experiment in HepG2 cells stimulated with 
rifaximin (10 μM) and compounds 61, 62, 67 and 68 at a concentration of 50 μM 
each. As shown in Figure 4.1 b, all compounds failed to reverse the induction of 
luciferase caused by rifaximin, indicating that none of these solomonsterol A (60) 
derivatives is a PXR antagonist.  
 
 
Figure 4.2 Real-time PCR of CYP3A4 carried out on cDNA isolated from HepG2 not stimulated or 
primed with 10 μM rifaximin, and compounds 60–69. N.T., not treated. Rif, rifaximin. *P < 0.05 
versus N.T. cells. 
 
To further examine the activity of compound 67 as a PXR activator and further 
clarify the behavior of compounds 61, 62 and 68, we have tested the effects of all 
members of our series on the expression of CYP3A4, a canonical PXR target gene 




(Figure 4.2). Despite compounds 61, 62 and 68 causing a slight transactivation of 
PXR, they failed to modulate the expression of CYP3A4 at the concentration of 10 
μM. In contrast, confirming data shown in Figure 4.1, compound 67 effectively 
increased the expression of CYP3A4 (Figure 4.2) in HepG2 cells, with a magnitude 
similar to that of rifaximin and solomonsterol A (60). While these data do not 
exclude that compound 62 could also stimulate CYP3A4 expression in this system, 
the need for higher concentrations to display a full PXR agonistic activity 
precluded its further development. To further investigate whether compound 67 
displays a full PXR agonistic activity, we then evaluated the effect of 67 in 
regulating immune response using THP1 cells, a human macrophage/ monocytic 
cell line, challenged with lipopolysaccharide (LPS), a potent agonist of Toll like 
receptor (TLR)-4. Previous studies
231
 have shown that activation of PXR in this 
setting attenuates immune response triggered by LPS, a toll-like receptor 4 ligand, 
and key modulator of innate immunity. 
Results shown in Figure 4.3, demonstrate that compound 67 effectively 
attenuates induction of IL-1β, TNFα and MCP-1 induced by LPS. 
 
 
Figure 4.3 Effect of compound 67 on cytokine release induced by LPS in THP1 cells. 3x10
6
 
THP-were starved for 24 h and then pre-treated with 10 M of compound 67 for 3 h and then 
stimulated for 18 h with LPS 1
 
g/ml. Cytokine expression was assessed by RT-PCR. Data shown 
are m mean ± SE of 9 assays from three different sets of experiments. *P<0.05 versus control cells; 
** P<0.05 versus LPS alone. 




Because the above mentioned data indicate that compound 67 effectively 
modulates immune response in human monocytes, additional experiments were 
carried out to investigate the effect of this compound in another model of 
inflammation-driven activation, using hepatic stellate cells (HSCs). HSCs are a 
liver-resident cell population that proliferate in response to liver injury. In response 
to immune activation, HSCs undergo a complex phenotype rearrangement 
characterized by resetting expression of nuclear receptors, including PXR, and 
acquisition of an activated, myofibroblast-like phenotype whose main characteristic 
is the ability to express α-smooth muscle actin (αSMA). HSCs are recognized as 
the main source of extracellular matrix production in the fibrotic liver. Previous 
studies have shown that, along with other nuclear receptors, PXR ligands reverse 





Figure 4.4 Hepatic stellate cells (HSC) were starved for 24 h and then stimulated with thrombin, 
10 U/ml, in the presence of solomonsterol A or compound 67, 10 M each. α-SMA expression was 
assessed by RT-PCR. Data shown are mean ± of three experiments.* P<0.05 versus control cells; ** 
P<0.05 thrombin versus control cells; ***P<0.05 versus thrombin alone. 
 




For this purpose HSCs were exposed to thrombin, a proteinase activated 
receptor (PAR)-1 agonist alone or in combination with compound 67. Previous 
studies have shown that thrombin drives HSCs trans-differentiation and its 
inhibition reverses HSCs from an activated to a quiescent phenotype.
235
 Results 
shown in Figure 4.4 demonstrate that, similarly to solomonsterol A (60), not only 
does compound 67 effectively reduce basal expression of αSMA, but it also 
attenuates HSCs trans-differentiation (i.e. induction of αSMA expression) triggered 
by thrombin.  
 
4.1.2 Molecular modelling studies 
In order to clarify the different activities of the here described compounds at a 
molecular level we performed docking calculations, using the Autodock 4.2 
software,
27
 we examined the positioning of all the compounds in the binding site of 
PXR,
236
 and in particular we analyzed the crucial interactions with the Ser247, 
His407 and finally with the Lys210.  




The three sulfate groups of the agonist solomonsterol A (60) act as key points of 
interactions with these amino acids, and contribute to accommodate the steroid 
nucleus in a mostly hydrophobic part of the binding site of PXR. The compound 
establishes hydrogen bonds (Figure 4.5) with the Cys284 (2-O-sulfate) and with the 




ColdiSolf (67), presenting the C8 aliphatic side chain of cholesterol, is well 
superimposed with the binding pose of 60, and is able to interact with the  
 





Figure 4.5 Solomonsterol A (60) (coloured by atom types: C grey, O red, S yellow) in docking 
with PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N blue). 
Hydrogen bonds are displayed with green spheres. 
 
 
Figure 4.6 ColdiSolf (67) (coloured by atom types: C light green, O red, S yellow) in docking 
with PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N blue). 
Hydrogen bonds are displayed with green spheres. 
 
Ser247, Cys284 and the His407 through its two sulfate groups in the ring A (Figure 
4.6). Moreover, 67 establishes hydrophobic interactions with almost all the residues 
observed for solomonsterol A (60) (Leu209, Val211, Pro228, Leu239, Met243, 
Phe281, Phe288, Leu411). The presence of a hydrophobic chain allows to gain two 
more Van der Waals interactions (with the Leu209 and Val211) that may counter 
the loss of electrostatic interaction observed for the sulfate group at C24 of parent 




solomonsterol A. Nevertheless, the weaker nature of this Van der Waals interaction 
could explain the decrease of the activity of coldiSolf (67) on PXR (difference of 
predicted binding energies 60-67=1.05 kcal/mol). 
On the other hand, the absence of the sulfate group at C-2 in the steroid nucleus 
causes the observed lack of activity, due to an inability to interact simultaneously 
with the three key point of contact previously described. 
For example, compounds 68 and 69 are able to interact with the Lys210 but they 
fail to respect the key interactions involving the internal part of the binding site. 
Regarding compound 62, its tetracyclic nucleus is well superimposed with 60, but 
its shorter side chain causes a poor interaction with the nitrogen of Lys210. The 
two oxygens of its terminal carboxylic part are not well overlapped with the 
oxygens of the 24-O-sulfate of the 60, and the different arrangement of the side 
chain causes also a loss of two Van der Waals interactions with the Leu239 and 
Pro227. In other cases a displacement of the compound to the solvent part is 
observable. For example, the rings A of compounds 61 and 66 are in the place 
occupied by the ring B of 60 and, as a consequence, the 2-O-sulfate and/or 3-O-
sulfate are in a less deep position. Compounds 63, 64 and 65 present a longer and 
more functionalized side chain compared with the previous derivatives, but also in 
this case the steroid nucleus are placed toward the external part of the binding site 
of PXR (63, 65). Moreover, compound 64 is unable to bind in the above described 
fashion and accommodates in a reverse orientation (a flipping of ~ 180° along the 
major axis of the steroid nucleus) of their steroid nucleus. The overall result is an 
inverted disposition of all the chemical groups (sulfates/methyl groups, and side 
chain) in the binding pocket of PXR and then a different pattern of interactions. 
(Figure 4.7) 
 






Figure 4.7 Superimposition between 60 (coloured by atom types: C grey, O red, S yellow) and: 
a) 68 (coloured by atom types: C sky-blue, O red, S yellow); b) 69 (coloured by atom types: C 
brown, O red, S yellow); c) 62 (coloured by atom types: C orange, O red, S yellow); d) 61 (coloured 
by atom types: C purple, O red, S yellow); e) 66 (coloured by atom types: C turquoise green, O red, 
S yellow); f) 63 (coloured by atom types: C dodger blue, O red, S yellow); g) 64 (coloured by atom 
types: C dark green, O red, S yellow); h) 65 (coloured by atom types: C pink, O red, S yellow) in 
PXR-LBD (residues are coloured by atom type: C green, H light grey, O red, N blue). 
 
4.1.3 Final remarks 
In summary, coldiSolf (67) has been identified as a new PXR agonist. The 
ability of this compound to a function as a PXR agonist was first demonstrated in 
transactivation assay using HepG2 cells transiently transfected with a PXR vector. 
The results of this experiments demonstrate that compound 67, and less effectively 
compounds 61, 62, 68, efficiently transactivates human PXR with a relative 




potency that was very similar to that of rifaximin a well know PXR agonist. The 
functionality of the interaction of compound 67 with PXR was further investigated 
in two different cell models. Using THP1 cells, a mielo-monocytic cell line, we 
have provided evidence that compound 67 attenuates cytokine generation induced 
by LPS. Moreover, in agreement with transactivation experiments, the PCR data 
demonstrate that compound 67 increases the expression of CYP3A4, a well 
characterized PXR responsive gene, in liver cells. The functionality of the 
interaction of compound 67 with PXR was further investigated in two different cell 
models. Using THP1 cells, a monocytic cell line, we have provided evidence that 
compound 67 attenuates cytokine generation induced by LPS. Because previous 
studies have provided robust evidence that PXR activation by rifaximin and 
solomonsterol A
226 
exerts anti-inflammatory activity in rodent models of colitis by 
attenuating inflammation driven-immune dysfunction and cytokine accumulation in 
inflamed tissues, the present results extend on the role of PXR ligands in regulating 
immune function, and pave the way for the use of compound 67 in preclinical 
models of inflammation. Despite the fact that we have not investigated the 
mechanism mediating inhibition of cytokines by compound 67, we and others have 
provided evidence that PXR agonists inhibit NF-κB activation.
226,238
 Extending on 
the role of PXR as an endogenous braking signal for inflammation, we have then 
examined whether compound 67 would have been effective in reducing collagen 
production by HSCs, a myofibroblast-like cell line. HSCs acquire an activated 
phenotype in response to liver injury and release collagen and express αSMA in 
response to toxic and immunological stimuli in a variety of liver disorders. 
Previous studies have provided evidence that nuclear receptors, including FXR, 
SHP and PPARγ, modulate a collagen release by HSCs and might function as 
important therapeutic targets for treating liver fibrosis.
239
 PXR ligation attenuates 
liver fibrosis and HSCs activation.
240
 Here we have shown that solomonsterol A 




(60) and compound 67 reduce αSMA accumulation triggered by thrombin. There is 
substantial evidence to support the notion that PXR activators are anti-fibrogenic in 
human liver myofibroblasts in vitro
241
 and in in vivo animal models of liver 
fibrosis. The role of the PXR in regulating HSCs activation has been unequivocally 
established using mice with a disrupted PXR gene. The mechanism throughout 
which PXR regulates production of extracellular matrix proteins is likely 
associated with a function for the PXR that is not related with its recognized 
function as a regulator of genes associated with endobiotic and xenobiotic 
clearance, and might be linked to inhibition of intracellular signaling including NF-
κB, or involved in the regulation of transdifferentiation of these fat-storing cells as 




Because of its simplified structure and efficacy in attenuating immune activation 
in macrophages and HSCs, compound 67 is a suitable candidate for further 
development in preclinical models of inflammatory diseases. 
 
  




4.2 Plakilactones from the marine sponge Plakinastrella 
mamillaris, a new class of marine ligands of peroxisome 
proliferator-activated receptor γ 
The peroxisome proliferator-activated receptors (PPARs) are ligand activated 
transcription factors belonging to the nuclear receptor superfamily. Three distinct 
receptor subtypes, PPARα, PPARγ and PPARβ(δ), have been identified. While the 
PPAR subtypes share a high level of sequence and structural homology, each 
subtype has distinct physiological functions and exhibits a unique tissue expression 
pattern. PPARγ, the most widely investigated PPAR subtype, is predominately 
expressed in the adipose tissue with lower levels in heart, colon, kidney, spleen, 
intestine, skeletal muscle, liver and macrophages. PPARγ is generally recognized 
as a pivotal transcription factor in the regulation of adipocyte gene expression and 
differentiation. In addition, PPARγ has been shown to be an important regulator of 
target genes involved in glucose and lipid metabolism and is the mainstay of 
therapy for type 2 diabetes.
243,244
 Furthermore, PPARγ transrepresses the 
expression of genes involved in inflammatory responses,
245
 and suppression of the 
inflammatory response by PPARγ agonists is closely linked to the anti-diabetic and 
anti-atherosclerotic effects of this receptor. Thus, PPARγ agonists have been found 
effective in the treatment of several inflammatory and degenerative disorders 
including cancer, atherosclerosis, rheumatoid arthritis and inflammatory bowel 
disease. 
The ligand binding domain (LBD) of PPARγ allows the accommodation of a 
large variety of structurally different chemicals, including many food-derived 
substances such as polyunsaturated fatty acids, flavonoids, terpenoids and 
polyphenols.
246
 Despite the extraordinary chemical diversity exhibited by marine 
natural products, only two reports have identified marine natural products as 
putative PPAR agonists. Thus, the screening of 2688 extracts from marine 




organisms led to the identification of psammaplin A as the first PPARγ agonist 
from a marine sponge.
247
 Similarly, from the screening of a library of 90 bioactive 
marine extracts for their ability to stimulate PPAR and PPAR transcriptional 
activity, sargaquinoic acid and sargahydroquinoic acid were identified as novel 
PPAR/ dual agonists from Sargassum yezoense.
248
  
As part of our search for human nuclear receptor modulators from marine 
organisms,
217,218,219,220,221,222,223,224,226
 a library of oxygenated polyketides from the 
sponge Plakinastrella mamillaris, collected at Fiji Islands, was investigated as 
PPARγ modulators. Marine sponges of the genera Plakortis and Plakinastrella are 
known to produce a great variety of oxygenated polyketides, formed by the 
combination of acetyl-, propionyl-, and/or butiryl-CoA units. They include 
plakortolide, plakinic acid, plakortic acid, plakortone, or plakortide families.
249
 
Several activities have been ascribed to the members of this class, including anti-
proliferative,
250
 antifungal, anti-inflammatory or activation of cardiac SR-Ca
2+
-
pumping ATPase.  
Interestingly, compounds containing the 1,2 dioxolane system such as plakortin, 
plakortides and gracilioether A exhibit potent antiprotozoan activity against 
Plasmodium falciparum and Leishmania major.
251-259
 A specimen of P. mamillaris 
Kirkpatrick, 1900 (Homoscleromorpha) was collected at the Fiji Islands. The 
lyophilized sponge was extracted with MeOH, and the combined extracts were 
fractionated according to the Kupchan partitioning procedure.
260
 
The major components of the hexane extract were proved to be the previously 




 the -lactone 74
261
 (Figure 4.8) and the new 
-lactone 78 (Figure 4.9), which we named plakilactone A. A careful analysis of 
the chloroformic extract afforded several more polar derivatives such as 
gracilioethers A-C (75-77), previously reported from the marine sponge Agelas 
gracilis (Figure 4.8),
259
 five new non-peroxy plakortin derivatives, plakilactones B-




F (79-83), featuring the ,-unsaturated  lactone moiety, and gracilioether D (84) 
















































































Gracilioether D (84)Plakilactone F  (83)Plakilactone E  (82)
Plakilactone D  (81)Plakilactone C  (80)Plakilactone B  (79)
 
Figure 4.9. New compounds from Plakinastrella mamillaris. 
 
The structural characterizations of these compounds were determined by 
detailed analysis of HRESIMS and NMR experiments (
13
C and 2D NMR data, 
namely COSY, HSQC, HMBC and ROESY ).  




4.2.1 Biological studies 
PPARγ can be activated by a number of natural lipid metabolites, including 
oxidized fatty acids, several cyclooxygenase (COX) and lipoxygenase (LOX) 
metabolites and 15-deoxy-Δ12,14- prostaglandin J2 (15d-PGJ2), the first 
endogenous ligand identified. These molecules act as covalent ligands possessing a 
common core moiety, an α,β-unsaturated ketone, able to form a covalent bond with 
a cysteine residue in the PPARγ-LBD through a Michael addition.
263,264,265
 Thus, 
the presence of a Michael acceptor, an α,β-unsaturated ketone or alternatively an 
-unsaturated methyl ester moiety, in all polyketides isolated from 
Plakinastrella prompted us to investigate their capability to transactivate PPAR.  
 
 
Figure 4.10 PPAR transactivation assay. HepG2 cells were transiently transfected with a 
chimeric receptor expressing plasmid pSG5GAL4-PPARLBD and with the reporter vector 
p(UAS)5xTK-Luc. 24 h post transfection cells were stimulated for 18 h with (A) 100 nM 
rosiglitazone (R) and compounds 72-84, 10 µM. (B) 100 nM Rosiglitazone (R) alone or in 
combination with compounds 72-84, 50 µM. Data are the mean ± S.E. of three experiments. *P,0.05 
versus not treated cells (NT). #P<0.05 versus rosiglitazone stimulated cells. 
 
As shown in the Figure 4.10, several members of this series effectively 
transactivated PPAR with compounds 76, 77 and 80 being the most potent 
agonists. In addition, when incubated in presence of the synthetic ligand 




rosiglitazone, methyl esters 72 and 73 attenuated the transactivation induced by this 
agent, thus acting as PPAR antagonists. Analysis of the concentration/response 
curves for transactivation of PPAR in response to rosiglitazione and to 
gracilioether B (76), gracilioether C (77) and plakilactone C (80) demonstrates that 
the marine compounds activate PPAR in a dose-dependent manner with a relative 
EC50 of ≈ 5, 10 and 2 µM for compounds 76, 77 and 80, respectively (Figure 4.11). 
We then moved to a detailed analysis of the interaction mechanism at a molecular 
level, in order to assess the binding mode of these agents within PPAR-LBD. 
First, a liquid chromatography-ESI MS (LC-ESI-MS)
266,267,268
 approach was 
applied to detect the potential formation of PPARγ-LBD covalent complexes with 
gracilioether B (76), gracilioether C (77), plakilactone C (80), the methyl ester 72, 
the γ-lactone 74 and plakilactone B (79), in physiologically relevant conditions. 
 
 
Figure 4.11 HepG2 cells were transiently transfected with pSG5GAL4-PPARLBD and 
p(UAS)5xTK-Luc. 24 h Post transfection cells were treated with increasing concentrations of (A) 
rosiglitazone, (B) gracilioether B (76), (C) gracilioether C (77), (D) plakilactone C (80) and cell 
extracts subsequently assayed for luciferase activity. Data are the mean ± S.E. of three experiments.  
 




After incubation with PPARγ-LBD, a time-course analysis of the reaction 
mixtures was performed for each ligand, and the chromatograms revealed the 
presence of stable covalent complexes solely in presence of gracilioether B (76) 
and plakilactone C (80). Two species were detected in the LC-MS runs of 
gracilioether B (76) and plakilactone C (80), (Figure 4.12 panel A), that were 
identified, on the basis of their MW, as the unmodified PPARγ-LBD (MW of 
36172.7±0.3 Da) and as the 1:1 PPARγ-LBD/gracilioether B (76) or plakilactone C 
(80) covalent adducts, the last ones giving mass increments of 320 Da and 264 Da, 
respectively, compared to the free protein (Figure 4.12 panel A). These mass 
differences supported the hypothesis of a Michael addition between the natural 
compounds and PPARγ-LBD (Figure 4.12 panel C). 
 
 
Figure 4.12 Panel A: deconvoluted spectra of PPARγ-LBD alone (back), upon gracilioether B 
(76) (middle) and plakilactone C (80) incubation (front). Panel B: mechanism of the covalent 
modification of PPARγ-LBD by Michael addition on the α,β-unsaturated ketone moiety in the side 
chain of 76 (or 80). Panel C: MALDI-MS spectrum of PPARγ-LDB/gracilioether B (76) complex 
tryptic digestion and MALDI-MS/MS analysis of the ion at m/z 1318.66. 




Then, we moved to the identification of the punctual site of the covalent 
modification on PPARγ-LBD by gracilioether B (76) through a combination of 
classical protein chemistry protocols, MALDI-MS and MS/MS techniques. The 
chromatographic fraction containing the covalent complex was subjected to an 
extensive proteolysis with trypsin and analyzed by MALDI-MS. As reported in 
Figure 4.12 panel C and, the MALDI spectrum led us to identify a peak at m/z 
1318.66, corresponding to the peptide 281-288 (NH2-IFQGCQFR-COOH) 
containing the Cys285 and increased of 320.2 Da in its MW. Finally, MALDI-
MS/MS analysis confirmed the correct peptide identification through the formation 
of the daughter ions at m/z 390.92, 446.55, and 1205.65, attributed to b3, b4 and y7 
fragmentations, respectively. Thus, Cys285 was unequivocally determined as the 
protein residue involved in the covalent binding with gracilioether B (76). 
On the basis of structural considerations, the α,β-unsaturated carbonyl moiety 
exclusively present in the side chain of gracilioether B (76) and plakilactone C (80) 
should act as specific Michael acceptor (Figure 4.12 panel B). To demonstrate this 
hypothesis, gracilioether B (76) and plakilactone C (80) were subjected to mild 
hydrogenation of the side chain double bond, giving the derivatives 85 and 86, 
respectively (Figure 4.13, panel A).  
Derivatives 85 and 86 were separately incubated with PPARγ-LBD, submitted 
to LC-ESI-MS analysis (see before) and, as expected, were unable to form covalent 
adducts with the PPARγ-LBD (covalent complex PPARγ-LBD/Agonists not found 
by LC-ESI-MS experiments) and, importantly, to transactivate PPARγ (Figure 
4.13, panel B). All these data unequivocally revealed that the Cys285 targets the 
α,β-unsaturated carbonyl moiety on the side chain of gracilioether B (76) and 
plakilactone C (80), moreover confirming graciliother C (77), methyl esters 72 and 
73 as non covalent PPARγ ligands. 
 





Figure 4.13 A) Mild hydrogenation of gracilioether C and plakilactone C (H2/Pt/C, 5 min, r.t). 
B) Luciferase reporter assay performed in HepG2 cells transiently transfected with a chimeric 
receptor expression plasmid pSG5GAL4-PPARLBD and with the reporter vector p(UAS)5xTK-
Luc. 24 h post transfection cells were stimulated for 18 h with 10 µM compounds 76, 80, 85 and 86. 
Data are the mean ± S.E. of three experiments. *P,0.05 versus not treated cells (NT). 
 
We next examined whether gracilioethers B (76) and C (77) and plakilactone C 
(80) regulate the expression of genes that are known target of PPAR in HepG2, a 
human hepatocarcinoma cell line, and in THP-1, a human monocytic leukemia cell 
line. For this purpose, HepG2 cells were exposed to rosiglitazone or gracilioethers 
B (76) and C (77) and plakilactone C (80) and the relative mRNA expression of 





 were assessed by quantitative 
RT-PCR. As shown in Figure 4.14, gracilioether B (76), gracilioether C (77) and 
plakilactone C (80) exhibited a pattern of pharmacological activities full 
compatible with their ability to bind and transactivate PPAR. All these agents 
increased the expression of SCD-1. Furthermore, gracilioether C (77) and 
plakilactone C (80) increased the expression of CD36, and gracilioethers B (76) 
and C (77) the expression of PEPCK. 
 





Figure 4.14. Serum starved HepG2 cells were stimulated for 18 h with 100 nM of rosiglitazone 
(R) or gracilioethers B (76), C (77) and plakilactone C (80), 10 μM. Total RNA was extracted to 
perform Real-Time PCR of (A) CD36, (B) SCD-1 and (C) PEPCK. Values were normalized 
relatively to GAPDH mRNA and are expressed relatively to content of these genes in untreated 
cells, which are arbitrarily set to 1. Analysis was carried out in triplicate and the experiment was 
repeated twice. *P<0.05 versus not treated cells. 
 
Finally, we measured whether glacilioether C (77), the non-covalent PPARγ 
agonist, effectively modulated PPAR-regulated genes in macrophages, a 
prototypical target of this nuclear receptor. As shown in Figure 4.15, pre-treating of 
THP-1 cells with rosiglitazone or gracilioether C (77) counter-regulated the 
induction of both the pro-inflammatory cytokine IL-6 (interleukine-6) and the 




Figure 4.15 Serum starved THP-1 cells were pre-treated for 3 h with 100 nM rosiglitazone (R) 
or gracilioether C (77), 10 μM, before the administration of LPS (1 µg/ml) for 18 h. Total RNA was 
extracted to analyze the relative mRNA expression of (A) IL-6 and (B) MCP-1 by Real-Time PCR. 
Values were normalized with respect to GAPDH mRNA and are expressed with respect to those of 
the untreated cells, which were arbitrarily set to 1. The analysis was carried out in triplicate and the 
experiment was repeated twice. *P<0.05 versus not treated cells. 
#
P<0.05 versus LPS treated cells. 




4.2.2 Molecular modelling studies 
In order to rationalize the binding mode in PPAR of the afore mentioned 
compounds, docking calculations and Molecular Dynamics simulations were 
performed using Autodock-Vina
28
 and Macromodel 8.5 software packages, 
respectively, taking into account that gracilioether B (76) and plakilactone C (80) 
are covalent ligands.  
In this context, it should be mentioned that the activation of PPAR by a 
covalent ligand depends also by its ability to establish, apart the covalent bond, 
additional weak interactions in the LBD.
263,264,271  




proposed a model, defined “dock and lock”, in which the 
first step (docking step) involves several non-covalent interactions of the putative 
ligand in the LBD, whereas in the second step (locking step) the covalent binding 
to the Cys285 is observed. As the apo and the locked form of this protein showed 
remarkable structural differences, in our docking studies on the covalent ligands 76 
and 80, two crystallographic structures of PPAR were used: the apo-form (PDB 
code: 2ZK0) and a covalent complexed form with nitro-233 (PDB code: 2ZK5),
265
 
that was removed before the docking of our compounds.  
The docking poses of gracilioether B (76), gracilioether C (77), and plakilactone 
C (80), the most active components of the library, were compared with the 
antagonists, methyl esters 72 and 73, and with the inactive compounds plakilactone 
B (79) and gracilioether D (84).  
Within this approach, we confirmed that the active covalent ligands are docked 
in the apo form in poses compatible with the positioning of their reactive moieties 
around the Cys285, showing at the same time several interactions with key amino 
acid residues in the LBD. In the locked form of the receptor, we firstly tried to 
analyze the formation of the covalent bond using the recent introduced covalent 
docking methodologies.
27
 Unfortunately, using the flexible side chain method, a 




restricted space in the binding site of PPAR was observed, thus determining steric 
clashes after the formation of the covalent bond.  
On the other hand, using the covalent grid based approach, poses compatible 
with the covalent bond were found but with unfavorable predicted binding 
energies.  
For these reasons, we concluded that putative models of the covalent ligands 
could be better detected by using Molecular Dynamics simulations, analyzing their 
motions in the LBD of PPAR  
Results from these experiments allowed us to identify some significant poses in 
which the distances between the reactive part of these molecules and the sulfur 
atom on the Cys285 were compatible with the formation of the C-S covalent bond. 
 
 
Figure 4.16 Gracilioether C (77), (coloured by atom types: C orange, O red, -OH hydrogen light 
grey) in docking with PPAR-LBD of the apo form. Residues are coloured by atom type: C green, 
H light grey, O red, N blu, S yellow. 
For what concerns non-covalent ligands, the docking model in the apo form 
shows that the agonist gracilioether C (77) entails a set of weak interactions, with 
the -OH group in the side chain determining a favorable accommodation in the 
LBD of PPARIn particular, in the apo form, 77 establishes Van der Waals 




interactions with the Ile341 and the Met348, and polar interactions with the 
Arg288.  
Three hydrogen bonds stabilize the compound in the LBD, between the ether 
oxygen of the cycle and the -NH of the Ser342, between the terminal oxygen of the 
ester moiety and the -NH of the Glu343, and finally between the -OH at position-
11 and the CO group of the Ile267 (Figure 4.16).  
Methyl esters 72 and 73 differ from gracilioether C (77) for the presence of a 
fully hydrophobic side chain that causes a different orientation in the PPAR-LBD, 
with a flip of the ring of ~ 180° on the major axis of the compounds (Figure 4.17 a) 
and then with the loss of some essential interactions. 
Indeed, we found alternative poses in which the ,,γ,δ-unsaturated methyl ester 
moiety of 77, 72 and 73 are well superimposed (Figure 4.17 b), but also in this case 
the hydrophobic side chains of 72 and 73 do not allow any polar interaction as 
observed for 77, mainly the hydrogen bond with the Ile267.  
As demonstrated for 15d-PGJ2, this residue plays a fundamental role in the 
activity of a putative PPAR covalent agonist. Indeed, even if the covalent binding 
at the Cys285 is maintained, mutations at this residue abolish the transcriptional 
activation induced by this endogenous PPAR agonist.
265  
Similar considerations could be done for gracilioether D (84). Also in this case, 
the superposition with the gracilioether C (77) shows a similar orientation of the 
,γ,δ-unsaturated methyl ester core but a different accommodation of the side 
chain with the -OH group at C-10 far from the Ile267 (Figure 4.17c). 
 






Figure 4.17 Superimposition between 77 (coloured by atom types: C orange, O red, -OH 
hydrogen light grey), and: a) first docking model and b) alternative docking model of 72 (coloured 
by atom types: C grey, O red), and 73 (coloured by atom types: C purple, O red); c) gracilioether D 
(84) (coloured by atom types: C violet, O red, -OH hydrogen light grey); d) plakilactone B (79) 
(coloured by atom types: C green, O red, -OH hydrogen light grey) in docking with PPARγ-LBD of 
the apo form. Residues are coloured by atom type: C green, H light grey, O red, N blue, S yellow. 
Hydrogen bonds are displayed with green spheres. 
 
In summary, the inverted configuration at C-10 and the presence of a 
8
 double 
bond with respect to the side chain of gracilioether C (77) could explain the loss of 
the bioactivity for 84. 
Of interest is the case of the inactive plakilactone B (79) displaying the same 
lactone moiety of plakilactone C (80) and the side chain of gracilioether C (77). Its 
accommodation in the PPAR-LBD is inverted (Figure 4.17 d), probably due to the 
absence of the ,γ,δ-unsaturated methyl ester moiety. As a consequence, the 




smaller cyclic α-β unsaturated lactone moiety is oriented to form a hydrogen bond 
with the Ile267, and the -OH in the side chain is able to establish only one 
hydrogen bond (Leu340) where 77 generated a wide set of polar interactions. In 
summary, 79 shows some potential interesting points in its chemical structure, but 
in perfect agreement with absence of activity towards PPARthe inability to create 
a covalent bond and the presence of a small cyclic part cause an unstable placement 
in the LBD. 
Regarding the covalent agonists, for gracilioether B (76) a docking pose in the 
apo form of PPAR in which the α-β unsaturated ketone in the side chain is 
oriented towards the Cys285 was found, and this conformation is stabilized by 
several hydrogen bonds between the ,,γ,δ-unsaturated methyl ester moiety and 
the Cys285, showing a strong point of attach of the compound in proximity of this 
residue. Moreover, 76 establishes further polar interactions with the Ile281and the 
Arg288, as well as hydrophobic interactions with the Met264, the Leu330, and the 
Ile341 (Figure 4.18 a). Therefore, as previously demonstrated,
265
 in the “docking 
step” a putative covalent ligand searches, through a wide range of weak 
interactions, the best conformation favorable to the covalent bond. 
In the locked form, a conformation in which the α-β unsaturated ketone of 76 is 
closed to the Cys285 (distance between the sulfur of Cys285 and the reactive β 
carbon of the α-β unsaturated ketone of 76 = 3.439 Å) was found. Starting from 
this conformation, several fast steps of Molecular Dynamics simulations were 
applied observing a gradual reduction of this distance. When a pose with a distance 
between these groups compatible with the C-S covalent bond was found (~1.8 Å), 
the covalent bond was manually generated and the complex was processed to a 
further fast step of Molecular Dynamics simulation (Figure 4.18b). 
 





Figure 4.18 Docking and covalent models of gracilioether B (76) (coloured by atom types: C 
sky blue, O red) in docking with PPARγ-LBD of a) apo form; b) locked form after Molecular 
Dynamics simulations. Residues are coloured by atom type: C green, H light grey, O red, N blue, S 
yellow; c) superimposition between the apo form of PPARγ (secondary structure represented in red) 
and the locked form complexed with gracilioether B (76) (secondary structure represented in blue, 
76 is in CPK representation and coloured by atom types: C sky blue, O red). 
 
As previously reported, several alterations in the regions following the helix H2’ 
and a considerable rearrangement of the helices H3 and H12 could be observed 
comparing the apo form and the locked form of the receptor (Figure 4.18c).
265 
 
Similarly, the side chain α-β unsaturated ketone of plakilactone C (80) is prone 
to function as Michael acceptor and, in Figure 4.19 a, a pose in the apo form in 
which this moiety is near to the Cys285 is shown. A hydrogen bond was observed 
between the carbonyl oxygen of the ,-unsaturated lactone moiety and the -NH of 
the Ile267 (Figure 4.19 a)
265 
as well as further polar interactions are established 
between the cyclic core and the Arg288 and the His266. In the locked form of 
PPAR, the docking results confirmed the nearness of the α-β unsaturated ketone in 
the side chain of 80 to the Cys285 (distance between the sulfur of Cys285 and the 
reactive β carbon of the α-β unsaturated ketone of 80 = 3.918 Å). 
 





Figure 4.19. Docking and covalent models of plakilactone C (80) (coloured by atom types: C 
light yellow, O red) in docking with PPARγ-LBD of a) apo form; b) locked form after Molecular 
Dynamics simulations. Residues are coloured by atom type: C green, H light grey, O red, N blue, S 
yellow. Hydrogen bonds are displayed with green spheres; c) superimposition between the apo form 
of PPARγ (secondary structure represented in red) and the locked form complexed with plakilactone 
C (80) (secondary structure represented in blue, 80 is in CPK representation and coloured by atom 
types: C light yellow, O red). 
 
As for 76, this complex (Figure 4.19 b) was processed through Molecular 
Dynamics simulations observing also in this case the rearrangement of the helices 
















4.2.3 Final remarks 
In summary, the isolation and pharmacological characterization of a family of 
oxygenated polyketides from the Plakinastrella mamillaris sponge was reported. 
The detailed analysis of pharmacological properties of these agents allowed us to 
demonstrate that members of this library are robust and selective ligands of the 
nuclear receptor PPAR. PPAR is a well validated pharmacological target. 
Thiazolidinedione, rosiglitazone and pioglitazone are potent PPARγ agonists and 
insulin-sensitizers and have been extensively used in the treatment of type 2 
diabetes.  
Thiazolidinediones induce the transcription of PPARγ responsive genes and 
control lipid synthesis and storage in the adipose tissue, liver and many other 
tissues, however their use is associated with side effects including weight gain, 
fluid retention, and increased risk of heart failure. Rosiglitazone has been 
withdrawn from the market in 2011, and pioglitazone is contraindicated in patients 
with New York Heart Association (NYHA) Class III or IV heart failure in USA, 




Despite pioglitazone does not increase the risk of myocardial infarction, and its 
use associates with a reduction in all-cause mortality, there is an urgent need for 
development of novel PPARγ agonists or modulators.  
Previous studies from our group have led to the demonstration that marine 
organisms are a rich source of ligands for nuclear receptors. Thus, we have 
identified ligands for two major targets, the farnesoid-X-receptor (FXR) and the 
pregnane-X-receptor (PXR).
246
 Furthermore marine environment, mainly sponge 
organisms, has been reported as the source of nuclear receptor antagonists,
278
 that 
are currently being developed for their biomedical potential.  




Members of this oxygenated polyketides library showed the ability to activate 
PPARγ in a transactivation assay in HepG2 cells transfected with a viral vector 
containing the LBD of the receptor whereas others reverted the effect of the 
synthetic ligand rosiglitazone, thus acting as PPARγ antagonists. Results from 
these studies demonstrated that gracilioether B (76), gracilioether C (77) and 
plakilactone C (80) activate the receptor with EC50 ranging from 2-9 µM, and are 
therefore 20-90 fold less potent than rosiglitazone whose EC50 is ≈100 nM in this 
assay.  
Despite their reduced potency, the efficacy of gracilioethers B (76), gracilioether 
C (77) and plakilactone C (80) in term of receptor transactivation was very similar 
to that of rosiglitazone (≈80%), and in addition, all three compounds effectively 
triggered the transcription of PPARγ-regulated genes, although with a difference in 
the relative potency (Figure 4.14). Using HepG2 cells, we have shown that 
gracilioether C (77) and plakilactone (80) induce the expression of CD36, a 
scavenger receptor involved in the hepatic uptake of oxidized lipoprotein, a typical 
effect of PPARγ ligands in the liver. Interestingly, gracilioether B (76) fails to 
increase the expression of this gene in HepG2.  
This finding might be of relevance because increased expression of CD36 
caused by PPARγ ligands is thought to mediate lipid accumulation in macrophages 
and liver. Thus, the fact that gracilioether B (76) causes a different pattern of gene 
expression in comparison to rosiglitazone, might be associated with a specific 
pharmacological profile in vivo. In addition, we also demonstrated that 
gracilioether B (76), gracilioether C (77) and plakilactone C (80) increase the 
expression of SCD-1 in liver cells. SCD-1 catalyzes the rate-limiting reaction of 
monounsaturated fatty acid synthesis and plays an important role in the 
development of fatty liver. Finally, we demonstrated that gracilioether B (76) and 
gracilioether C (77) but not plakilactone C (80) up-regulate the expression of 




PEPCK. PEPCK is a rate limiting enzyme involved in gluconeogenesis and 
glyceroneogenesis pathways and its expression is tightly regulated at the 
transcriptional level by hormones controlling glucose homeostasis with glucagon 
and glucocorticoids having a strong gluconeogenic action while insulin inhibiting 
hepatic gluconeogenesis by repressing the expression of this gene.
279
  
The expression of PEPCK is positively regulated by different transcription 
factors and co-activators including hepatic nuclear factor 4α (HNF4α), Forkhead 
box O1 (Foxo1) and PPARγ, while the PPARγ coactivator 1 alpha (PGC1-α) has 
been shown to cooperate in regulating the expression of this gene in the fasting 
state. Induction of PEPCK in HepG2 cells by rosiglitazone and gracilioethers B 
(76) and C (77) is therefore of interest. Indeed, since HepG2 cells are grown in a 
low glucose medium, induction of PEPCK expression drives cell metabolism to 
glycerogenesis rather that gluconeogenesis and might be involved in development 
of lipid accumulation in hepatocytes, a common side effect in the rosiglitazone 
therapy.
279
 All together these data suggest the possibility to develop novel PPARγ 
modulators. 
Because gracilioether C (77) activates PPARγ in a non covalent fashion, we 
have then investigated whether this agent still exerts the same range of effects of 
rosiglitazone. Using THP-1, a monocytic cell line, we demonstrated that 
gracilioether C (77) effectively modulates the expression of two inflammatory 
mediators, IL-6 and MCP-1.  
Thus, similarly to rosiglitazone, gracilioether C (77) causes a robust attenuation 
of the expression of IL-6 and MCP-1 triggered by LPS. Because the inhibition of 
pro-inflammatory mediators is a common theme in the pharmacology of PPARγ 
ligands, present data provide a robust evidence that gracilioether C (77) might be a 
potential agent in the treatment of inflammatory disorders.
280,281
 




At molecular level we demonstrated that gracilioether B (76) and plakilactone C 
(80) covalently bind to a cysteine residue in the PPAR-LBD through a Michael 
addition reaction to the ,-unsaturated ketone in their side chains. Such findings 
were also supported by an integrated analysis of docking and Molecular Dynamics 
simulations.  
Besides the Cys285 is conserved in all three PPAR subtypes, gracilioether B 
(76) and plakilactone C (80) showed a significant specificity towards PPAR. This 
finding indicates, as previously reported for several selective covalent PPAR 
ligands,
282,283
 that other amino acid residues confer specificity in the recognition 
process to PPARLBD and moreover points towards the importance of the 
docking step in which the putative covalent ligand establishes several non-covalent 
interactions. 
Also for gracilioether C (77) a detailed docking analysis was performed in order 
to rationalize the structural requirements for its non covalent interaction in the 
receptor’s LBD and insights were gained to explain its peculiar mode of action. 
The analysis of the docking poses in comparison with the antagonists methyl esters 
72 and 73 and several non active members of this series clarified the chemical 
requirements for the PPARγ agonistic activity and could be useful for the future de-
novo design and for the prediction of the bioactivity of a set of new ligands. 
Also the discovery that methyl esters 72 and 73 are PPARγ antagonists
284
 that 
counteract the receptor transactivation caused by rosiglitazone is noteworthy. 
Because PPARγ antagonists are of pharmacological and therapeutic relevance, we 
are currently elaborating on these structures to gain further insights on their 
pharmacological profiles.  
In conclusion this study discloses a new class of marine PPARγ ligands 
structurally unrelated to all synthetic and natural ligands so far reported and 




reaffirms the extraordinary chemodiversity and therapeutic potential of marine 
natural compounds.  
  




4.3 HSP70 1A as a Target for the Anticancer Diterpene Oridonin 
Kaurane diterpenes are a very important class of natural compounds, identified 
from numerous medicinal plants, possessing several biological activity such as 
plant growth regulators, antimicrobial, antiviral, inflammation, and antitumoral 
activity.
285
 Kaurane diterpene oridonin is the principal active metabolite of 
Rabdosia rubescens (Hemsl.) Hara (Donglingcao), Hook. f. (Leigongteng) used in 
Chinese medicine to treat several diseases. Numerous biological activities such as 
cytotoxic effect, antiproliferative, anticancer, anti-inflammatory and antibacterial 
activities have been reported for this compound.
286
 Oridonin (87) (Figure 4.20) has 
aroused high interest especially in cancer researchers due to its potential to be 
developed into tumor chemotherapeutic drug.  
 
 
Figure 4.20 Chemical structure of oridonin 
 
The ability to inhibit tumor cell growth either by in vitro as well by in vivo 
experimental models has indeed been repeatedly confirmed by many research 
groups.
287,288
 Inhibition of tumor cell growth by oridonin was ascribed to the ability 
of the drug to affect cell cycle progression and/or to promote cell death by 
apoptosis and autophagy.
289
 Depending on cell type, oridonin has been shown to 
induce cell cycle arrest in G2/M or G1/S and to modulate the expression/activity of 
different cell cycle regulatory proteins. Again, depending on the cell type and the 
experimental conditions used, oridonin has been shown to modulate the expression 
of proteins implicated in either death receptor–mediated (i.e. FAS, FAS ligand) or 




mitochondria-dependent apoptotic pathways (i.e. increased BAX/Bcl2 ratio, 
caspases). Moreover oridonin was reported to modulate several proteins, such as 
MAPKs, PI3K/Akt, and NFkB, responsible of death (apoptosis/autophagy) or 
survival cell fate have been observed in different cell lines.
290
 Modulation of some 
of the aforementioned proteins (i.e. p21 and NFkB)
291
 by oridonin was also related 
to the simultaneous induction of apoptosis and autophagy or changed balance 
between the two cell death mechanisms. 
 Despite the large number of proteins which activity and/or expression have 
been shown to be modulated by oridonin, it has not yet identified which is the 
primary target of this diterpene. Hence, we have tried to mine target proteins of 
oridonin by employing a chemical proteomic approach to gain more insight into the 
molecular mechanisms of oridonin.  
Chemical proteomics is a compound-centric approach aimed to describe the 
mechanism of action of bioactive small molecule at a molecular level; it is a 
powerful mass spectrometry (MS)-based affinity chromatography approach for 
identifying proteome-wide small molecule-protein interactions; mapping these 
interactions on signaling and metabolic pathways, could comprehensively 
characterize drug targets, profile toxicity of known drugs, and lead to the 
identification of possible off-target activities.
292
  
Recently, there is an increasing interest in application of chemical proteomics 
experiments to bioactive natural products. Indeed, even if natural products have 
been the single most productive source of leads for the development of drugs,
293
 
information concerning mechanism of action at a molecular level of many of them 
are very poor or completely missed.  
Chemical Proteomics revealed the binding and inhibition of oridonin to the 
multifunctional, stress-inducible molecular chaperone HSP70-1A. This specific 




activity was rationalized combining docking experiments and Molecular Dynamics 
simulations. 
However, since it is clearly emerging that many secondary metabolites can act 
on various targets at the same time,
293
 further studies will be performed to validate 
the possible interaction of oridonin with other proteins identified in chemical 
proteomics studies (i.e. Peroxiredoxin-1, α-Enolase, and Cofillin-1). 
 
4.3.1  Chemical proteomics results 
Chemical proteomics experiments were performed to identify oridonin 
molecular target(s) responsible for its anticancer activity. In that aim, oridonin was 
biotinylated, taking care to prevent the reaction of the α,β-unsaturated carbonyl 
group, essential for the activity of ent-kaurane diterpenes
294,295
 and known to 
contribute to the biological activity of many other natural compounds such as 
sesquiterpenes
296
 and indolizidine alkaloids.
297
 Before using biotinylated oridonin 
in chemical proteomic analysis for target identification, it was mandatory to verify 
that the chemical modification did not cause a marked loss of oridonin biological 
activity. To that aim, we compared Jurkat cell proliferation inhibition potential of 
biotinylated oridonin to that of oridonin.  
Chemically modified oridonin and oridonin inhibited cell growth to a 
comparable extent, as inferred by the 7.5 ± 0.5 M and 5 ± 0.3 M IC50 values (at 
24 h of exposure) measured for biotinylated oridonin and oridonin, respectively. 
Even if biotin conjugation can produce an alteration of small molecules membrane 
permeability,
298
 this result demonstrated that biotinylated oridonin could be used 
for identifying oridonin cellular target(s). In characterizing binding partners for a 
small molecule by chemical proteomics, the major challenge is to identify bona 
fide interacting partners since very high sensitivity of MS analysis can permit the 




identification of almost all proteins, even contaminants present at very low levels in 
the sample.  
Therefore, Jurkat cell lysates were incubated with biotinylated oridonin or with 
biotin, as a negative control, to discriminate between proteins specifically 
interacting with the diterpene and unspecific background.
292
 Samples were purified 
by affinity chromatography on a streptavidin resin and the resulting protein 
mixtures were resolved by SDS-PAGE; each gel line was then cut in 13 pieces, 
digested with trypsin, and analyzed by mass spectrometry through nanoflow 
reversed-phase HPLC MS/MS.  
Doubly and triply charged peptide species were fragmented, and all the MS/MS 
spectra were evaluated by a Mascot database search. Chemical proteomic 
experiments were performed in triplicate to ensure data reproducibility leading to 
the identification of about 85% of identical proteins in the three experiments.  
To establish the proteins specifically captured by biotinylated oridonin, we 
compared the list of the proteins detected with those in control experiment. This 
analysis led to the identification of four potential partners of oridonin (Table 4.1). 
These proteins were always detected in the samples incubated with biotynilated 
oridonin and never revealed in those from control gels.  
The same experiment was also performed using proteins extracted from PC3 cell 
line (human prostate cancer cell line) leading to the definition of the same putative 
targets. Among the four putative oridonin target the higher score was achieved for 
HSP70 1A.  
These findings together with the multiple role of HSP70 in the control of cell 
proliferation, apoptosis and autophagy,
299
 prompted us to further characterize the 
interaction of oridonin with this key target. 
 
 











Heat shock 70 kDa 
protein 1A/1B 
70052 17% 7 7 265 
ENOA_HUMAN Alpha-enolase 47169 36% 6 6 181 
PRDX1_HUMAN Peroxiredoxin-1 22110 15% 5 5 158 
COF1_HUMAN Cofilin-1 18502 28% 4 4 156 
 
Table 4.1 Proteins identified by chemical proteomic approach as putative oridonin molecular targets 
 
Heat shock protein 70 (HSP70) is a member of a ubiquitously expressed family 
of molecular chaperones that are involved in protein homeostasis. In its role as a 
mediator of protein fate, this chaperone has been linked to multiple tasks, including 
roles in de novo protein folding, subcellular trafficking, protein disaggregation, 
proteasome-mediated degradation, and autophagy. To accomplish its various 
chaperone functions, HSP70 physically interacts with the exposed hydrophobic 
residues of polypeptides via its C-terminal substrate binding domain (SBD). 
Hydrolysis of ATP in the adjacent, N-terminal nucleotide-binding domain (NBD) 
propagates an allosteric change to the SBD, resulting in an approximately 10-fold 
enhancement in substrate affinity. These findings suggest an important role for the 
nucleotide state in controlling the interactions of HSP70 with misfolded substrates.  
HSP70 has a long-term connection with the cancer problematic: at the initial 
stages of tumorigenesis, HSP70 can protect cells undergoing transformation from 
oncogenic stress induced by over- expression of oncogenes, e.g. c-myc.
299
 In 
addition, HSP70 has been shown to suppress cellular senescence, an important anti-
tumor mechanism at the early stages of tumorigenesis and also important in the 
proper response to anti-cancer therapy.  
HSP70 over-expression has been routinely associated with poor prognosis in 
multiple form of cancer and is thought to provide a survival advantage to cancer 




cells interacting with multiple component of both caspase-dependent and caspase–
independent apoptotic pathway. Moreover, many evidences demonstrated a critical 




With the critical roles played by HSP70s in cancer, neurodegenerative disease, 
viral infection, and injury, one might anticipate that many small molecule 
modulators for this class of chaperones have been identified, at moment few 
molecules are known as HSP70 inhibitors.
302,303
 Indeed, several compounds were 
demonstrated to modulate the ATPase activity of HSP70 and/or to affect its affinity 
towards client proteins or co-chaperones,
306
 but in most cases the exact site and 
mode of binding of these molecules to the chaperone are currently unknown.
304,305
 
The complete elucidation of the binding site is however not secondary, since it 
could also determine the selectivity and the efficiency of an inhibitor.
306
 Using a 
mass based-chemical proteomics approach, HSP70 was revealed as a molecular 
target of the anticancer diterpene oridonin.  
This finding was validate by different western blot analyses, also confirming 
that the diterpene can interact with HSP70 under pseudo-physiological conditions 
inside Jurkat cells and demonstrating the selectivity of oridonin towards this 
chaperone. Biochemical and structural studies were performed allowing to 
elucidate the molecular basis of the inhibition of HSP70 by oridonin, 
demonstrating that the interaction of the diterpene with the NBD of the chaperone 
prevents HSP70 interaction with ATP.
313
  
Using a molecular docking approach, a model that rationalize the inhibitory 
activity of oridonin describing the dynamic modification of the orientation of the 
helixes surrounding the NBD of HSP70 is proposed. Besides, our data 
demonstrated that oridonin interaction with HSP70 NBD is also stabilized by the 
formation of a covalent bond involving the thiolic group of Cys267; however, this 




covalent binding seems not to be critical for the biological activity of oridonin, as 
inferred by the observation that the diterpene also inhibits ATPase activity of a 
prokaryotic HSP70 (DnaK) lacking of this residue.  
The identification of NBD as the binding region of oridonin on HSP70 suggests 
that oridonin could affect both HSC70 and HSP70 activity because the N-terminal 
region of these two proteins shares about 99% of their structure.
307
  
This result is relevant since a study by Power et al. demonstrated that the 
simultaneous silencing of HSP70 and HSC70 is required to impair HSP90 function, 
thus enhancing the pro-apoptotic effects of HSP70 inhibition.
306 
 
Conformation changes occurring on the NBD could also account for the 
enhanced affinity between HSP70 and its co-chaperone BAG3, observed following 
oridonin interaction.  
 
4.3.2 Biological studies 
Oridonin/HSP70 interaction was investigated in Jurkat cells, taken as a more 
physiological model. Cells were exposed to doses (10 µM and 20 M) higher than 
IC50 of biotinylated oridonin for 5 h.  
We chose to use high doses to increase the possibility to detect the biotinylated 
oridonin-HSP70 complex.  
On the other hand, the time was shortened to 5 h to prevent extensive cell death. 
Binding of biotinylated oridonin with HSP70 or HSP90 was monitored in cell 
fishing procedure followed by Western blotting.  
Resulting blots (Figure 4.21) showed that also inside cells oridonin efficiently 
interacts with HSP70 1A, but not with HSP90 α.  
The affinity of oridonin towards HSP70 1A was evaluated by a surface plasmon 
resonance (SPR) based binding assay. 





Figure 4.21 In cell fishing procedure. Western blotting analysis of the binding of biotinylated 
oridonin to HSP70 or HSP90. The same blot, representative of two replicate experiments, was 
sequentially probed with anti-HSP70 and anti HSP90 antibodies. 
 
The diterpene efficiently interacted with the immobilized protein, as 
demonstrated by the concentration dependent responses and by the clearly 
discernible exponential curves, during both the association and dissociation phases 
(Figure 4.22 a).  
Fitting the achieved sensorgram to a single-site bimolecular interaction model 
(A+B=AB), a thermodynamic dissociation constant (KD) of 26.0 ± 1.2 nM and a 
kinetic dissociation constants (koff) of 2.7 ± 0.4 ms
–1
 were calculated for the 
HSP70/oridonin complex.  
This result demonstrated high affinity of oridonin towards the chaperone, and 
the low koff measured suggested a very high stability of the resulting complex. 
Since HSP70s are ATP dependent chaperones, SPR analysis was then performed 
adding 5 M ATP into the running buffer. Remarkably, the presence of an ATP 
concentration 10-times higher than its reported KD (500 nM)
308
 almost completely 
inhibited oridonin binding to the chaperone (Figure 4.22 b).  
 





Figure 4.22 SPR results. Sensorgrams obtained by injecting different concentrations (from 0.020 to 
1 µM) of oridonin on immobilized HSP70 using PBS (A) or 5 µM ATP in PBS as running buffer 
(B), or on immobilized HSP90 (C) 
 
This result could arise either from a competition of oridonin and ATP for the 
same binding site or from conformational changes occurring on the HSP70 
structure following ATP binding and preventing oridonin interaction. To verify the 
selectivity of oridonin towards HSP70, the diterpene was also injected on a HSP90 
α modified chip; the obtained sensorgrams (Figure 4.22 c) showed no interaction.  
To evaluate the effect of oridonin binding on HSP70, ATPase activity was 
measured in the presence of different amounts of oridonin using the approach 
described by Chang et al.
309
 oridonin was found to inhibit in a dose-dependent 
manner HSP70 ATPase activity (Figure 4.23 a). The ability of oridonin to affect 
the chaperone activity of HSP70 was tested monitoring the thermal-induced citrate 
synthase (CS) aggregation under different experimental conditions (Figure 4.23 b). 
Upon incubation at elevated temperatures, CS underwent quantitative protein 
aggregation, but the presence of stoichiometric amounts of HSP70 changed the 
aggregation kinetics. As expected, the addition of a 4-fold molar excess of ATP 
further decreased the curve slope, since ATP binding to the N-terminal domain of 
HSP70 enhances the kon of its interaction with substrate proteins.
310
 When also 




oridonin was added, CS aggregation curve became almost comparable to that 
observed without ATP, thus indicating that oridonin can revert the effect of the 
triphosphate nucleotide on HSP70 chaperone activity.  
Finally, we investigated whether oridonin binding to HSP70 affected the ability 
of the chaperone to interact with other proteins. In particular, since oridonin 
inhibits ATPase activity, we focused our attention on those co-chaperones 
modulating ADP release from HSP70 (Nucleotide Exchanging Factors, NEF), such 





Figure 4.23 Oridonin effect on HSP70 activity. Inhibition of the ATPase activity of HSP70 (DnaK) 
by different concentration of oridonin (A). Data are the mean of two independent experiments 
performed in triplicate and were analyzed by t student test (Control vs testing compounds): *p < 
0.05, **p < 0.005. Aggregation kinetics of CS at 43 °C determined by light scattering (B). The 
spontaneous aggregation of CS at 43 °C (♦) and the aggregation of CS at 43 °C in the presence of 
0.075 µM Hsp70 (■), of 0.075 µM HSP70 and 0.3 µM ATP (▲),of 0.075 µM HSP70 and 0.3 µM 
oridonin (x), or of 0.075 µM HSP70, 0.3 µM ATP and 0.3 µM oridonin (●) are shown. Kinetics 
traces reported are the averages of two measurements. 
 
Moreover, the effect of oridonin on chaperone interaction with some client 
proteins (i.e. EGFR and ERK1/2) was evaluated. Therefore, we performed co-




immunoprecipitation in Jurkat cells exposed to 5 M and 10 M oridonin for 5 h. 
The most interesting result was achieved on the interaction between HSP70 and its 
co-chaperone BAG3, since we found that oridonin, even though only at the highest 
concentration tested (10 M), promoted HSP70-BAG3 binding (Figure 4.24 a).  
To confirm the ability of oridonin to enhance the affinity of HSP70 towards 
BAG3, some SPR experiments were carried out injecting BAG3 on immobilized 
HSP70, in the presence of different concentrations of the diterpene. The interaction 
was firstly tested using PBS as running buffer, allowing measuring a KD for the 
HSP70/BAG3 complex of 49.8 ± 1.9 nM (Figure 4.24 b); when the same analyses 
were performed using 1 M or 10 M oridonin in PBS as running buffers (Figure 
4.24 c,d), the KD of the resulting complex lowered to 12.1 ± 0.7 nM and 8.5 ± 0.5 
nM, respectively, indicating that the interaction of oridonin with HSP70 increased 
the binding efficiency of the chaperone with its partner.  
The high stability of the HSP70/oridonin complex observed in SPR analyses and 
the presence of the -unsaturated carbonyl group in the structure of the diterpene, 
led us to investigate the possible formation of covalent bond(s) between oridonin 
and protein thiol group(s), via Michael reaction.  
Therefore, HSP70 was incubated with a 2-fold molar excess of oridonin under 
pseudo-physiological conditions and the resulting complex underwent a classical 
peptide mapping procedure aimed to identify possible covalently modified 
peptides. 





Figure 4.24 Effect of oridonin binding on HSP70-BAG3 interaction. Jurkat cells were exposed to 5 
µM and 10 µM oridonin or vehicle only (control) for 5 h. Lysates were immunoprecipitated with 
anti-HSP70 antibody or IgGs and blots probed with anti-BAG3 antibody (A). The blot shown is 
representative of two replicate experiments. Sensorgrams obtained by injecting different 
concentrations (from 0.010 to 1 µM) of BAG3 on immobilized HSP70 using PBS (B), 1 µM 
oridonin in PBS (C), or 10 µM oridonin in PBS as running buffer (D). 
 
This analysis also revealed the presence of two species displaying a molecular 
mass of 1693.661 and 1566.835 respectively, assigned to peptides 259-269 and 
262-271, both carrying one oridonin linked on the same Cys residue (Cys267). This 
identification was confirmed by MS/MS spectra (Figure 4.25), and indicated 
Cys267 as the only covalent binding site of oridonin on HSP70.  
 





Figure 4.25 MS/MS analysis of oridonin-modified peptide. CID fragmentation spectrum of the 
double charged ion [M+2H]
2+
 at m/z 784.43, assigned to HSP70 peptide 259-269 modified by one 
oridonin linked on the Cys267. The peptide sequence is also reported. 
 
It is noteworthy that the Cys267 is in the ATPase domain of HSP70; it has been 
experimentally demonstrated that molecules able to covalently bind this residue of 
the inducible members of the HSP70 family cause a deep reduction of the affinity 
for ATP, and this because of the proximity of Cys267 to the NBD with a 




4.3.3  Molecular modelling studies 
The binding mode of oridonin in HSP70 was rationalized through docking 
calculations and Molecular Dynamics simulations, using respectively Autodock 
4.0
26
 and Macromodel 8.5 (Schrödinger, LLC, New York, 2003) software 
packages. The activity of oridonin is related to the presence in its chemical 
structure of theα,β-unsaturated ketone conjugate moiety, that represents a Michael 
acceptor function to the Cys267 in the binding site of HSP70.  
For these reasons, we firstly tried to analyze the formation of the covalent 
linkage using the recent introduced covalent docking methodologies,
27
 using the 




crystallographic structure of the N-terminal domain of HSP70, in which the protein 
is complexed with the ADP, magnesium and inorganic phosphate (PDB code: 
3JXU).
313
 Unfortunately, using the flexible side chain method we firstly observed a 
restricted space in the binding site of HSP70. This feature determined steric clashes 
in the binding site after the formation of the covalent bond required for the next 
phase of flexible docking.  
Moreover, using the covalent grid based approach we did not find poses 
compatible with the covalent linkage, because also in this case the restricted space 
did not allow the contact between the reactive part of oridonin and the Cys267 
counterpart of HSP70. Moreover, the predicted binding energy values related to 
these conformations confirmed the poor results, with presence of steric clashes in 
this binding site.  
Therefore, a putative models of oridonin covalently bound to HSP70 was 
possible with better accuracy using Molecular Dynamics simulations, analyzing its 
motions in the binding site of this target In particular, using this method we found 
some poses of these compounds in which the distances between their reactive parts 
and the sulfur of the Cys267 were compatible with the C-S linkage experimentally 
determined. Combining docking calculations and Molecular Dynamics simulations, 
we were able to build the models of these compounds covalently bound to the 
target.  
It is noteworthy that the Cys267 is in the ATPase domain of HSP70. It has been 
experimentally demonstrated that molecules able to covalently bind this residue in 
the HSP72 inducible member of the HSP70 family cause a deep reduction of the 
affinity for ATP, and this because of the proximity of Cys267 to the NBD with a 
consequent steric inhibition of nucleotide binding.
312
  
It has also been suggested that nucleotide-dependent conformational changes 
due to subdomain reorientations represent an intrinsic property of all NBDs, crucial 






 Nucleotides bind at the bottom of the deep central cleft at 
the interface between subdomains IB and IIB, close to the site in which oridonin is 
able to covalently bind HSP70.  
Starting from the docked conformation, we applied several fast steps of 
Molecular Dynamics simulations using Macromodel 8.5 (Schrödinger, LLC, New 
York, 2003), observing a gradual reduction of the distance between the α-β 
unsaturated ketone of oridonin to the sulfur of the Cys267. When we found a pose 
with a distance between these groups compatible with the covalent linkage C-S 
(~1.8 Å), we manually generated the covalent linkage. During the simulated 
approach of oridinin, we noticed a significant conformational change of the protein, 
and especially in the nucleotide binding site. In particular, as shown in Figure 4.26, 
a re-orientation of the α-helix presenting the Cys267 toward the binding site is 
observable, causing the exit of the nucleotide complex on the outer part of the 
protein.  
The RMSD plot, showing considerable variations during this step, confirmed 
these observations (Figure 4.27). Moreover, a Molecular Dynamics simulation of 
this generated complex was performed for 10 ns, and the results highlighted the 
stabilization of this inhibited conformation of HSP70 induced by the covalent 
linkage of oridonin, able in this bound state to establish interactions with several 
polar residues on different helixes in the nucleotide binding site (Figure 4.28).  
In agreement with this hypothesis, in this case the RMSD plot showed a more 
stable trend (Figure 4.29). 





Figure 4.26 Superposition between the crystal structure of HSP70 (PDB code: 3JXU, secondary 
structure of the protein, ADP, magnesium and inorganic phosphate as stick and balls colored in red) 
and the covalent model of oridonin (represented as CPK and colored by atom types: C green, O red) 
with HSP70 after Molecular Dynamics simulations (secondary structure of the protein, ADP, 
magnesium and inorganic phosphate as stick and balls colored in yellow). 
 
 
Figure 4.27 RMSD plot related to the simulated approach of oridonin to the identified binding site 
of HSP70. 





Figure 4.28 Covalent model of oridonin (colored by atom types: C green, O red) bound to the 
Cys267 of HSP70 (secondary structure colored in yellow, molecular surface colored in light grey, 
residues in contact with oridonin represented as stick and balls, colored by atom types: C gray, O 
red, N blue). 
 
 
Figure 4.29 RMSD plot related to the Molecular Dynamics simulation of HSP70-oridonin complex. 
 
In order to exclude the possibility of an artifact from the computational 
methodology used, a “blank” Molecular Dynamics simulation of 10 ns was 
performed starting from the crystal structure of HSP70 without oridonin. As 
expected, the protein preserved its conformation, without movements of the α-helix 
involved in the binding of oridonin, and also the nucleotide complex did not show 
significant movements in the binding site (Figure 4.30 and Figure 4.31). 





Figure 4.30 Superposition between the crystal structure of HSP70 (secondary structure of the 
protein, molecular surface of ADP, magnesium and inorganic phosphate colored in red) and the 
final structure obtained after a “blank” Molecular Dynamics simulation of 10 ns (secondary 





Figure 4.31 RMSD plot related to the Molecular Dynamics simulation of HSP70 not complexed 
with oridonin. 




4.3.4 Final remarks 
In summary, the model here proposed rationalizes the inhibitory activity of the 
covalent binder oridonin describing the dynamic modification of the orientation of 
the helixes surrounding the NBD of HSP70. 
Our observations revealed a mechanism of action of oridonin consistent with the 
multiple biological activities described for this diterpenes. Oridonin, inhibiting 
HSP70 activity can affect the activity of many client proteins of this chaperone, 
simultaneous affecting several molecular pathways. Moreover, our data could also 
account for the effects of oridonin treatment on intracellular level of HSP70 
reported elsewhere.
316
 Shedding light on the molecular basis of the biological 
activity of oridonin, our findings may be relevant for possible therapeutic 
applications of oridonin, such as its use in combination and the design of new 
therapeutic approaches. Even if efficacy of HSPs inhibitors as single-agent therapy 
is still limited for pharmacological and pharmaco-dynamic reasons, they have been 
reported to enhance cytotoxicity of various antitumor agents
317
 or the efficiency of 
HSP90 inhibitors.
318
 Indeed, recent preclinical and clinical studies exploring the 
effect of a combination of HSPs inhibitors with other anticancer agents in cancer 
therapy, demonstrated that in most cases they produce additives or synergic 
effects.
319,320,321
 On the other hand, discovering small molecules ATP competitive 
inhibitors of the NBD of HSP70 has proved extremely challenging providing an 
effective tool to study the biology of this protein;
304
 oridonin could therefore 
represent a promising new tool to advance basic investigations on the varied 



























5.1 Inverse Virtual Screening 
 
Pilot Inverse Virtual Screening study: LIBIOMOL library  
 
Chemical structure preparation. The library of compounds was downloaded 
from the website www.libiomol.unina.it. Chemical structures were built through 
MacroModel Maestro software Version 8.5. Optimization of the three-dimensional 
structures was applied with Monte Carlo Conformational Search and Molecular 
Dynamics simulations. Molecular mechanics/dynamics calculations were 
performed on a Pentium IV 2008 using the Macromodel 9.0 software package and 
the OPLS force field. The Monte-Carlo multiple minimum (MCMM) method 
(5000 steps) was used first in order to allow a full exploration of the 
conformational space. Molecular Dynamics simulations were performed at a 
temperature of 600K. A constant dielectric term mimicking the presence of water 
was used in the calculations to reduce artifacts derived from the absence of the 
solvent. 
Inverse Virtual Screening. Protein targets, known to be involved in tumor 
processes, were prepared by a search of crystallized structures on the Protein Data 
Bank database. Water molecules were removed and polar hydrogens were added 
with AutodockTools 1.4.5. 
Molecular docking calculations were performed using Autodock-Vina software. 
The grids focused on receptors were built using as reference the binding mode of 
crystallized ligands in PDB files. For the docking studies, we used an 
exhaustiveness of 16. For all the investigated compounds, all open-chain bonds 
were treated as active torsional bonds. Autodock-Vina results were analyzed with 






Re-evaluation of the biological activity of a small library of natural 
compounds 
 
Chemical structure preparation. We built and processed the chemical 
structures of the library of compounds with Macromodel 8.5 (Schrödinger, LLC, 
New York, 2003). Molecular mechanics/dynamics calculations were performed on 
a 4 × AMD Opteron SixCore 2.4 GHz using Macromodel 8.5 and the OPLS force 
field. To allow a full exploration of the conformational space, we used the Monte 
Carlo multiple minimum (MCMM) method (5000 steps). Molecular Dynamics 
simulations were performed at a temperature of 600 K and with a simulation time 
of 10 ns. A constant dielectric term, mimicking the presence of the solvent, was 
used in the calculations to reduce artifacts. To identify a possible three-dimensional 
starting model of each compounds for the subsequent docking calculations, we 
applied an optimization (Conjugate Gradient, 0.05 Å convergence threshold) of the 
structures.  
Inverse Virtual Screening. We built the panel of protein targets by a search of 
crystallized structures in the Protein Data Bank database (www.rcsb.org). Water 
molecules were removed, and polar hydrogens were added with AutodockTools 
1.4.5. Molecular docking calculations were performed using Autodock-Vina
28
 
software and then normalized. In the configuration file we specified only the 
exhaustiveness value to 64 and the coordinate values for the targets, focusing the 
grids on the sites of presumable pharmacological interest. When it was possible, we 
used as reference the binding mode of crystallized ligands in PDB files. For all the 
investigated compounds, all open-chain bonds were treated as active torsional 





Discovery of peptidase inhibitory activity of the new-anabaenopeptin 
cyclopeptide namalide 
 
Chemical structure preparation. The chemical structures of 54 and 56 were 
built and processed with Macromodel 8.5 (Schroedinger, New York, 2003). 
Molecular mechanics/dynamics calculations were performed on a quad-core Intel 
Xeon 3.4 GHz using Macromodel 8.5 and the OPLS force field. The Monte Carlo 
multiple minimum (MCMM) method (5000 steps) was used first to allow a full 
exploration of the conformational space. Molecular dynamics simulations were 
performed at 600 K and with a simulation time of 10 ns. A constant dielectric term, 
mimicking the presence of the solvent, was used in the calculations to reduce 
artifacts. Finally, an optimization (Conjugate Gradient, 0.05 Å convergence 
threshold) of the structures was applied for the identification of a possible 3-D 
starting models of 54 and 56 for the subsequent steps of docking calculations.  
Inverse Virtual Screening. The panel of protein targets was prepared by a 
search of crystallized structures in the Protein Data Bank. Water molecules were 
removed, and polar hydrogens were added with AutodockTools 1.4.5. Molecular 
docking calculations were performed using Autodock-Vina software using an 
exhaustiveness of 64. The selected grids focused on presumed sites of 
pharmacological interest on the basis of the binding modes of crystallized ligands 
in the PDB files wherever possible. A more accurate analysis of the interaction 
between 54 and CPA was conducted with the Autodock 4.2 software package. To 
have an accurate weight of the electrostatics, we derived the partial charge of Zn = 
1.136 and of the amino acids involved in the catalytic center by DFT calculations at 
the B3LYP level by the 6-31G(d) basis set and ChelpG
322
 method for population 
analysis (Gaussian 03 Package software
323
). Ten calculations consisting of 256 runs 





algorithm was used for dockings. An initial population of 450 randomly placed 
individuals, a maximum number of 10.0 × 10
6
 energy evaluations, and a maximum 
number of 8.0 × 10
6
 generations was taken into account. A mutation rate of 0.02 
and a crossover rate of 0.8 were used. Results differing by <3.0 Å in positional 
root-mean-square deviation (rmsd) were clustered together. For all of the 
investigated compounds, all open-chain bonds were treated as active torsional 
bonds. Autodock Vina results were analyzed with Autodock Tools 1.4.5. 
 
5.2 High-Throughput Molecular Dynamics for the accurate 
calculations of the binding affinities 
 
Compounds data set. In order to investigate the performance of LIE, we used 
the trypsin receptor and data set from the directory of useful decoys (DUD, 
http://dud.docking.org/).  
The trypsin data set is composed of 49 ligands and 1664 decoys. Since the 
presence for the same ligand or decoys of more IDs, mainly characterized by 
different protonation states, we provided a final library of unique ligands (44 
ligands and 1544 decoys).  
Molecular Dynamics. Regarding the Molecular Dynamics simulations, all the 
ligands were parameterized using the Antechamber software (AmberTools 1.5), 
assuming the compounds already with charges (.mol2 files), adding GAFF atom 
types, and then all the ligand-specific parameters not included in the GAFF 
forcefield were guessed with the parmchk command.  
Compounds-protein systems and the compounds systems were solvated and 
neutralized with sleap software (AmberTools 1.5). In particular, all the systems 





distant from this point 10 Å) with TIP3P water molecules and neutralized, and then 
minimized and equilibrated before the MD runs.  
After the minimization step, the systems were equilibrated in two phases. The 
first phase was conducted under NVT conditions at 300 K atm for 0.1 ns, with a 
time step of 4 fs. Then a second equilibration phase was done under NPT 
conditions at 300 K and 1 atm for 2ns, and a time step of 4 fs. During this run, Cα 





 harmonic potential to prevent the system reorienting.  
Then all the systems were submitted to the production runs: 3 × 10 ns MD 
simulation runs were performed for each complex and ligand alone related to the 
same system, under NVT conditions, at 300 K, using a time step of 4 fs. For all the 
simulations, a cutoff of 9 Å and particle-mesh Ewald long range electrostatic were 
set.  
The minimization phases were performed on standard GPU desktop server, 
while the production runs (~ 9500 simulations) were performed on the distributed 
computing project GPUGRID, using ACEMD software.  
Energy extraction was performed using NAMD energy plugin, version 1.4, and 
for each simulation an average of the energies related to each frame was 
considered. Finally, the average of the three simulations was calculated and used 










5.3 Further applications of in silico screenings on natural 
compounds 
 
Discovery of cholestan disulfate as a potent pregnane-X-receptor agonist  
 
Chemical structure preparation. Prior to docking calculations, we built and 
processed the chemical structures of the compounds with Macromodel 8.5 
(Schrödinger, LLC, New York, 2003). Molecular Mechanics/Dynamics 
calculations were performed on a 4 × AMD Opteron SixCore 2.4 GHz using 
Macromodel 8.5 and the OPLS force field. The Monte Carlo multiple minimum 
(MCMM) method (5000 steps) was used first in order to allow a full exploration of 
the conformational space. Molecular Dynamics simulations were performed at a 
temperature of 600 K and with a simulation time of 10 ns. A constant dielectric 
term, mimicking the presence of the solvent, was used in the calculations to reduce 
artifacts. Finally, we applied an optimization (Conjugate Gradient, 0.05 Å 
convergence threshold) of the structures for the identification of a possible three-
dimensional starting models for the subsequent steps of docking calculations. 
Docking calculations. Docking calculations were performed using Autodock 
4.2 software. A grid box size of 90×108×96 with spacing of 0.375 Å between the 
grid points and centered  at 14.282 (x), 74.983 (y), and 0.974 (z) was used for the 
PXR receptor. We performed 10 calculations consisting of 256 runs, obtaining 
2560 structures (256 × 10), using the Lamarckian genetic algorithm for dockings. 
An initial population of 450 randomly placed individuals, a maximum number of 
5.0 × 10
6
 energy evaluations, and a maximum number of 6.0 × 10
6
 generations 
were taken into account. A mutation rate of 0.02 and a crossover rate of 0.8 were 
used. We clustered together results differing by less than 3.0 Å in positional root-





bonds were treated as active torsional bonds. Docking results were analyzed with 
Autodock Tools 1.4.5.  
 
Plakilactones from the marine sponge Plakinastrella mamillaris, a new class 
of marine ligands of peroxisome proliferator-activated receptor γ 
 
Chemical structure preparation. The chemical structures of the compounds 
were built and processed with Macromodel 8.5 (Schrödinger, LLC, New York, 
2003). Molecular mechanics/dynamics calculations were performed on a 4 × AMD 
Opteron SixCore 2.4 GHz using Macromodel 8.5 and the OPLS force field. The 
Monte Carlo multiple minimum (MCMM) method (5000 steps) was used to allow 
a full exploration of the conformational space. Molecular Dynamics simulations 
were performed at 600 K and with a simulation time of 10 ns. A constant dielectric 
term, mimicking the presence of the solvent, was used to reduce artifacts. Finally, 
the optimization (Conjugate Gradient, 0.05 Å convergence threshold) of the 
structures was applied to identify the three-dimensional starting models for the 
subsequent steps of docking calculations. 
Docking calculations. Docking calculations were performed using the 
Autodock-Vina software. In the configuration files of the two crystallographic 
structures of PPAR we specified only the exhaustiveness value to 64 and the 
coordinate values for the targets, focusing the grid on the site of presumable 
pharmacological interest. In particular a grid box size of 22 × 22 × 30 and centered 
at 17.464 (x), 64.919 (y), and 19.625 (z) was used for the PPAR receptor (apo 
form), and of 20 × 20 × 20 and centered at 17.654 (x), 64.696 (y), and 11.136 (z) 
(locked form), with spacing of 1.0 Å between the grid points.  
For all the investigated compounds, all open-chain bonds were treated as active 





Molecular Dynamics simulations. Molecular Dynamics simulations steps were 
performed for the compounds 76 and 80 in order to observe their contacts with the 
reactive counterpart of PPAR, using Macromodel 8.5. In each step the distances 
between the sulfur of the Cys285 and the reactive β carbon of the α-β unsaturated 
ketone parts of 76 and 80 were constrained in order to reduce the distance at 0.5 Å. 
The obtained structures were reprocessed until a distance and an orientation of the 
reactive moieties compatible with the C-S bond were found. In all these steps, for 
the equilibration phase, an equilibration time of 10 ps was considered. Molecular 
Dynamics simulations were performed at 300 K , with a time step of 4.0 fs and a 
simulation time of 0.1 ns. Then the covalent bond between the reactive points was 
manually built, and the two covalent complexes (76 or 80 with PPAR) were 
subjected to a further fast Molecular Dynamics simulation in order to eliminate 
eventual steric clashes. In all the simulations, a constant dielectric term, mimicking 
the presence of the solvent, was used in to reduce artifacts. 
 
HSP70 1A as a Target for the Anticancer Diterpene Oridonin  
 
Chemical structure preparation. We built and processed the chemical 
structure of oridonin (87) with Macromodel 8.5 (Schrödinger, LLC, New York, 
2003). Molecular mechanics/dynamics calculations were performed on a 4 × AMD 
Opteron 16 Core 2.3 GHz using Macromodel 8.5 and the OPLS force field. The 
Monte Carlo multiple minimum (MCMM) method (5000 steps) was used first in 
order to allow a full exploration of the conformational space. Molecular Dynamics 
simulations were performed at a temperature of 600 K and with a simulation time 
of 10 ns. A constant dielectric term, mimicking the presence of the solvent, was 
used in the calculations to reduce artifacts. Finally, we applied an optimization 





identification of a possible three-dimensional starting models for the subsequent 
steps of docking calculations. 
Docking calculations. We performed covalent docking calculations using the 
Autodock 4.0 software using the recently introduced grid based approach.
27
 In the 
configuration file of the crystallographic structure of HSP70 (PDB code: 3JXU) we 
specified a grid box size of 48 × 46 × 48 with spacing of 0.375 Å and centered at -
9.765(x), -29.49 (y), and 20.277 (z).  
We performed 3 calculations consisting of 256 runs, obtaining 768 structures 
(256 × 3), using the Lamarckian genetic algorithm for dockings. An initial 
population of 450 randomly placed individuals, a maximum number of 5.0 × 10
6
 
energy evaluations, and a maximum number of 6.0 × 10
6
 generations were taken 
into account. A mutation rate of 0.02 and a crossover rate of 0.8 were used. We 
clustered together results differing by less than 3.0 Å in positional root-mean-
square deviation (rmsd). 
For the investigated compound, all open-chain bonds were treated as active 
torsional bonds. Docking results were analyzed with Autodock Tools 1.4.5.  
Molecular Dynamics simulations. Molecular Dynamics simulations steps were 
performed for the oridonin in order to observe their contacts with the reactive 
counterpart of HSP70, using Macromodel 8.5. We constrained the distances 
between the sulfur of Cys267 and the reactive β carbon of the α-β unsaturated 
ketone parts of oridonin in order to reduce the distance of from the sulfur in the 
side chain of Cys267. The obtained structures were reprocessed until we found a 
distance and an orientation of the reactive moieties compatible with the C-S 
linkage. In all these steps, for the equilibration phase an equilibration time of 50 ps 
was considered. Molecular Dynamics simulations were performed at a temperature 
of 300 K , with a time step of 2.0 fs and a simulation time of 0.5 ns. Then we 





covalent complex was submitted to a further Molecular Dynamics simulation of 10 
ns after an equilibration phase of 1 ns. Also in this case, a time step of 2.0 fs was 
considered. In parallel we performed also a Molecular Dynamics simulation of 10 
ns on the crystal structure of HSP70 complexed with ADP, magnesium and 
inorganic phosphate, using the same parameters previously described. In all the 
simulations, a constant dielectric term, mimicking the presence of the solvent, was 


























Classical computational studies are oriented towards the evaluation of the 
predicted affinities on one defined target protein, in order to perform subsequent 
biological assays for the evaluation of the biological activity. This represents the 
main concept on which is based the Virtual Screening in silico protocol. Thus, the 
main risk is to confine these studies to a single target of a pathological process.  
In this thesis, the concept of Inverse Virtual Screening has been introduced and 
examined. The application of this method may facilitate the prediction of the 
activity of secondary metabolites from natural or synthetic sources on known 
different receptors involved in the development of a pathology (i.e. cancer; viral, 
bacterial, mycotic infections).  
However, the most important evidence arising from the analysis of the results 
was the impossibility of consider the mere predicted binding energies as parameter 
of selection of the best results, and this was mainly due to the variability of the 
binding sites of the different targets. To overcome this problem, a normalization of 
the matrix that collects all values of predicted binding energies from the 
calculations (Equation 2.5, Paragraph 2.2.4) was applied. The different results 
pointed out in this thesis demonstrate that through docking calculations on large 
panels of ligands and targets, a screening of energies after normalization is possible 
in order to select the best interactions. From these selections, experimental tests 
could be started on a restricted number of proteins. Thus, Inverse Virtual Screening 
may be considered as a new accurate tool to facilitate the drug discovery process. 
From a general point of view, Inverse Virtual Screening represents a new 
computational tool for the identification of targets of pharmacological interest 
rather than a method for the precise prediction of the range of activity for one or 
more compounds. Indeed, the normalization of the predicted binding energies 





the ligands) is useful to identify significant results by a large set of data from 
heterogeneous sources. 
On the other hand, this approach makes possible the discovery of new molecular 
scaffolds on a specific receptor as lead compounds and suggested a possible 
improvement of their potency and selectivity focused on a precise and defined 
biological context. In particular, precise modifications in the pharmacophore 
models of the compounds identified could increase their inhibition on the targets 
selected from the screening.  
As shown in the first pilot attempt (Paragraph 2.2), applying this mathematical 
normalization, compounds 19 and 20 on Topoisomerase I target were selected. 
These data represented encouraging results regarding the reliability of this 
approach. In fact, in the library of 43 molecules used, compounds 19 and 20 
corresponded in point of fact to internal “standard” compounds, because their 
bioactivity on Topoisomerase I was yet known. 
Proceeding on this research line, the Inverse Virtual Screening method was 
implemented using another library of 10 compounds extracted from plants against a 
panel of 163 target involved in the cancer events (Paragraph 2.3). The 
normalization of the predicted affinities addressed the biological tests on 2 
compounds (52 and 53) against three targets (PDK1, PKC-α and PKC-θ). Also in 
this case, a good correlation between the Inverse Virtual Screening results and the 
biological data, corroborated by 5 prediction of activity/inactivity on 6, was 
observed. 
For compounds 52 and 53 identified in this study moderate biological activities 
were found (μM range). This is in line with the hypothesis of a modulatory role of 
these molecules in the cancer events. Moreover, the μM range of activity is fully 
compatible with the role of cancer prevention that is achievable by a consistent 





Moreover, in order to explain this moderate activities found for the best results, 
another Inverse Virtual Screening study was performed considering 52, 53, and the 
ligands crystallized in the binding sites of the targets PDK1, PKC-α, and PKC-θ 
(namely PDK1_lig, PKC-α_lig, and PKC-θ_lig). The biological activity of this 
“standard” compounds in the nM range on their respective targets allowed a more 
precise comparison with the V values calculated for the compounds 52 and 53 
emerging from this new screening (Paragraph 2.3, Table 2.11 ), because in this case 
their normalized results are related to a new scale of values. 
In parallel, the case of the Inverse Virtual Screening on a single compound was 
also considered, and specifically for the cyclopeptide namalide (54, Paragraph 2.4), 
featuring a new mini-anabaenopeptin scaffold.  
A modification of the way to normalize the docking results was proposed, 
introducing “blank” compounds for the calculations of the affinities indispensable 
for the normalization. 54 belongs to the family of anabaenopeptides, known to 
inhibit carboxipeptidases. Using a panel of 159 targets involved in the cancer, 
Carboxypeptidase A (CPA) protein was identified as the third best hit in the final 
ranking, while the isoform Carboxipeptidase U (CPU) was on position 149. These 
results were found to be in total accordance with the biological results (IC50 = 250 
nM), that highlighted the nM inhibitory activity and selectivity of 54 against CPA, 
with a total absence of activity on CPU. The fact that 54 inhibits CPA with 
potencies comparable to the more common hexapeptides, together with the docking 
analysis and rationalization of the inactivity of other cyclopeptides synthetized, can 
open the way to further QSAR investigations in order to design other namalide 
analogs against CPA and related hydrolases. 
Virtual Screening combined with accuracy of the calculated affinities was also 
examined using methods other than molecular docking. In particular, high-





and decoys specific for the trypsin receptor. In general, these libraries are open-
source available on Internet, and are very useful for comparing the efficiency of 
different computational methods in distinguishing true positive results from false 
positive ones. In the specific case, a comparison between the docking results, LIE 
(Linear Interaction Energy) and MM-GB(PB)SA was taken into account. So far, 
only preliminary results are available and are related to molecular docking and LIE 
method, considering for the latter method four results deriving from four different 
combinations of scaling factors. The efficacy of these two approaches was 
investigated and graphically summarized using ROC and enrichment curves. In 
general, LIE show better results than molecular docking only on the 2% of the 
ranked database, and after this point docking shows enrichment factors particularly 
better than those of LIE.  
MM-GBSA and MM-PBSA evaluation of the binding affinities are ongoing and 
will be compared with the results obtained until now, in order to offer a more 
comprehensive view in the field of the calculations of the binding affinities by 
Molecular Dynamics-based methods. 
In silico screenings for the detailed study of natural compounds whose activities 
are known a priori were performed on different targets. In these case studies, the 
main aim was to offer qualitative considerations regarding the absence/presence 
and orientations of the pharmacophoric points of these compounds in the binding 
sites of the targets investigated. The rationalization of the molecular basis of these 
interactions can be useful for the next design of new molecules for these specific 
systems. 
In more details, a small library of 9 compounds derivated by the modification of 
the side chain of the natural compound Solomonsterol A, a potent agonist of PXR 





In particular, compound 67 showed a remarkable agonistic activity (μM range) 
that was clarified at molecular level, elucidating the fundamental presence of two 
sulfate group in precise positions on the ring A, and of an hydrophobic side chain 
derived from the cholesterol. For all the other inactive compounds in the library, 
the absence of this pharmacophoric points or their shift in different positions were 
identified as the cause of their total absence of activity on PXR. 
Moreover, a set of compounds extracted from the marine sponge Plakinastrella 
Mamillaris was analyzed on the target PPAR At molecular level it was 
demonstrated that gracilioether B (76) and plakilactone C (80) covalently bind to a 
cysteine residue in the PPAR-ligand binding site (LBD) through a Michael 
addition reaction to the ,-unsaturated ketone in their side chains.  
An integrated analysis of docking and Molecular Dynamics simulations showed, 
as previously reported for several selective covalent PPAR ligands, that steps 
based on non-covalent interactions confer specificity in the recognition process to 
PPARLBD and then, after the covalent binding, a conformational change in the 
protein is observable, accounting for the agonist activity observed in the biological 
tests. For gracilioether C (77) a detailed docking analysis laid the basis for the 
structural requirements for its non covalent interaction in the receptor’s LBD. 
Further insights were gained to explain the antagonist activities of methyl esters 72 
and 73 and several non active members of this series. 
In a similar way, computational studies based on molecular docking and 
Molecular Dynamics simulations assisted the experimental evidences from 
Chemical Proteomics and several biological studies about the inhibitory activity of 
compound oridonin (87) on the target HSP70 1A.  
The formation of the covalent bond between its ,-unsaturated ketone moiety 


























A.1 Cancer: some data 
 
Cancer represents today a global public health burden, and the summary of 
cancer incidence and mortality patterns in the relative rankings by cancer site 
reveal differences between industrialized and developing nations. Reliable data on 
the magnitude of the cancer problem are essential for monitoring the health of the 
community, assessing the performance of the health care system and allowing 
authorities to make informed decisions. Several migrant studies have documented 
that cancer rates in successive generations of migrants shift in the direction of the 
prevailing rates in the host country, suggesting that the international variations in 
cancer rates for most cancers largely reflect differences in environmental risk 





Figure 5.1 Distribution of several specific tissue cancer types in: a)usa (2008) b)southafrica 
(2009) c)Italy (2009) d)japan (2010) 
 
Cancer research has generated a rich and complex body of knowledge, revealing 
this pathology to be a disease involving dynamic changes in the genome. In 





tumor suppressor genes with recessive loss of function have been identified 
through their alteration in human and animal cancer cells. To date, many pathways 
involving several protein with different locations (extracellular, intracellular and 
nuclear) and structural features are known.  
 
A.2 Cancer pathways 
In the next paragraphs an overview of the main pathways in the cancer process 
are reported. 
 
A.2.1 Apoptosis  
Apoptosis has been recognized and accepted as a distinctive and important mode 
of “programmed” cell death, which involves the genetically determined elimination 
of cells. Irradiation or drugs used for cancer chemotherapy results in DNA damage 
in some cells, which can lead to apoptotic death through a p53-dependent pathway. 
The mechanisms of apoptosis are complex and sophisticated, involving an energy-
dependent cascade of molecular events. More specifically, caspases are widely 
expressed in an inactive proenzyme form in most cells and once activated can often 
activate other pro-caspases, allowing initiation of a protease cascade. Caspases 
have proteolytic activity and are able to cleave proteins at aspartic acid residues, 
although different caspases have different specificities involving recognition of 
neighboring amino acids. Once caspases are initially activated, there seems to be an 
irreversible commitment towards cell death. To date, ten major caspases have been 
identified and broadly categorized into initiators (caspase-2,-8,-9,-10), effectors or 
executioners (caspase-3,-6,-7) and inflammatory caspases (caspase-1,-4,-5).
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 The 
other caspases that have been identified include caspase-11, which is reported to 
regulate apoptosis and cytokine maturation during septic shock, caspase-12, which 





13, which is suggested to be a bovine gene, and caspase-14, which is highly 
expressed in embryonic tissues but not in adult tissues.
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It is possible to distinguish two main apoptotic pathways: the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway. However, there is 
now evidence that the two pathways are linked and that molecules in one pathway 
can influence the other (Figure 5.2).  
 
 
Figure 5.2 Intrinsic and extrinsic apoptotic pathways 
The extrinsic signaling pathways that initiate apoptosis involve transmembrane 
receptor-mediated interactions. These involve death receptors that are members of 
the tumor necrosis factor (TNF) receptor gene superfamily. The sequence of events 
that define the extrinsic phase of apoptosis are best characterized with the 
FasL/FasR and TNF-α/TNFR1 models. In these models, there is clustering of 
receptors and binding with the homologous trimeric ligand. Upon ligand binding, 





domains that bind with the receptors. The binding of Fas ligand to Fas receptor 
results in the binding of the adapter protein FADD and the binding of TNF ligand 
to TNF receptor results in the binding of the adapter protein TRADD with 
recruitment of FADD and RIP. FADD then associates with procaspase-8 via 
dimerization of the death effector domain. At this point, a death-inducing signaling 
complex (DISC) is formed, resulting in the autocatalytic activation of procaspase-
8. Once caspase-8 is activated, the execution phase of apoptosis is triggered.  
Apoptosis can also occur via Intrinsic pathways. The Intrinsic Apoptosis 
pathway begins when an injury occurs within the cell. Intrinsic stresses such as 
Oncogenes, direct DNA damage, Hypoxia, and survival factor deprivation, can 
activate the Intrinsic Apoptotic pathway. p53 is a sensor of cellular stress and is a 
critical activator of the intrinsic pathway. The DNA checkpoints proteins, ATM 
(Ataxia Telangiectasia Mutated protein), and Chk2 (Checkpoints Factor-2) directly 
phosphorylate and stabilize p53 and inhibit MDM2 (Mouse Double Minute-2 
Homolog) mediated ubiquitination of p53. MDM2 binds p53 and mediates the 
nuclear export. When bound to MDM2, p53 can no longer function as an activator 
of transcription. p53 initiates Apoptosis by transcriptionally activating proapoptotic 
Bcl2 family members and repressing antiapoptotic Bcl2 proteins and CIAPs. Other 
p53 targets include BAX, Noxa, PUMA (p53-Upregulated Modulator of 
Apoptosis) and BID. p53 also transactivates other genes that may contribute to 
Apoptosis including PTEN (Phosphatase and Tensin Homolog Deleted On 
Chromosome-10), APAF1, Perp, p53AIP1 (p53-regulated Apoptosis-Inducing 
Protein-1), and genes that lead to increases in ROS (Reactive Oxygen Species). 
These ROS lead to generalized oxidative damage to all Mitochondrial components. 
Damage to Mitochondrial DNA disrupts Mitochondrial oxidative phosphorylation, 
contributing to a number of Human diseases.
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 Other proteins released from 





Caspase)/ Diablo, Arts and Omi/HTRA2 (High Temperature Requirement Protein-
A2), counteract the effect of IAPs (Inhibitor of Apoptosis Proteins), which 
normally bind and prevent activation of Caspase3. The interaction between Bcl 
family members, IAPs, SMAC and Omi/HTRA2 is central to the intrinsic 
Apoptosis pathway. Another nuclease, EndoG (Endonuclease-G), is specifically 
activated by Apoptotic stimuli and is able to induce nucleosomal fragmentation of 
DNA independently of Caspase and DFF (DNA-Fragmentation Factor)/ CAD 
(Caspase-Activated DNAse). EndoG is a mitochondrion-specific nuclease that 
translocates to the nucleus and cleaves chromatin DNA during Apoptosis. Another 
protein, AIF (Apoptosis Inducing Factor) has also been attributed a role in 
Apoptosis, becoming active upon translocation from mitochondria to nuclei, where 
it initiates chromatin condensation and large-scale DNA fragmentation.
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 Gain and 
loss of function models of genes in the core Apoptotic pathway indicate that the 
violation of cellular homeostasis can be a primary pathogenic event that results in 
disease. Evidence indicates that insufficient Apoptosis can manifest as Cancer or 
Autoimmunity, while accelerated cell death is evident in Acute and Chronic 
Degenerative diseases, Immunodeficiency, and Infertility.
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 One important way of 
blocking apoptosis in cancer cells is by inactivating the p53 tumour-suppressor 
pathway. Levels of this transcription factor increase in response to a wide range of 
genotoxic insults, and many of its target genes encode pro-apoptotic proteins (for 
simplicity, only BAX is shown).
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 p53 is targeted for degradation in the 
proteasome by MDM2, an oncogenic ubiquitin ligase
331
. In turn, MDM2 is 
inhibited by ARF (also known as p14 in humans and p19 in mice).
332
  
As well as blocking pro-apoptotic pathways, cancer cells can upregulate anti-
apoptotic pathways. The growth-factor-mediated activation of phosphatidylinositol 






A.2.2 Replicative lifespan 
One of the hallmarks of cancer is unlimited replicative potential. In human cells, 
telomere maintenance serves as a generational clock that counts cell divisions and 
regulates cell lifespan.
333,334
 Cancer cells have at least two ways of maintaining 
their telomeres. The more common mechanism, which is active in 85-90% of 
human cancer cells, is to switch on TERT, the protein component of telomerase (a 
ribonucleoprotein enzyme that synthesizes telomeres and maintains telomeric 
ends). A small proportion of cancer cells use a yet undefined pathway that is 
known as alternative lengthening of telomeres (ALT) and allows telomere 
maintenance in the absence of active telomerase. As indicated, although telomeres 
have a crucial function in specifying cell lifespan, other pathways contribute to the 
replicative potential of a tumour cell. 
 
A.2.3 Proliferative signals 
Extracellular signals have important functions in the homeostatic regulation of 
cell growth and proliferation. Many of these signals impinge on a linear series of 
signalling molecules that link the cell surface to intracellular machinery that effects 
cell growth and division. Activating mutations in many of these genes are 
oncogenic and serve to liberate cancer cells from these normal homeostatic 
mechanisms, allowing self-sufficient proliferation. Proliferative signalling 
pathways often begin with the activation of a receptor tyrosine kinase (RTK) by a 
growth factor, although activation of some G-protein-coupled receptors (GPCRs) 
can also activate certain branches of this signalling pathway.  
Depending on the proteins that are subsequently recruited by the activated 
receptor, several downstream signalling pathways might be activated. It would be 
impossible to illustrate all of these permutations here, but two important pathways 





The first of these is the RAS pathway. The binding of a growth factor to an RTK 
recruits and activates the adaptor proteins GRB2 and SHC which, in turn, enable 
SOS to activate the small GTP-binding protein RAS.  
This association activates a cascade of serine/threonine kinases (such as RAF 
and MEK), culminating in the activation of a mitogen-activated protein kinase 
(MAPK, usually an extracellular signal regulated kinase ERK).  
MAPKs are translocated to the nucleus where, by phosphorylating transcription 
factors such as FOS and JUN, they modulate the expression of a wide range of 
genes that are involved in cell growth and survival. RAS has a number of effectors 
other than MAPK (not all shown),
335
 and many of these might also impinge on the 
neoplastic phenotype.  
A second branch downstream of growth factors that is often deregulated in 
cancer is the phosphatidylinositol 3-kinase (PI3K) pathway, which activates the 
serine/threonine kinase AKT.
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 Inactivation of PTEN, a lipid phosphatase, also 
results in activation of this pathway, and inherited loss of PTEN confers 
susceptibility to many types of cancer.
337
  
RAS activation can also lead to activation of PI3K, indicating that these 
pathways are interconnected at several levels. 
 
A.2.4 Cell cycle 
Several tumour-suppressor proteins monitor intrinsic and extrinsic signals and 
integrate these inputs to decide whether the cell should remain in a quiescent state 
or enter into the cycle of active growth and division. In addition to these decisions, 
which are made in the G1 phase of the cell cycle, checkpoints that operate in other 
phases of the cycle exert quality control by determining that certain steps have been 





Two tumour-suppressor pathways that block progression through the cell cycle - 
the retinoblastoma (RB) pathway and the p53 pathway - are inactivated in most, if 
not all, cancer cells.
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 RB represses the transcriptional activation of genes 
controlled by E2Fs, a family of transcription factors that regulate the expression of 
several genes involved in cell-cycle progression.
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 The cyclin-D-CDK4/6 (cyclin-
dependent kinase 4/6) complexes and cyclin-E-CDK2 complexes regulate RB 
activity by phosphorylation; hyperphosphorylation of RB renders it unable to 
suppress the activity of the E2Fs. These cyclin-D-CDK4/6 complexes are, in turn, 
antagonized by a series of CDK inhibitors, known as INKs. The two best studied of 
these, INK4A (also known as p16) and INK4B (also known as p15), have 
prominent functions in blocking RB phosphorylation in many cell types. 
As well as activating apoptosis (see apoptosis box, p53 blocks progression 
through the cell cycle by activating the transcription of another CDK inhibitor, 
WAF1 (also known as p21). WAF1 inhibits the activity of a number of cyclin-
CDK complexes, among them cyclin-E-CDK2. 
Normal cells seem to have a hard-wired safety mechanism that defends the cell 
against illegitimate activation of oncogenic stimuli. One of the best-characterized is 
the response of cells to persistent activation of the RAS pathway, which activates 
both the RB and the p53 pathways, thereby leading to cell-cycle arrest.
340,341
 
Oncogenic activation of RAS therefore does not lead to tumorigenicity unless this 
safety catch is removed by inactivation of the p53 and RB pathways.  
Another mechanism for putting the brakes on the cell cycle, at least in some cell 
types, is the transforming growth factor-b (TGF-b) pathway.
342
 Members of the 
TGF-b family activate the intrinsic serine/threonine kinase activity of their 
receptors (TGF-bRs), leading to the phosphorylation and nuclear translocation of a 
group of transcription factors called SMADs. Depending on the presence of other 





wide range of molecules that are involved in cell-cycle regulation. For example, 
they can upregulate the expression of the INK4B CDK inhibitor and can repress the 
expression of the MYC oncogene. However, there is a darker side to TGF-b 
activation as, under some circumstances, it can lead to invasion and metastasis. 
Progression through the cell cycle is activated by many oncogenic signalling 
pathways, including those that activate RAS, which indirectly induces cyclin D 
expression. The WNT-Frizzled signalling pathway also stimulates cell-cycle 
progression and is dysregulated in many colorectal cancers.
343
 Activation of the 
Frizzled receptor leads to the inhibition of glycogen synthase kinase-3β (GSK3β); 
this regulates the assembly of a ubiquitin ligase complex that normally keeps levels 
of free cytoplasmic b-catenin low. When GSK3β is inhibited, free b-catenin 
accumulates and gains access to the nucleus, where it acts as a co-activator for a 
transcription factor called TCF. The TCF-b-catenin complex induces the 
transcription of several important regulators of the cell cycle, such as cyclin D and 
MYC, but evidence is also accumulating that some of the targets of the TCF-b-
catenin complex are important for driving metastasis.  
 
A.2.5 Mobilization of resources 
Many of the intracellular and extracellular changes that are found in cancer cells 
lead to changes in gene expression and protein metabolism. Activation of these 
pathways is necessary to mobilize the cellular resources that are necessary for the 
cancer-cell phenotype. In particular, some of these changes lead to expression of 
inappropriate gene programs and activation of metabolic programs that confer 
specific advantages to a continuously dividing cancer cell. Among the alterations 
that are included in this category are those that affect ribosome biosynthesis, 
expression of differentiation-associated antigens, enzymes involved in nutrient 





For example, as well as blocking apoptotic pathways, the PI3K-AKT-PTEN 
pathway might be involved in regulating cell size by activating biosynthetic 
pathways.
344
 Protein phosphatase 2A (PP2A) and the serine/threonine kinase TOR 
are also thought to be involved in this biosynthetic route; both of these can activate 
ribosomal S6 kinase (RSK), an important regulator of ribosome assembly. PP2A 
also activates eukaryotic initiation factor 4E (eIF4E), a protein that is involved in 
ribosome biogenesis. The identification of gene mutation or loss of each of these 
molecules in human cancers indicates that these biosynthetic pathways have 
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